WO2012087913A2 - Peptide reagents and methods for detection of colon dysplasia - Google Patents
Peptide reagents and methods for detection of colon dysplasia Download PDFInfo
- Publication number
- WO2012087913A2 WO2012087913A2 PCT/US2011/065804 US2011065804W WO2012087913A2 WO 2012087913 A2 WO2012087913 A2 WO 2012087913A2 US 2011065804 W US2011065804 W US 2011065804W WO 2012087913 A2 WO2012087913 A2 WO 2012087913A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- seq
- reagent
- cells
- set out
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 412
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 77
- 238000000034 method Methods 0.000 title claims abstract description 53
- 206010071161 Colon dysplasia Diseases 0.000 title claims description 18
- 238000001514 detection method Methods 0.000 title description 14
- 210000001072 colon Anatomy 0.000 claims abstract description 60
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 30
- 201000011510 cancer Diseases 0.000 claims abstract description 25
- 230000027455 binding Effects 0.000 claims description 128
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 119
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical group O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims description 44
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 37
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 27
- 230000003902 lesion Effects 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 24
- 206010009944 Colon cancer Diseases 0.000 claims description 23
- 230000001225 therapeutic effect Effects 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 15
- 208000029742 colonic neoplasm Diseases 0.000 claims description 13
- 238000001574 biopsy Methods 0.000 claims description 10
- 230000000994 depressogenic effect Effects 0.000 claims description 9
- 238000000386 microscopy Methods 0.000 claims description 9
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- YMZMTOFQCVHHFB-UHFFFAOYSA-N 5-carboxytetramethylrhodamine Chemical group C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(C(O)=O)C=C1C([O-])=O YMZMTOFQCVHHFB-UHFFFAOYSA-N 0.000 claims description 6
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 229940127089 cytotoxic agent Drugs 0.000 claims description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 3
- 206010027476 Metastases Diseases 0.000 claims description 3
- 230000009401 metastasis Effects 0.000 claims description 3
- 238000002595 magnetic resonance imaging Methods 0.000 claims description 2
- 238000012285 ultrasound imaging Methods 0.000 claims 1
- 206010058314 Dysplasia Diseases 0.000 abstract description 41
- 230000008685 targeting Effects 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 212
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 76
- 239000002953 phosphate buffered saline Substances 0.000 description 66
- 210000004877 mucosa Anatomy 0.000 description 59
- 241000699670 Mus sp. Species 0.000 description 54
- 208000003200 Adenoma Diseases 0.000 description 49
- 235000001014 amino acid Nutrition 0.000 description 42
- 210000001519 tissue Anatomy 0.000 description 41
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 39
- 101710176384 Peptide 1 Proteins 0.000 description 36
- 229940024606 amino acid Drugs 0.000 description 36
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 35
- 208000037062 Polyps Diseases 0.000 description 33
- 150000001413 amino acids Chemical class 0.000 description 31
- 238000002073 fluorescence micrograph Methods 0.000 description 30
- 230000000112 colonic effect Effects 0.000 description 29
- 238000003384 imaging method Methods 0.000 description 28
- 239000000178 monomer Substances 0.000 description 28
- 238000001727 in vivo Methods 0.000 description 27
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 25
- 238000001839 endoscopy Methods 0.000 description 23
- 230000005284 excitation Effects 0.000 description 22
- -1 Asp or Glu) Chemical class 0.000 description 20
- 229940127121 immunoconjugate Drugs 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 20
- 238000000684 flow cytometry Methods 0.000 description 19
- 206010048832 Colon adenoma Diseases 0.000 description 18
- 239000000835 fiber Substances 0.000 description 18
- WBSCNDJQPKSPII-KKUMJFAQSA-N Lys-Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O WBSCNDJQPKSPII-KKUMJFAQSA-N 0.000 description 17
- 208000009956 adenocarcinoma Diseases 0.000 description 17
- 210000000988 bone and bone Anatomy 0.000 description 17
- 229940098773 bovine serum albumin Drugs 0.000 description 17
- 230000003211 malignant effect Effects 0.000 description 17
- 230000000921 morphogenic effect Effects 0.000 description 17
- 206010001233 Adenoma benign Diseases 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 238000005516 engineering process Methods 0.000 description 15
- 230000003595 spectral effect Effects 0.000 description 15
- 238000004091 panning Methods 0.000 description 14
- 238000002823 phage display Methods 0.000 description 14
- 238000005406 washing Methods 0.000 description 14
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 13
- 239000000975 dye Substances 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
- 238000000799 fluorescence microscopy Methods 0.000 description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 229930040373 Paraformaldehyde Natural products 0.000 description 12
- 210000000056 organ Anatomy 0.000 description 12
- 229920002866 paraformaldehyde Polymers 0.000 description 12
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 12
- 239000011347 resin Substances 0.000 description 12
- 229920005989 resin Polymers 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 11
- 201000009030 Carcinoma Diseases 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 11
- 229920001213 Polysorbate 20 Polymers 0.000 description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 11
- 238000005286 illumination Methods 0.000 description 11
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 11
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 11
- 229920001184 polypeptide Polymers 0.000 description 11
- 238000010186 staining Methods 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 238000013019 agitation Methods 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 10
- 230000009870 specific binding Effects 0.000 description 10
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 10
- 208000004804 Adenomatous Polyps Diseases 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 9
- 239000010931 gold Substances 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 239000003643 water by type Substances 0.000 description 9
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 8
- 108700028369 Alleles Proteins 0.000 description 8
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000012091 fetal bovine serum Substances 0.000 description 8
- 206010020718 hyperplasia Diseases 0.000 description 8
- 230000002390 hyperplastic effect Effects 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 230000003287 optical effect Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000008399 tap water Substances 0.000 description 8
- 235000020679 tap water Nutrition 0.000 description 8
- 238000012800 visualization Methods 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 101150105104 Kras gene Proteins 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000000903 blocking effect Effects 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 238000010494 dissociation reaction Methods 0.000 description 7
- 230000005593 dissociations Effects 0.000 description 7
- 210000004921 distal colon Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000012326 endoscopic mucosal resection Methods 0.000 description 7
- 229910052737 gold Inorganic materials 0.000 description 7
- 238000011503 in vivo imaging Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- FCWWPVBPSMLENC-UHFFFAOYSA-N 4-(diethylamino)-2-oxochromene-3-carboxylic acid Chemical compound C1=CC=CC2=C1OC(=O)C(C(O)=O)=C2N(CC)CC FCWWPVBPSMLENC-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 108010051219 Cre recombinase Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- 102000004142 Trypsin Human genes 0.000 description 6
- 108090000631 Trypsin Proteins 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 6
- 230000001613 neoplastic effect Effects 0.000 description 6
- 210000004940 nucleus Anatomy 0.000 description 6
- 238000010647 peptide synthesis reaction Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000010532 solid phase synthesis reaction Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 6
- 239000012588 trypsin Substances 0.000 description 6
- 238000010200 validation analysis Methods 0.000 description 6
- JDDWRLPTKIOUOF-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl n-[[4-[2-[bis(4-methylphenyl)methylamino]-2-oxoethoxy]phenyl]-(2,4-dimethoxyphenyl)methyl]carbamate Chemical compound COC1=CC(OC)=CC=C1C(C=1C=CC(OCC(=O)NC(C=2C=CC(C)=CC=2)C=2C=CC(C)=CC=2)=CC=1)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 JDDWRLPTKIOUOF-UHFFFAOYSA-N 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 5
- 229930182555 Penicillin Natural products 0.000 description 5
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 108010009583 Transforming Growth Factors Proteins 0.000 description 5
- 102000009618 Transforming Growth Factors Human genes 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 210000000981 epithelium Anatomy 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 238000003364 immunohistochemistry Methods 0.000 description 5
- 238000010832 independent-sample T-test Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 229940049954 penicillin Drugs 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 238000012552 review Methods 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 238000007619 statistical method Methods 0.000 description 5
- 229960005322 streptomycin Drugs 0.000 description 5
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 4
- HSHNITRMYYLLCV-UHFFFAOYSA-N 4-methylumbelliferone Chemical compound C1=C(O)C=CC2=C1OC(=O)C=C2C HSHNITRMYYLLCV-UHFFFAOYSA-N 0.000 description 4
- WHCPTFFIERCDSB-UHFFFAOYSA-N 7-(diethylamino)-2-oxochromene-3-carboxylic acid Chemical compound C1=C(C(O)=O)C(=O)OC2=CC(N(CC)CC)=CC=C21 WHCPTFFIERCDSB-UHFFFAOYSA-N 0.000 description 4
- 206010069754 Acquired gene mutation Diseases 0.000 description 4
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 150000008575 L-amino acids Chemical class 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000002869 basic local alignment search tool Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 238000004624 confocal microscopy Methods 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000001917 fluorescence detection Methods 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000003068 molecular probe Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 238000002953 preparative HPLC Methods 0.000 description 4
- 238000004445 quantitative analysis Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 230000037439 somatic mutation Effects 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 210000005166 vasculature Anatomy 0.000 description 4
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 3
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 3
- UNGMOMJDNDFGJG-UHFFFAOYSA-N 5-carboxy-X-rhodamine Chemical compound [O-]C(=O)C1=CC(C(=O)O)=CC=C1C1=C(C=C2C3=C4CCCN3CCC2)C4=[O+]C2=C1C=C1CCCN3CCCC2=C13 UNGMOMJDNDFGJG-UHFFFAOYSA-N 0.000 description 3
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 3
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 3
- 108010039627 Aprotinin Proteins 0.000 description 3
- 101710132601 Capsid protein Proteins 0.000 description 3
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 3
- 101710094648 Coat protein Proteins 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 3
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 3
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 3
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 3
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 3
- 102000006992 Interferon-alpha Human genes 0.000 description 3
- 108010047761 Interferon-alpha Proteins 0.000 description 3
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 3
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 3
- 101710125418 Major capsid protein Proteins 0.000 description 3
- 241000449980 Mansa Species 0.000 description 3
- 101710141454 Nucleoprotein Proteins 0.000 description 3
- 206010036618 Premenstrual syndrome Diseases 0.000 description 3
- 101710083689 Probable capsid protein Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 229960004405 aprotinin Drugs 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 238000002052 colonoscopy Methods 0.000 description 3
- 230000009137 competitive binding Effects 0.000 description 3
- 230000006957 competitive inhibition Effects 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 229940126864 fibroblast growth factor Drugs 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 3
- 230000003118 histopathologic effect Effects 0.000 description 3
- PNDZEEPOYCVIIY-UHFFFAOYSA-N indo-1 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C=2N=C3[CH]C(=CC=C3C=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 PNDZEEPOYCVIIY-UHFFFAOYSA-N 0.000 description 3
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 3
- 108010052968 leupeptin Proteins 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000013307 optical fiber Substances 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 102000029947 transforming growth factor beta binding proteins Human genes 0.000 description 3
- 108091014793 transforming growth factor beta binding proteins Proteins 0.000 description 3
- 241001515965 unidentified phage Species 0.000 description 3
- 238000001429 visible spectrum Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- DOMDXTIMIZCSNC-UHFFFAOYSA-N (2Z)-2-[(2E,4E)-5-[3-[6-(2,5-dioxopyrrolidin-1-yl)oxy-6-oxohexyl]-1,1-dimethyl-6,8-disulfobenzo[e]indol-3-ium-2-yl]penta-2,4-dienylidene]-3-ethyl-1,1-dimethyl-8-sulfobenzo[e]indole-6-sulfonate Chemical compound CC1(C)C(C2=CC(=CC(=C2C=C2)S([O-])(=O)=O)S(O)(=O)=O)=C2N(CC)\C1=C/C=C/C=C/C(C(C1=C2C=C(C=C(C2=CC=C11)S(O)(=O)=O)S(O)(=O)=O)(C)C)=[N+]1CCCCCC(=O)ON1C(=O)CCC1=O DOMDXTIMIZCSNC-UHFFFAOYSA-N 0.000 description 2
- BMJRTKDVFXYEFS-XIFFEERXSA-N (2s)-2,6-bis(9h-fluoren-9-ylmethoxycarbonylamino)hexanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(=O)O)CCCCNC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 BMJRTKDVFXYEFS-XIFFEERXSA-N 0.000 description 2
- QVHJQCGUWFKTSE-YFKPBYRVSA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)OC(C)(C)C QVHJQCGUWFKTSE-YFKPBYRVSA-N 0.000 description 2
- UQWNNUPJBDWRHC-UWVGGRQHSA-N (3s,4s)-4-amino-5-cyclohexyl-3-hydroxypentanoic acid Chemical compound OC(=O)C[C@H](O)[C@@H](N)CC1CCCCC1 UQWNNUPJBDWRHC-UWVGGRQHSA-N 0.000 description 2
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
- SNPQRYOQWLOTFA-UHFFFAOYSA-N 2,2-dimethyl-1,3-thiazolidine Chemical compound CC1(C)NCCS1 SNPQRYOQWLOTFA-UHFFFAOYSA-N 0.000 description 2
- JNGRENQDBKMCCR-UHFFFAOYSA-N 2-(3-amino-6-iminoxanthen-9-yl)benzoic acid;hydrochloride Chemical compound [Cl-].C=12C=CC(=[NH2+])C=C2OC2=CC(N)=CC=C2C=1C1=CC=CC=C1C(O)=O JNGRENQDBKMCCR-UHFFFAOYSA-N 0.000 description 2
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 2
- JAJQQUQHMLWDFB-UHFFFAOYSA-N 4-azaniumyl-3-hydroxy-5-phenylpentanoate Chemical compound OC(=O)CC(O)C(N)CC1=CC=CC=C1 JAJQQUQHMLWDFB-UHFFFAOYSA-N 0.000 description 2
- DFVFTMTWCUHJBL-UHFFFAOYSA-N 4-azaniumyl-3-hydroxy-6-methylheptanoate Chemical compound CC(C)CC(N)C(O)CC(O)=O DFVFTMTWCUHJBL-UHFFFAOYSA-N 0.000 description 2
- VWOLRKMFAJUZGM-UHFFFAOYSA-N 6-carboxyrhodamine 6G Chemical compound [Cl-].C=12C=C(C)C(NCC)=CC2=[O+]C=2C=C(NCC)C(C)=CC=2C=1C1=CC(C(O)=O)=CC=C1C(=O)OCC VWOLRKMFAJUZGM-UHFFFAOYSA-N 0.000 description 2
- DJFNQJJTTPMBIL-UHFFFAOYSA-N 7-nitrobenzoxadiazole-6-aminohexanoic acid Chemical compound OC(=O)CCCCCNC1=CC=C([N+]([O-])=O)C2=NON=C12 DJFNQJJTTPMBIL-UHFFFAOYSA-N 0.000 description 2
- FWEOQOXTVHGIFQ-UHFFFAOYSA-N 8-anilinonaphthalene-1-sulfonic acid Chemical compound C=12C(S(=O)(=O)O)=CC=CC2=CC=CC=1NC1=CC=CC=C1 FWEOQOXTVHGIFQ-UHFFFAOYSA-N 0.000 description 2
- WEJVZSAYICGDCK-UHFFFAOYSA-N Alexa Fluor 430 Chemical compound CC[NH+](CC)CC.CC1(C)C=C(CS([O-])(=O)=O)C2=CC=3C(C(F)(F)F)=CC(=O)OC=3C=C2N1CCCCCC(=O)ON1C(=O)CCC1=O WEJVZSAYICGDCK-UHFFFAOYSA-N 0.000 description 2
- 239000012103 Alexa Fluor 488 Substances 0.000 description 2
- WHVNXSBKJGAXKU-UHFFFAOYSA-N Alexa Fluor 532 Chemical compound [H+].[H+].CC1(C)C(C)NC(C(=C2OC3=C(C=4C(C(C(C)N=4)(C)C)=CC3=3)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=C2C=3C(C=C1)=CC=C1C(=O)ON1C(=O)CCC1=O WHVNXSBKJGAXKU-UHFFFAOYSA-N 0.000 description 2
- IGAZHQIYONOHQN-UHFFFAOYSA-N Alexa Fluor 555 Chemical compound C=12C=CC(=N)C(S(O)(=O)=O)=C2OC2=C(S(O)(=O)=O)C(N)=CC=C2C=1C1=CC=C(C(O)=O)C=C1C(O)=O IGAZHQIYONOHQN-UHFFFAOYSA-N 0.000 description 2
- 239000012114 Alexa Fluor 647 Substances 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000006277 CDX2 Transcription Factor Human genes 0.000 description 2
- 108010083123 CDX2 Transcription Factor Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 2
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 2
- 102000003956 Fibroblast growth factor 8 Human genes 0.000 description 2
- OZLGRUXZXMRXGP-UHFFFAOYSA-N Fluo-3 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(Cl)C(=O)C=C3OC3=CC(O)=C(Cl)C=C32)N(CC(O)=O)CC(O)=O)=C1 OZLGRUXZXMRXGP-UHFFFAOYSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 101100175482 Glycine max CG-3 gene Proteins 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102100020873 Interleukin-2 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 238000012313 Kruskal-Wallis test Methods 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
- 206010054949 Metaplasia Diseases 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical compound CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- AWZJFZMWSUBJAJ-UHFFFAOYSA-N OG-514 dye Chemical compound OC(=O)CSC1=C(F)C(F)=C(C(O)=O)C(C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)=C1F AWZJFZMWSUBJAJ-UHFFFAOYSA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 102000003666 Placenta Growth Factor Human genes 0.000 description 2
- 108010082093 Placenta Growth Factor Proteins 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- 239000007984 Tris EDTA buffer Substances 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- APERIXFHHNDFQV-UHFFFAOYSA-N [2-[2-[2-[bis(carboxymethyl)amino]-5-methylphenoxy]ethoxy]-4-[3,6-bis(dimethylamino)xanthen-9-ylidene]cyclohexa-2,5-dien-1-ylidene]-bis(carboxymethyl)azanium;chloride Chemical compound [Cl-].C12=CC=C(N(C)C)C=C2OC2=CC(N(C)C)=CC=C2C1=C(C=1)C=CC(=[N+](CC(O)=O)CC(O)=O)C=1OCCOC1=CC(C)=CC=C1N(CC(O)=O)CC(O)=O APERIXFHHNDFQV-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 108010004469 allophycocyanin Proteins 0.000 description 2
- 229960000473 altretamine Drugs 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 2
- 229960003437 aminoglutethimide Drugs 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 108091005948 blue fluorescent proteins Proteins 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 2
- IDMLRIMDYVWWRJ-UHFFFAOYSA-N calcium crimson Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=CC=C1OCCOC1=CC(NS(=O)(=O)C=2C=C(C(C=3C4=CC=5CCCN6CCCC(C=56)=C4OC4=C5C6=[N+](CCC5)CCCC6=CC4=3)=CC=2)S([O-])(=O)=O)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O IDMLRIMDYVWWRJ-UHFFFAOYSA-N 0.000 description 2
- NMUGYJRMGWBCPU-UHFFFAOYSA-N calcium orange Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C(C(=C1)C([O-])=O)=CC=C1NC(=S)NC(C=1)=CC=C(N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)C=1OCCOC1=CC=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O NMUGYJRMGWBCPU-UHFFFAOYSA-N 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000005773 cancer-related death Effects 0.000 description 2
- 210000004534 cecum Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960004630 chlorambucil Drugs 0.000 description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000001886 ciliary effect Effects 0.000 description 2
- 201000010897 colon adenocarcinoma Diseases 0.000 description 2
- 210000004922 colonic epithelial cell Anatomy 0.000 description 2
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 108010082025 cyan fluorescent protein Proteins 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 238000000295 emission spectrum Methods 0.000 description 2
- 108010045262 enhanced cyan fluorescent protein Proteins 0.000 description 2
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 238000000695 excitation spectrum Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000002189 fluorescence spectrum Methods 0.000 description 2
- 108010021843 fluorescent protein 583 Proteins 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 229960002074 flutamide Drugs 0.000 description 2
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 150000002333 glycines Chemical class 0.000 description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229960004502 levodopa Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- NGCVJRFIBJVSFI-UHFFFAOYSA-I magnesium green Chemical compound [K+].[K+].[K+].[K+].[K+].C1=C(N(CC([O-])=O)CC([O-])=O)C(OCC(=O)[O-])=CC(NC(=O)C=2C=C3C(C4(C5=CC(Cl)=C([O-])C=C5OC5=CC([O-])=C(Cl)C=C54)OC3=O)=CC=2)=C1 NGCVJRFIBJVSFI-UHFFFAOYSA-I 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- MLEBFEHOJICQQS-UHFFFAOYSA-N monodansylcadaverine Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(=O)(=O)NCCCCCN MLEBFEHOJICQQS-UHFFFAOYSA-N 0.000 description 2
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical class CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 238000002887 multiple sequence alignment Methods 0.000 description 2
- SCIFESDRCALIIM-UHFFFAOYSA-N n-methylphenylalanine Chemical compound CNC(C(O)=O)CC1=CC=CC=C1 SCIFESDRCALIIM-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 238000012633 nuclear imaging Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 229960002378 oftasceine Drugs 0.000 description 2
- BRJCLSQFZSHLRL-UHFFFAOYSA-N oregon green 488 Chemical compound OC(=O)C1=CC(C(=O)O)=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 BRJCLSQFZSHLRL-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- VYNDHICBIRRPFP-UHFFFAOYSA-N pacific blue Chemical compound FC1=C(O)C(F)=C2OC(=O)C(C(=O)O)=CC2=C1 VYNDHICBIRRPFP-UHFFFAOYSA-N 0.000 description 2
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 239000013308 plastic optical fiber Substances 0.000 description 2
- 229960003171 plicamycin Drugs 0.000 description 2
- 208000014081 polyp of colon Diseases 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- 229910052724 xenon Inorganic materials 0.000 description 2
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- DNDVHMGBCGSRIY-ZCFIWIBFSA-N (2r)-2-amino-3-(1,3-benzothiazol-2-yl)propanoic acid Chemical compound C1=CC=C2SC(C[C@@H](N)C(O)=O)=NC2=C1 DNDVHMGBCGSRIY-ZCFIWIBFSA-N 0.000 description 1
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 1
- QFQYGJMNIDGZSG-YFKPBYRVSA-N (2r)-3-(acetamidomethylsulfanyl)-2-azaniumylpropanoate Chemical compound CC(=O)NCSC[C@H]([NH3+])C([O-])=O QFQYGJMNIDGZSG-YFKPBYRVSA-N 0.000 description 1
- WBNIBXIBXCPMOW-JTQLQIEISA-N (2s)-2-(ethoxyamino)-3-(4-hydroxyphenyl)propanoic acid Chemical compound CCON[C@H](C(O)=O)CC1=CC=C(O)C=C1 WBNIBXIBXCPMOW-JTQLQIEISA-N 0.000 description 1
- FPDYKABXINADKS-LURJTMIESA-N (2s)-2-(methylazaniumyl)hexanoate Chemical compound CCCC[C@H](NC)C(O)=O FPDYKABXINADKS-LURJTMIESA-N 0.000 description 1
- XQBUAEBDRUXSPI-ZETCQYMHSA-N (2s)-2-(piperidin-1-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NN1CCCCC1 XQBUAEBDRUXSPI-ZETCQYMHSA-N 0.000 description 1
- WTYDPHLGAWMABS-LURJTMIESA-N (2s)-2-(pyrrolidin-1-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NN1CCCC1 WTYDPHLGAWMABS-LURJTMIESA-N 0.000 description 1
- KWIPUXXIFQQMKN-VIFPVBQESA-N (2s)-2-amino-3-(4-cyanophenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(C#N)C=C1 KWIPUXXIFQQMKN-VIFPVBQESA-N 0.000 description 1
- CBNRCFKJVUHIRM-LBPRGKRZSA-N (2s)-2-amino-3-[4-[bis(dimethylaminooxy)phosphoryloxy]phenyl]propanoic acid Chemical compound CN(C)OP(=O)(ON(C)C)OC1=CC=C(C[C@H](N)C(O)=O)C=C1 CBNRCFKJVUHIRM-LBPRGKRZSA-N 0.000 description 1
- SJTPYAOZAPSOLO-REOHCLBHSA-N (2s)-2-hydrazinyl-3-hydroxypropanoic acid Chemical compound NN[C@@H](CO)C(O)=O SJTPYAOZAPSOLO-REOHCLBHSA-N 0.000 description 1
- UTEYHKAJNNCEDX-VIFPVBQESA-N (2s)-3-(4-hydroxyphenyl)-2-(methoxyamino)propanoic acid Chemical compound CON[C@H](C(O)=O)CC1=CC=C(O)C=C1 UTEYHKAJNNCEDX-VIFPVBQESA-N 0.000 description 1
- MCOLRSXARZXGCL-HNNXBMFYSA-N (2s)-3-(4-phenylmethoxyphenyl)-2-(phosphonoamino)propanoic acid Chemical compound C1=CC(C[C@@H](C(=O)O)NP(O)(O)=O)=CC=C1OCC1=CC=CC=C1 MCOLRSXARZXGCL-HNNXBMFYSA-N 0.000 description 1
- ARMHACFUZZJJSF-VIFPVBQESA-N (2s)-3-phenylmethoxy-2-(phosphonoamino)propanoic acid Chemical compound OP(=O)(O)N[C@H](C(=O)O)COCC1=CC=CC=C1 ARMHACFUZZJJSF-VIFPVBQESA-N 0.000 description 1
- XJODGRWDFZVTKW-LURJTMIESA-N (2s)-4-methyl-2-(methylamino)pentanoic acid Chemical compound CN[C@H](C(O)=O)CC(C)C XJODGRWDFZVTKW-LURJTMIESA-N 0.000 description 1
- WCYLQLNJSDTVPN-BQBZGAKWSA-N (2s,3s)-2-amino-n-methoxy-n,3-dimethylpentanamide Chemical compound CC[C@H](C)[C@H](N)C(=O)N(C)OC WCYLQLNJSDTVPN-BQBZGAKWSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- LDXFNKACRSEQND-ULUSZKPHSA-N (5R)-1-azabicyclo[3.1.0]hexane-5-carboxylic acid Chemical compound C1CC[C@@]2(C(=O)O)N1C2 LDXFNKACRSEQND-ULUSZKPHSA-N 0.000 description 1
- IADUEWIQBXOCDZ-VKHMYHEASA-N (S)-azetidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCN1 IADUEWIQBXOCDZ-VKHMYHEASA-N 0.000 description 1
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- BLCJBICVQSYOIF-UHFFFAOYSA-N 2,2-diaminobutanoic acid Chemical compound CCC(N)(N)C(O)=O BLCJBICVQSYOIF-UHFFFAOYSA-N 0.000 description 1
- OMGHIGVFLOPEHJ-UHFFFAOYSA-N 2,5-dihydro-1h-pyrrol-1-ium-2-carboxylate Chemical compound OC(=O)C1NCC=C1 OMGHIGVFLOPEHJ-UHFFFAOYSA-N 0.000 description 1
- PRSWALMQXKFZFA-UHFFFAOYSA-N 2-(piperidin-1-ylamino)acetic acid Chemical compound OC(=O)CNN1CCCCC1 PRSWALMQXKFZFA-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- ICBKJQDJWHBQAX-UHFFFAOYSA-N 2-aminooxane-4-carboxylic acid Chemical compound NC1CC(C(O)=O)CCO1 ICBKJQDJWHBQAX-UHFFFAOYSA-N 0.000 description 1
- VRFJLUHAQPBTLE-UHFFFAOYSA-N 2-aminopiperidine-1-carboxylic acid Chemical compound NC1CCCCN1C(O)=O VRFJLUHAQPBTLE-UHFFFAOYSA-N 0.000 description 1
- WTOFYLAWDLQMBZ-UHFFFAOYSA-N 2-azaniumyl-3-thiophen-2-ylpropanoate Chemical compound OC(=O)C(N)CC1=CC=CS1 WTOFYLAWDLQMBZ-UHFFFAOYSA-N 0.000 description 1
- CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-n-methyl-1,3,5-triazine-2,4,6-triamine Chemical compound CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 description 1
- RUJDFARUCNPRBA-UHFFFAOYSA-N 3',6'-dihydroxy-2',4',5',7'-tetraiodo-6-isothiocyanatospiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 RUJDFARUCNPRBA-UHFFFAOYSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- YHFKJGZDKILHTL-UHFFFAOYSA-N 3-(aminomethyl)-1h-pyrrole-2-carboxylic acid Chemical compound NCC=1C=CNC=1C(O)=O YHFKJGZDKILHTL-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 1
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical group Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- DKIDEFUBRARXTE-UHFFFAOYSA-N 3-mercaptopropanoic acid Chemical class OC(=O)CCS DKIDEFUBRARXTE-UHFFFAOYSA-N 0.000 description 1
- LLTDOAPVRPZLCM-UHFFFAOYSA-O 4-(7,8,8,16,16,17-hexamethyl-4,20-disulfo-2-oxa-18-aza-6-azoniapentacyclo[11.7.0.03,11.05,9.015,19]icosa-1(20),3,5,9,11,13,15(19)-heptaen-12-yl)benzoic acid Chemical compound CC1(C)C(C)NC(C(=C2OC3=C(C=4C(C(C(C)[NH+]=4)(C)C)=CC3=3)S(O)(=O)=O)S(O)(=O)=O)=C1C=C2C=3C1=CC=C(C(O)=O)C=C1 LLTDOAPVRPZLCM-UHFFFAOYSA-O 0.000 description 1
- XWHHYOYVRVGJJY-QMMMGPOBSA-N 4-fluoro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(F)C=C1 XWHHYOYVRVGJJY-QMMMGPOBSA-N 0.000 description 1
- GTVVZTAFGPQSPC-UHFFFAOYSA-N 4-nitrophenylalanine Chemical compound OC(=O)C(N)CC1=CC=C([N+]([O-])=O)C=C1 GTVVZTAFGPQSPC-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- JGZVUTYDEVUNMK-UHFFFAOYSA-N 5-carboxy-2',7'-dichlorofluorescein Chemical compound C12=CC(Cl)=C(O)C=C2OC2=CC(O)=C(Cl)C=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 JGZVUTYDEVUNMK-UHFFFAOYSA-N 0.000 description 1
- NJYVEMPWNAYQQN-UHFFFAOYSA-N 5-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 NJYVEMPWNAYQQN-UHFFFAOYSA-N 0.000 description 1
- LLENVBUPWUQAGL-UHFFFAOYSA-N 6,8-difluoro-7-hydroxy-4-methylcoumarin Chemical compound FC1=C(O)C(F)=CC2=C1OC(=O)C=C2C LLENVBUPWUQAGL-UHFFFAOYSA-N 0.000 description 1
- HWQQCFPHXPNXHC-UHFFFAOYSA-N 6-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=CC=2)OC(=O)C1=CC=2NC1=NC(Cl)=NC(Cl)=N1 HWQQCFPHXPNXHC-UHFFFAOYSA-N 0.000 description 1
- WVLHHJGFWORTSI-UHFFFAOYSA-N 6-carboxy-2',4,7,7'-tetrachlorofluorescein succinimiyl ester Chemical compound C1=2C=C(Cl)C(O)=CC=2OC2=CC(O)=C(Cl)C=C2C21OC(=O)C(C(=C1)Cl)=C2C(Cl)=C1C(=O)ON1C(=O)CCC1=O WVLHHJGFWORTSI-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 108700001666 APC Genes Proteins 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000012109 Alexa Fluor 568 Substances 0.000 description 1
- 239000012111 Alexa Fluor 610 Substances 0.000 description 1
- 239000012115 Alexa Fluor 660 Substances 0.000 description 1
- 239000012116 Alexa Fluor 680 Substances 0.000 description 1
- 239000012117 Alexa Fluor 700 Substances 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- 102100022987 Angiogenin Human genes 0.000 description 1
- 102000009840 Angiopoietins Human genes 0.000 description 1
- 108010009906 Angiopoietins Proteins 0.000 description 1
- 101001010152 Aplysia californica Probable glutathione transferase Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000023514 Barrett esophagus Diseases 0.000 description 1
- 208000023665 Barrett oesophagus Diseases 0.000 description 1
- 108010081589 Becaplermin Proteins 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000004225 Cathepsin B Human genes 0.000 description 1
- 108090000712 Cathepsin B Proteins 0.000 description 1
- 102100021391 Cationic amino acid transporter 3 Human genes 0.000 description 1
- 108010008951 Chemokine CXCL12 Proteins 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- 108091005960 Citrine Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- BRDJPCFGLMKJRU-UHFFFAOYSA-N DDAO Chemical compound ClC1=C(O)C(Cl)=C2C(C)(C)C3=CC(=O)C=CC3=NC2=C1 BRDJPCFGLMKJRU-UHFFFAOYSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 108010002156 Depsipeptides Proteins 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 102000012545 EGF-like domains Human genes 0.000 description 1
- 108050002150 EGF-like domains Proteins 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 101800004490 Endothelin-1 Proteins 0.000 description 1
- 102400000686 Endothelin-1 Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- NIGWMJHCCYYCSF-UHFFFAOYSA-N Fenclonine Chemical compound OC(=O)C(N)CC1=CC=C(Cl)C=C1 NIGWMJHCCYYCSF-UHFFFAOYSA-N 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 102100028412 Fibroblast growth factor 10 Human genes 0.000 description 1
- 108090001047 Fibroblast growth factor 10 Proteins 0.000 description 1
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 description 1
- 102000003969 Fibroblast growth factor 4 Human genes 0.000 description 1
- 102000003967 Fibroblast growth factor 5 Human genes 0.000 description 1
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 description 1
- 102000003968 Fibroblast growth factor 6 Human genes 0.000 description 1
- 108090000382 Fibroblast growth factor 6 Proteins 0.000 description 1
- 102100037665 Fibroblast growth factor 9 Human genes 0.000 description 1
- 108090000367 Fibroblast growth factor 9 Proteins 0.000 description 1
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 1
- 206010061968 Gastric neoplasm Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 101001023784 Heteractis crispa GFP-like non-fluorescent chromoprotein Proteins 0.000 description 1
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 1
- 101000871708 Homo sapiens Proheparin-binding EGF-like growth factor Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 102000003815 Interleukin-11 Human genes 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 102000049772 Interleukin-16 Human genes 0.000 description 1
- 101800003050 Interleukin-16 Proteins 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102000000585 Interleukin-9 Human genes 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 102100020880 Kit ligand Human genes 0.000 description 1
- 101710177504 Kit ligand Proteins 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-YGVKFDHGSA-N L-methionine S-oxide Chemical compound CS(=O)CC[C@H](N)C(O)=O QEFRNWWLZKMPFJ-YGVKFDHGSA-N 0.000 description 1
- UCUNFLYVYCGDHP-BYPYZUCNSA-N L-methionine sulfone Chemical compound CS(=O)(=O)CC[C@H](N)C(O)=O UCUNFLYVYCGDHP-BYPYZUCNSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 1
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102100026933 Myelin-associated neurite-outgrowth inhibitor Human genes 0.000 description 1
- OLYPWXRMOFUVGH-LURJTMIESA-N N(2)-methyl-L-lysine Chemical compound CN[C@H](C(O)=O)CCCCN OLYPWXRMOFUVGH-LURJTMIESA-N 0.000 description 1
- MXNRLFUSFKVQSK-QMMMGPOBSA-O N(6),N(6),N(6)-trimethyl-L-lysine Chemical compound C[N+](C)(C)CCCC[C@H]([NH3+])C([O-])=O MXNRLFUSFKVQSK-QMMMGPOBSA-O 0.000 description 1
- RYFOQDQDVYIEHN-ZETCQYMHSA-N N,N-Dimethyllysine Chemical compound CN(C)[C@H](C(O)=O)CCCCN RYFOQDQDVYIEHN-ZETCQYMHSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- KSPIYJQBLVDRRI-WDSKDSINSA-N N-methyl-L-isoleucine Chemical compound CC[C@H](C)[C@H](NC)C(O)=O KSPIYJQBLVDRRI-WDSKDSINSA-N 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
- 108090000742 Neurotrophin 3 Proteins 0.000 description 1
- 102100029268 Neurotrophin-3 Human genes 0.000 description 1
- 102000003683 Neurotrophin-4 Human genes 0.000 description 1
- 108090000099 Neurotrophin-4 Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- CIQHWLTYGMYQQR-QMMMGPOBSA-N O(4')-sulfo-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(OS(O)(=O)=O)C=C1 CIQHWLTYGMYQQR-QMMMGPOBSA-N 0.000 description 1
- 108010064527 OSM-LIF Receptors Proteins 0.000 description 1
- 102000015278 OSM-LIF Receptors Human genes 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 101710164680 Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 101710103506 Platelet-derived growth factor subunit A Proteins 0.000 description 1
- 102100037596 Platelet-derived growth factor subunit A Human genes 0.000 description 1
- 102100040990 Platelet-derived growth factor subunit B Human genes 0.000 description 1
- 101710103494 Platelet-derived growth factor subunit B Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- 102100033762 Proheparin-binding EGF-like growth factor Human genes 0.000 description 1
- 101710151715 Protein 7 Proteins 0.000 description 1
- 101710150593 Protein beta Proteins 0.000 description 1
- 101710179016 Protein gamma Proteins 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 description 1
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 description 1
- 108091008103 RNA aptamers Proteins 0.000 description 1
- 101500026849 Rattus norvegicus C3a anaphylatoxin Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 108091006230 SLC7A3 Proteins 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 238000011869 Shapiro-Wilk test Methods 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 102000004584 Somatomedin Receptors Human genes 0.000 description 1
- 108010017622 Somatomedin Receptors Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102100031372 Thymidine phosphorylase Human genes 0.000 description 1
- 108700023160 Thymidine phosphorylases Proteins 0.000 description 1
- GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000011117 Transforming Growth Factor beta2 Human genes 0.000 description 1
- 101800000304 Transforming growth factor beta-2 Proteins 0.000 description 1
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 description 1
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 1
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 1
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 1
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 102000004504 Urokinase Plasminogen Activator Receptors Human genes 0.000 description 1
- 108010042352 Urokinase Plasminogen Activator Receptors Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 108010072788 angiogenin Proteins 0.000 description 1
- RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical class C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940045687 antimetabolites folic acid analogs Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 239000005667 attractant Substances 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical class N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- AMKVJCBQCWSOLQ-UHFFFAOYSA-H calcium green 1 Chemical compound [K+].[K+].[K+].[K+].[K+].[K+].[O-]C(=O)CN(CC([O-])=O)C1=CC=CC=C1OCCOC1=CC(NC(=O)C=2C=C3C(C4(C5=CC(Cl)=C([O-])C=C5OC5=CC([O-])=C(Cl)C=C54)OC3=O)=CC=2)=CC=C1N(CC([O-])=O)CC([O-])=O AMKVJCBQCWSOLQ-UHFFFAOYSA-H 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 239000012578 cell culture reagent Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000031902 chemoattractant activity Effects 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000011035 citrine Substances 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
- 201000011024 colonic benign neoplasm Diseases 0.000 description 1
- 230000008984 colonic lesion Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000000942 confocal micrograph Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- GLNDAGDHSLMOKX-UHFFFAOYSA-N coumarin 120 Chemical compound C1=C(N)C=CC2=C1OC(=O)C=C2C GLNDAGDHSLMOKX-UHFFFAOYSA-N 0.000 description 1
- JLYVRXJEQTZZBE-UHFFFAOYSA-N ctk1c6083 Chemical compound NP(N)(N)=S JLYVRXJEQTZZBE-UHFFFAOYSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- MYLMURYPGCSIQM-UHFFFAOYSA-N dapoxyl (2-aminoethyl)sulfonamide Chemical compound C1=CC(N(C)C)=CC=C1C1=CN=C(C=2C=CC(=CC=2)S(=O)(=O)NCCN)O1 MYLMURYPGCSIQM-UHFFFAOYSA-N 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- ADFOJJHRTBFFOF-RBRWEJTLSA-N estramustine phosphate Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 ADFOJJHRTBFFOF-RBRWEJTLSA-N 0.000 description 1
- 229960004750 estramustine phosphate Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229940098448 fibroblast growth factor 7 Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229960005304 fludarabine phosphate Drugs 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 229960001751 fluoxymesterone Drugs 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 238000011773 genetically engineered mouse model Methods 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical class C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000055691 human APC Human genes 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 208000017819 hyperplastic polyp Diseases 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 102000028416 insulin-like growth factor binding Human genes 0.000 description 1
- 108091022911 insulin-like growth factor binding Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- XJENLUNLXRJLEZ-UHFFFAOYSA-M lissamine rhodamine Chemical compound [Na+].C=12C=C(C)C(N(CC)CC)=CC2=[O+]C=2C=C(N(CC)CC)C(C)=CC=2C=1C1=CC=C(S([O-])(=O)=O)C=C1S([O-])(=O)=O XJENLUNLXRJLEZ-UHFFFAOYSA-M 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- SHXOKQKTZJXHHR-UHFFFAOYSA-N n,n-diethyl-5-iminobenzo[a]phenoxazin-9-amine;hydrochloride Chemical compound [Cl-].C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=[NH2+])C2=C1 SHXOKQKTZJXHHR-UHFFFAOYSA-N 0.000 description 1
- KRKPYFLIYNGWTE-UHFFFAOYSA-N n,o-dimethylhydroxylamine Chemical compound CNOC KRKPYFLIYNGWTE-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 229940032018 neurotrophin 3 Drugs 0.000 description 1
- 229940097998 neurotrophin 4 Drugs 0.000 description 1
- VOFUROIFQGPCGE-UHFFFAOYSA-N nile red Chemical compound C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=O)C2=C1 VOFUROIFQGPCGE-UHFFFAOYSA-N 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 239000003956 nonsteroidal anti androgen Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000012634 optical imaging Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- 238000012831 peritoneal equilibrium test Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 108010000685 platelet-derived growth factor AB Proteins 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000012636 positron electron tomography Methods 0.000 description 1
- 238000012877 positron emission topography Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 210000004777 protein coat Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 238000006862 quantum yield reaction Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- MYFATKRONKHHQL-UHFFFAOYSA-N rhodamine 123 Chemical compound [Cl-].COC(=O)C1=CC=CC=C1C1=C2C=CC(=[NH2+])C=C2OC2=CC(N)=CC=C21 MYFATKRONKHHQL-UHFFFAOYSA-N 0.000 description 1
- XLXOKMFKGASILN-UHFFFAOYSA-N rhodamine red-X Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(=O)(=O)NCCCCCC(O)=O)C=C1S([O-])(=O)=O XLXOKMFKGASILN-UHFFFAOYSA-N 0.000 description 1
- 108700038288 rhodamine-phalloidin Proteins 0.000 description 1
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 1
- 102200076454 rs104894848 Human genes 0.000 description 1
- 239000010979 ruby Substances 0.000 description 1
- 229910001750 ruby Inorganic materials 0.000 description 1
- 229910052594 sapphire Inorganic materials 0.000 description 1
- 239000010980 sapphire Substances 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 229940055619 selenocysteine Drugs 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 235000016491 selenocysteine Nutrition 0.000 description 1
- 238000011894 semi-preparative HPLC Methods 0.000 description 1
- 229960003440 semustine Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- ZSOMPVKQDGLTOT-UHFFFAOYSA-J sodium green Chemical compound C[N+](C)(C)C.C[N+](C)(C)C.C[N+](C)(C)C.C[N+](C)(C)C.COC=1C=C(NC(=O)C=2C=C(C(=CC=2)C2=C3C=C(Cl)C(=O)C=C3OC3=CC([O-])=C(Cl)C=C32)C([O-])=O)C(OC)=CC=1N(CCOCC1)CCOCCOCCN1C(C(=C1)OC)=CC(OC)=C1NC(=O)C1=CC=C(C2=C3C=C(Cl)C(=O)C=C3OC3=CC([O-])=C(Cl)C=C32)C(C([O-])=O)=C1 ZSOMPVKQDGLTOT-UHFFFAOYSA-J 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- COIVODZMVVUETJ-UHFFFAOYSA-N sulforhodamine 101 Chemical compound OS(=O)(=O)C1=CC(S([O-])(=O)=O)=CC=C1C1=C(C=C2C3=C4CCCN3CCC2)C4=[O+]C2=C1C=C1CCCN3CCCC2=C13 COIVODZMVVUETJ-UHFFFAOYSA-N 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 229960001712 testosterone propionate Drugs 0.000 description 1
- QOFZZTBWWJNFCA-UHFFFAOYSA-N texas red-X Chemical compound [O-]S(=O)(=O)C1=CC(S(=O)(=O)NCCCCCC(=O)O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 QOFZZTBWWJNFCA-UHFFFAOYSA-N 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 229940072041 transforming growth factor beta 2 Drugs 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 229960001099 trimetrexate Drugs 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000006663 ubiquitin-proteasome pathway Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 238000011311 validation assay Methods 0.000 description 1
- 238000012418 validation experiment Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 1
- ORQXBVXKBGUSBA-QMMMGPOBSA-N β-cyclohexyl-alanine Chemical compound OC(=O)[C@@H](N)CC1CCCCC1 ORQXBVXKBGUSBA-QMMMGPOBSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0039—Coumarin dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
- A61K49/0043—Fluorescein, used in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Definitions
- the present invention is directed to peptide reagents, methods for detecting colon pre-cancer (dysplasia with non-polypoid or polypoid morphology) or cancer using the peptide reagents, and methods for targeting pre-cancerous or cancerous colon cells using the peptide reagents.
- Colorectal cancer is one of the most common causes of cancer-related deaths in the world. In 2009, there were more than 146,000 new cases of colorectal cancer diagnosed, and colorectal cancer was the cause of nearly one out of every five cancer-related deaths in the United States. Jemal et al, CA Cancer J Clin, 59:225-49 (2009). White light colonoscopy is currently the primary method for performing colorectal cancer screening. This technique is sensitive to morphological changes in the mucosa, such as polyps and masses. However, this method is not sensitive to the detection of flat and depressed lesions, and the polyp miss rates can be as high as 22%. van Rijn et al., Am J Gastroenterol.
- Adenomatous polyps or adenomas, appear to be major precursors to CRC, even though only a fraction of adenomas progress to CRC.
- the transformation from pre-malignant mucosa to carcinoma occurs over a period of many years, thus providing window of opportunity for early detection.
- the presence of flat dysplastic lesions in the setting of chronic ulcerative colitis presents a significantly increased risk for the development of frank carcinoma.
- adenomatous polyposis coli (APC) gene are likely to be critical events in the initiation of the majority of adenomas and CRC.
- Previously-reported genetically engineered mouse models that mimic human APC gene mutations mainly develop adenomas in the small intestine (e.g., APC Min model> Su gt al > Science 256(5057):668-670 (1992)), not the distal colon, making it difficult to image the polyps and their progression in vivo using currently available small animal endoscopy tools.
- Hinoi et al., Cancer Res., 67(20): 9721-9730 (2007) describes genetically engineered mice (termed CPC:Apc mice) in which a somatic mutation in an Ape allele leads to a truncated Ape protein and causes the development of adenomas in the distal colon as early as 10 weeks.
- Others have developed mouse models that grow tumors in the distal colon using implantation of cancerous cells [Alencar et al., Radiology, 244: 232-238 (2007)] or adenovirus activated mutations [Hung et al., Proc. Natl. Acad. Sci. USA, 107: 1565-1570 (2010)] and report binding of cathepsin B smart probes, but surgical intervention was needed to generate polyps and the ensuing response to injury may have resulted in target alteration.
- Endoscopic imaging with use of exogenous fluorescent-labeled probes is a promising method for achieving greater specificity in the detection of neoplastic lesions by identifying the expression of unique molecular targets. Imaging provides precise
- RNA aptamers represent a new class of imaging agent that is compatible with clinical use in the digestive tract, in particular with topical administration.
- Phage display is a powerful combinatorial technique for peptide discovery that uses methods of recombinant DNA technology to generate a complex library of peptides, often expressing up to 107-109 unique sequences, that can bind to cell surface antigens.
- the DNA of candidate phages can be recovered and sequenced, elucidating positive binding peptides that can then be synthetically fabricated.
- Phage display identified peptide binders to high grade dysplasia in Barrett's esophagus [Li et al., Gastroenterology, 139: 1472-80 (2010)] and human colonic dysplasia [Hsiung et al., Nat. Med., 14: 454-458 (2008)] using the
- NEB Ml 3 phage system commercially available NEB Ml 3 phage system.
- the T7 system has proven effective in in vivo panning experiments identifying peptides specific to pancreatic islet vasculature [Joyce et al., Cancer Cell, 4: 393-403 (2003)], breast vasculature [Essler and Ruoslahti, Proc. Natl. Acad. Sci. USA, 99: 2252-2257 (2002)] , bladder tumor cells [Lee et al., Mol. Cancer Res., 5(1): 11-19 (2007)], and liver tissue [Ludtke et al., Drug Deliv., 14: 357-369 (2007)] .
- Panning with intact tissue presents additional relevant cell targets while accounting for subtle features in the tissue microenvironment that may affect binding.
- Transformed cells and tissues express molecular changes well in advance of gross morphological changes, thus providing a unique opportunity for the early detection of cancer.
- Peptides that bind to pre-cancerous colorectal lesions have the potential to guide tissue biopsy for lesions that are endoscopically "invisible,” and such peptides can be isolated using combinatorial phage display screening. Peptides have in vivo advantages in the
- gastrointestinal tract because they can be delivered topically to identify early molecular changes on the surface of epithelial cells located on the most superficial layer of mucosa where cancer originates. In addition, they can exhibit rapid binding kinetics and also diffuse into diseased mucosa.
- the invention provides peptides that bind to dysplastic colon cells and/or cancerous colon cells.
- peptides that bind to dysplastic colon cells and/or cancerous colon cells. Examples of peptides provided are
- NGTTSSNNQLINENNIQN (SEQ ID NO: 3), EHMYNTPHTYHTTMKNNK (SEQ ID NO: 4), QPIHPNNM (SEQ ID NO: 1), NKLAAALE (SEQ ID NO: 5), KNYKN (SEQ ID NO: 6), TNTHN (SEQ ID NO: 7) and KHTNN (SEQ ID NO: 8).
- SILPYPY SEQ ID NO: 9
- KCCFPAQ SEQ ID NO: 2
- YRAPWPP SEQ ID NO: 10
- QPWPTSI SEQ ID NO: 11
- WPTPPYA SEQ ID NO: 12
- MHAPPFY SEQ ID NO: 13
- VRPTLPM SEQ ID NO: 22, NFMES LPRLGMH (SEQ ID NO: 23), HYKL (SEQ ID NO: 24)
- a reagent comprising a peptide consisting of an amino acid sequence selected from NGTTSSNNQLINENNIQN (SEQ ID NO: 3), EHMYNTPHTYHTTMKNNK (SEQ ID NO: 4), QPIHPNNM (SEQ ID NO: 1), NKLAAALE (SEQ ID NO: 5), KNYKN (SEQ ID NO: 6), TNTHN (SEQ ID NO: 7), KHTNN (SEQ ID NO: 8), SILPYPY (SEQ ID NO: 9), KCCFPAQ (SEQ ID NO: 2), YRAPWPP (SEQ ID NO: 10), QPWPTSI (SEQ ID NO: 11), WPTPPYA (SEQ ID NO: 12), MHAPPFY (SEQ ID NO: 13), VRPTLPM (SEQ ID NO: 22,
- NFMES LPRLGMH SEQ ID NO: 23
- HYKL SEQ ID NO: 24
- AKPGYLS SEQ ID NO: 25
- LTTHKYL SEQ ID NO: 26
- the disclosure further provides a peptide consisting of an amino acid sequence selected from NGTTSSNNQLINENNIQN (SEQ ID NO: 3), EHMYNTPHTYHTTMKNNK (SEQ ID NO: 4), QPIHPNNM (SEQ ID NO: 1),
- NKLAAALE (SEQ ID NO: 5), KNYKN (SEQ ID NO: 6), TNTHN (SEQ ID NO: 7), KHTNN (SEQ ID NO: 8), SILPYPY (SEQ ID NO: 9), KCCFPAQ (SEQ ID NO: 2), YRAPWPP (SEQ ID NO: 10), QPWPTSI (SEQ ID NO: 11), WPTPPYA (SEQ ID NO: 12), MHAPPFY (SEQ ID NO: 13), VRPTLPM (SEQ ID NO: 22, NFMESLPRLGMH (SEQ ID NO: 23), HYKL (SEQ ID NO: 24), AKPGYLS (SEQ ID NO: 25), and LTTHKYL (SEQ ID NO: 26). Also provided is a reagent comprising a peptide consisting essentially of an amino acid sequence selected from NGTTSSNNQLINENNIQN (SEQ ID NO: 3),
- EHMYNTPHTYHTTMKNNK (SEQ ID NO: 4), QPIHPNNM (SEQ ID NO: 1),
- NKLAAALE SEQ ID NO: 5
- KNYKN SEQ ID NO: 6
- TNTHN SEQ ID NO: 7
- KHTNN SEQ ID NO: 8
- SILPYPY SEQ ID NO: 9
- KCCFPAQ SEQ ID NO: 2
- YRAPWPP SEQ ID NO: 10
- QPWPTSI SEQ ID NO: 11
- WPTPPYA SEQ ID NO: 12
- MHAPPFY SEQ ID NO: 13
- a peptide is also provided consisting essentially of an amino acid sequence selected from NGTTSSNNQLINENNIQN (SEQ ID NO: 3), EHMYNTPHTYHTTMKNNK (SEQ ID NO: 4), QPIHPNNM (SEQ ID NO: 1), NKLAAALE (SEQ ID NO: 5), KNYKN (SEQ ID NO: 6), TNTHN (SEQ ID NO: 7), KHTNN (SEQ ID NO: 8), SILPYPY (SEQ ID NO: 9), KCCFPAQ (SEQ ID NO: 2), YRAPWPP (SEQ ID NO: 10), QPWPTSI (SEQ ID NO: 11), WPTPPYA (SEQ ID NO: 12), MHAPPFY (SEQ ID NO: 13), VRPTLPM (SEQ ID NO: 22, NFMESLPRLGMH (SEQ ID NO: 23), HYKL (SEQ ID NO: 24), AKPGYLS (SEQ ID NO: 25), and LTTHKYL (SEQ
- a reagent comprising a peptide comprising an amino acid sequence selected from NGTTSSNNQLINENNIQN (SEQ ID NO: 3), EHMYNTPHTYHTTMKNNK (SEQ ID NO: 4), QPIHPNNM (SEQ ID NO: 1), NKLAAALE (SEQ ID NO: 5), KNYKN (SEQ ID NO: 6), TNTHN (SEQ ID NO: 7), KHTNN (SEQ ID NO: 8), SILPYPY (SEQ ID NO: 9), KCCFPAQ (SEQ ID NO: 2), YRAPWPP (SEQ ID NO: 10), QPWPTSI (SEQ ID NO: 11), WPTPPYA (SEQ ID NO: 12), MHAPPFY (SEQ ID NO: 13), VRPTLPM (SEQ ID NO: 22, NFMESLPRLGMH (SEQ ID NO: 23), HYKL (SEQ ID NO: 24), AKPGYLS (SEQ ID NO: 25), and LTTHKY
- a peptide comprising an amino acid sequence selected from NGTTSSNNQLINENNIQN (SEQ ID NO: 3), EHMYNTPHTYHTTMKNNK (SEQ ID NO: 4), QPIHPNNM (SEQ ID NO: 1), NKLAAALE (SEQ ID NO: 5), KNYKN (SEQ ID NO: 6), TNTHN (SEQ ID NO: 7), KHTNN (SEQ ID NO: 8), SILPYPY (SEQ ID NO: 9), KCCFPAQ (SEQ ID NO: 2), YRAPWPP (SEQ ID NO: 10), QPWPTSI (SEQ ID NO: 11), WPTPPYA (SEQ ID NO: 12), MHAPPFY (SEQ ID NO: 13), VRPTLPM (SEQ ID NO: 22, NFMESLPRLGMH (SEQ ID NO: 23), HYKL (SEQ ID NO: 24), AKPGYLS (SEQ ID NO: 25), and LTTHKYL (SEQ ID NO: 3
- the invention provides reagents comprising a peptide of the invention.
- the reagents comprise a detectable label attached to a peptide of the invention.
- the detectable label may be detectable, for example, by
- microscopy ultrasound, PET, SPECT, or magnetic resonance imaging.
- the label detectable by microscopy is fluorescein isothiocyanate (FITC), 7- diethylaminocoumarin-3-carboxylic acid (DEAC), CF-633 or 5- carboxytetramethylrhodamine (TAMRA) .
- FITC fluorescein isothiocyanate
- DEAC 7- diethylaminocoumarin-3-carboxylic acid
- TAMRA 5- carboxytetramethylrhodamine
- a detectable label is attached to a peptide of the invention by a peptide linker.
- the terminal amino acid of the linker by be a lysine such as in the exemplary linker GGGSK (SEQ ID NO: 14).
- the linker is an Ahx linker, an amino terminal linker comprising 6-amino hexanoic acid.
- the reagents comprise a therapeutic moiety attached to a peptide of the invention.
- the therapeutic moiety may be a chemopreventative or
- the therapeutic moiety is celecoxib, 5- fluorouracil, and/or chlorambucil.
- the invention provides a composition comprising a reagent of the invention and a pharmaceutically acceptable excipient.
- the invention provides a method for detecting colon dysplasia in a patient comprising the steps of administering a reagent comprising a peptide of the invention attached to a detectable label to the colon of the patient and detecting binding of the reagent to dysplastic cells.
- the detectable binding takes place in vivo.
- the detectable binding takes places in vitro.
- the detectable binding takes place in situ.
- the transformation from pre-malignant mucosa to carcinoma involves the development of flat and depressed (non-polypoid) lesions, adenomatous polyps (polypoid lesions) and then frank carcinoma (colon cancer cells).
- Detecting colon dysplasia includes detecting binding to flat and depressed lesions, adenomatous polyps and/or cancer cells.
- a reagent of the invention specifically detects cells of flat and depressed lesions.
- a reagent of the invention specifically detects cells of adenomatous polyps.
- a reagent of the invention specifically detects colon cancer cells.
- a reagent of the invention may specifically detect two or more of cells of flat and depressed lesions, cells of adenomatous polyps and colon cancer cells.
- the phrase "specifically detects” means that the reagent binds to and is detected in association with a type of cell, and the reagent does not bind to and is not detected in association with another type of cell at the level of sensitivity at which the method is carried out.
- Flat dysplastic lesions are also observed in the setting of chronic ulcerative colitis and are also contemplated to be detectable by methods of the invention.
- the invention provides a method of determining the effectiveness of a treatment for colon cancer and/or cancer metastasis, or recurrence of cancer in a patient comprising the step of administering a reagent comprising a peptide of the invention attached to a detectable label to the colon of the patient, visualizing a first amount of cells labeled with the reagent, and comparing the first amount to a previously- visualized second amount of cells labeled with the reagent, wherein a decrease in the first amount cells labeled relative to the previously- visualized second amount of cells labeled is indicative of effective treatment. In some embodiments, a decrease of 5% is indicative of effective treatment.
- a decrease of about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95% or more is indicative of effective treatment.
- the method further comprises obtaining a biopsy of the cells labeled by the reagent.
- the invention provides a method for delivering a therapeutic agent to dysplastic colon cells of a patient comprising the step of administering a reagent comprising a peptide of the invention attached to a therapeutic moiety to the patient.
- the invention provides a method for delivering a therapeutic agent to colon cancer cells of a patient comprising the step of administering a reagent comprising a peptide of the invention attached to a therapeutic moiety to the patient.
- the invention provides a kit for administering a composition of the invention to a patient in need thereof, where the kit comprises a composition of invention, instructions for use of the composition and a device for administering the composition to the patient.
- a "linker” is a sequence of amino acids, generally uncharged, located at a terminus of a polypeptide of the disclosure. In some embodiments, the linker sequence terminates with a lysine residue. Uncharged amino acids contemplated by the present disclosure include, but are not limited to, glycine, serine, cysteine, threonine, histidine, tyrosine, asparagine, and glutamine.
- the presence of a linker results in at least a 1% increase in detectable binding of a reagent of the invention to dysplastic colon cells or cancerous colon cells compared to the detectable binding of the reagent in the absence of the linker.
- the increase in detectable binding is at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, at least about 2-fold, at least about 3- fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold
- peptide refers to molecules of 2 to 50 amino acids, molecules of 3 to 20 amino acids, and those of 6 to 15 amino acids.
- Peptides and linkers as contemplated by the invention may be 5 amino acids in length.
- a polypeptide or linker may be 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or more amino acids in length.
- Exemplary peptides are, in various aspects, randomly generated by methods known in the art, carried in a polypeptide library (for example and without limitation, a phage display library), derived by digestion of proteins, or chemically synthesized.
- a polypeptide library for example and without limitation, a phage display library
- Peptides exemplified in the present disclosure have been developed using techniques of phage display, a powerful combinatorial method that uses recombinant DNA technology to generate a complex library of polypeptides for selection by preferential binding to cell surface targets [Scott et al., Science, 249:386-390 (1990)].
- the protein coat of bacteriophage such as the filamentous M13 or icosahedral T7, is genetically engineered to express a very large number (>10 9 ) of different polypeptides with unique sequences to achieve affinity binding [Cwirla et al, Proc. Natl. Acad. Sci. USA, 87:6378-6382 (1990)]. Selection is then performed by biopanning the phage library against cultured cells and tissues that over express the target. The DNA sequences of these candidate phage are then recovered and used to synthesize the polypeptide [Pasqualini et al., Nature, 380:364-366 (1996)].
- the polypeptides that preferentially bind to dysplastic mucosa are optionally labeled with fluorescence dyes, including but not limited to, FITC, Cy 5.5, Cy 7, and Li-Cor. These polypeptide-dye reagents have been developed and have demonstrated preferential binding to colon cancer (HT29) cells in culture and to pre-clinical xenograft models [Kelly et al., Cancer Res., (54:6247-51 (2004)].
- Peptides include D and L forms, either purified or in a mixture of the two forms. Also contemplated by the present disclosure are peptides that compete with peptides of the invention for binding to colon cells.
- a peptide of a reagent of the invention is presented in multimer form.
- Various scaffolds are known in the art upon which multiple peptides can be presented.
- peptide AKPGYLS SEQ ID NO: 25
- Other scaffolds known in the art include, but are not limited to, other dendrimers and polymeric (e.g., PEG) scaffolds.
- the compound is a peptide analog having a structure based on one of the peptides disclosed herein (the "parent peptide") but differs from the parent peptide in one or more respects. Accordingly, as appreciated by one of ordinary skill in the art, the teachings regarding the parent peptides provided herein may also be applicable the peptide analogs.
- the peptide analog comprises the structure of a parent peptide, except that the peptide analog comprises one or more non-peptide bonds in place of peptide bond(s). In some embodiments, the peptide analog comprises in place of a peptide bond, an ester bond, an ether bond, a thioether bond, an amide bond, and the like. In some embodiments, the peptide analog is a depsipeptide comprising an ester linkage in place of a peptide bond.
- the peptide analog comprises the structure of a parent peptide described herein, except that the peptide analog comprises one or more amino acid substitutions, e.g., one or more conservative amino acid substitutions.
- Conservative amino acid substitutions are known in the art, and include amino acid substitutions in which one amino acid having certain physical and/or chemical properties is exchanged for another amino acid that has the same chemical or physical properties.
- the conservative ammo acid substitution may be an acidic amino acid substituted for another acidic amino acid (e.g., Asp or Glu), an amino acid with a nonpolar side chain substituted for another amino acid with a nonpolar side chain (e.g., Ala, Gly, Val, He, Leu, Met, Phe, Pro, Trp, Val, etc.), a basic amino acid substituted for another basic amino acid (Lys, Arg, etc.), an amino acid with a polar side chain substituted for another amino acid with a polar side chain (Asn, Cys, Gin, Ser, Thr, Tyr, etc.), etc.
- an amino acid with a nonpolar side chain substituted for another amino acid with a nonpolar side chain e.g., Ala, Gly, Val, He, Leu, Met, Phe, Pro, Trp, Val, etc.
- a basic amino acid substituted for another basic amino acid Lys, Arg, etc.
- the peptide analog comprises one or more synthetic amino acids, e.g., an amino acid non-native to a mammal.
- Synthetic amino acids include ⁇ -alanine ( ⁇ - Ala), N-a-methyl- alanine (Me-Ala), aminobutyric acid (Abu), ⁇ -aminobutyric acid ( ⁇ -Abu), aminohexanoic acid ( ⁇ -Ahx), aminoisobutyric acid (Aib), aminomethylpyrrole carboxylic acid, aminopiperidinecarboxylic acid, aminoserine (Ams), aminotetrahydropyran-4- carboxylic acid, arginine N-methoxy-N-methyl amide, ⁇ -aspartic acid ( ⁇ -Asp), azetidine carboxylic acid, 3-(2-benzothiazolyl)alanine, cc-iert-butylglycine, 2-amino-5-ureido-n-valeric acid (S)
- DMTA dimethylthiazolidine
- ⁇ -Glutamic acid ⁇ -Glu
- homoserine Hse
- hydroxyproline Hyp
- isoleucine N-methoxy-N-methyl amide methyl-isoleucine (Melle), isonipecotic acid (Isn), methyl-leucine (MeLeu), methyl-lysine, dimethyl-lysine, trimethyl-lysine,
- methanoproline methionine- sulfoxide (Met(O)), methionine- sulf one (Met(0 2 )), norleucine (Nle), methyl-norleucine (Me-Nle), norvaline (Nva), ornithine (Orn), para-aminobenzoic acid (PABA), penicillamine (Pen), methylphenylalanine (MePhe), 4-Chlorophenylalanine (Phe(4- Cl)), 4-fluorophenylalanine (Phe(4-F)), 4-nitrophenylalanine (Phe(4-N0 2 )), 4- cyanophenylalanine ((Phe(4-CN)), phenylglycine (Phg), piperidinylalanine,
- piperidinylglycine 3,4-dehydroproline, pyrrolidinylalanine, sarcosine (Sar), selenocysteine (Sec), O-Benzyl-phosphoserine, 4-amino-3-hydroxy-6-methylheptanoic acid (Sta), 4-amino- 5-cyclohexyl-3-hydroxypentanoic acid (ACHPA), 4-amino-3-hydroxy-5-phenylpentanoic acid (AHPPA), l,2,3,4,-tetrahydro-isoquinoline-3-carboxylic acid (Tic),
- tetrahydropyranglycine thienylalanine (Thi) , O-benzyl-phosphotyrosine, O- Phosphotyrosine, methoxytyrosine, ethoxytyrosine, O-(bis-dimethylamino-phosphono)- tyrosine, tyrosine sulfate tetrabutylamine, methyl-valine (MeVal), and alkylated 3- mercaptopropionic acid.
- Thi thienylalanine
- O-benzyl-phosphotyrosine O- Phosphotyrosine
- methoxytyrosine methoxytyrosine
- ethoxytyrosine O-(bis-dimethylamino-phosphono)- tyrosine
- tyrosine sulfate tetrabutylamine methyl-valine (MeVal)
- MeVal methyl-valine
- the peptide analog comprises one or more non-conservative amino acid substitutions and the peptide analog still functions to a similar extent, the same extent, or an improved extent as the parent peptide.
- the peptide analog comprising one or more non-conservative amino acid substitutions exhibits about the same or greater binding to the colon cell in comparison to the parent peptide.
- the peptide analog comprises one or more amino acid insertions or deletions, in comparison to the parent peptide described herein. In some embodiments, the peptide analog comprises an insertion of one or more amino acids in comparison to the parent peptide. In some embodiments, the peptide analog comprises a deletion of one or more amino acids in comparison to the parent peptide. In some
- the peptide analog comprises an insertion of one or more amino acids at the N- or C-terminus in comparison to the parent peptide. In some embodiments, the peptide analog comprises a deletion of one or more amino acids at the N- or C-terminus in comparison to the parent peptide. In these embodiments, the peptide analog still exhibits about the same or greater binding to colon cells in comparison to the parent peptide.
- a "detectable marker” is any label that can be used to identify the binding of a composition of the disclosure to colon tissue.
- detectable markers are fluorophores, chemical or protein tags that enable the visualization of a polypeptide.
- Visualization in certain aspects is carried out with the naked eye, or a device (for example and without limitation, an endoscope) and may also involve an alternate light or energy source.
- Fluorophores, chemical and protein tags that are contemplated for use in the invention include, but are not limited to, FITC, Cy 5.5, Cy 7, Li-Cor, a radiolabel, biotin, luciferase, 1,8-ANS (l-Anilinonaphthalene-8-sulfonic acid), l-Anilinonaphthalene-8-sulfonic acid (1,8-ANS), 5-(and-6)-Carboxy-2', 7'-dichlorofluorescein pH 9.0, 5-FAM pH 9.0, 5-ROX (5-Carboxy-X-rhodamine, triethylammonium salt), 5-ROX pH 7.0, 5-TAMRA, 5 -T AMR A pH 7.0, 5-TAMRA-MeOH, 6 JOE, 6,8-Difluoro-7-hydroxy-4-methylcoumarin pH 9.0, 6- Carboxyrhodamine 6G pH 7.0, 6-Carboxyrhodamine 6G,
- Non-limiting examples of chemical tags contemplated by the invention include radiolabels.
- radiolabels that contemplated in the compositions and methods of the present disclosure include 11 C, 13 N, 15 O, 18 F, 32 P, 52 Fe , 62 Cu, ⁇ Cu, 67 Cu, 67 Ga, 68 Ga, 86 Y, 89 Zr, 90 Y, 94 mTc, 94 Tc, 95 Tc, "mTc, 103 Pd, 105 Rh, 109 Pd, m Ag, m In, 123 I, 124 I, 125 I, 131 I, 140 La, 149 Pm, 153 Sm, 154"159 Gd, 165 Dy, 166 Dy, 166 Ho, 169 Yb, 175 Yb, 175 Lu, 177 Lu, 186 Re, 188 Re, 192 Ir, 198 Au, 199 Au, and 212 Bi.
- Therapeutic moieties contemplated by the invention include, but are not limited to polypeptides or peptides, small molecules, therapeutic agents, chemotherapeutic agents, or combinations thereof.
- small molecule refers to a chemical compound, for instance a peptidometic or oligonucleotide that may optionally be derivatized, or any other low molecular weight organic compound, either natural or synthetic.
- low molecular weight is meant compounds having a molecular weight of less than 1000 Daltons, typically between 300 and 700 Daltons.
- Low molecular weight compounds are about 100, about 150, about 200, about 250, about 300, about 350, about 400, about 450, about 500, about 550, about 600, about 650, about 700, about 750, about 800, about 850, about 900, about 1000 or more Daltons.
- the therapeutic moiety is a protein therapeutic.
- therapeutics include, without limitation, cellular or circulating proteins as well as fragments and derivatives thereof. Still other therapeutic moieties include polynucleotides, including without limitation, protein coding polynucleotides, polynucleotides encoding regulatory polynucleotides, and/or polynucleotides which are regulatory in themselves.
- the compositions comprise a combination of the compounds described herein.
- protein therapeutics include cytokines or hematopoietic factors including without limitation IL-1 alpha, IL-1 beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-11, colony stimulating factor- 1 (CSF-1), M-CSF, SCF, GM-CSF, granulocyte colony stimulating factor (G-CSF), EPO, interferon- alpha (IFN-alpha), consensus interferon, IFN-beta, IFN-gamma, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, thrombopoietin (TPO), angiopoietins, for example Ang-1, Ang-2, Ang-4, Ang-Y, the human angiopoietin- like polypeptide, vascular endothelial growth factor (VEGF), angiogen
- transforming growth factor ⁇ transforming growth factor ⁇ , transforming growth factor ⁇ .2, transforming growth factor ⁇ 2, transforming growth factor ⁇ 3, transforming growth factor ⁇ 5, latent transforming growth factor ⁇ , transforming growth factor ⁇ binding protein I, transforming growth factor ⁇ binding protein II, transforming growth factor ⁇ binding protein III, tumor necrosis factor receptor type I, tumor necrosis factor receptor type II, urokinase-type plasminogen activator receptor, vascular endothelial growth factor, and chimeric proteins and biologically or immunologically active fragments thereof.
- Therapeutic moieties also include, as one embodiment, chemotherapeutic agents.
- a chemotherapeutic agent contemplated for use in a reagent of the invention includes, without limitation, alkylating agents including: nitrogen mustards, such as mechlor-ethamine, cyclophosphamide, ifosfamide, melphalan and chlorambucil; nitrosoureas, such as carmustine (BCNU), lomustine (CCNU), and semustine (methyl-CCNU);
- ethylenimines/methylmelamine such as thriethylenemelamine (TEM), triethylene, thiophosphoramide (thiotepa), hexamethylmelamine (HMM, altretamine); alkyl sulfonates such as busulfan; triazines such as dacarbazine (DTIC); antimetabolites including folic acid analogs such as methotrexate and trimetrexate, pyrimidine analogs such as 5-fluorouracil, fluorodeoxyuridine, gemcitabine, cytosine arabinoside (AraC, cytarabine), 5-azacytidine, 2,2'-difluorodeoxycytidine, purine analogs such as 6-mercaptopurine, 6-thioguanine, azathioprine, 2'-deoxycoformycin (pento statin), erythrohydroxynonyladenine (EHNA), fludarabine phosphate, and 2-chlorodeoxyadeno
- epipodophylotoxins such as etoposide and teniposide
- antibiotics such as actimomycin D, daunomycin (rubidomycin), doxorubicin, mitoxantrone, idarubicin, bleomycins, plicamycin (mithramycin), mitomycinC, and actinomycin
- enzymes such as L-asparaginase
- biological response modifiers such as interferon-alpha, IL-2, G-CSF and GM-CSF
- miscellaneous agents including platinium coordination complexes such as cisplatin and carboplatin, anthracenediones such as mitoxantrone, substituted urea such as hydroxyurea,
- methylhydrazine derivatives including N-methylhydrazine (MIH) and procarbazine, adrenocortical suppressants such as mitotane ( ⁇ , ⁇ '-DDD) and aminoglutethimide; hormones and antagonists including adrenocortico steroid antagonists such as prednisone and equivalents, dexamethasone and aminoglutethimide; progestin such as hydroxyprogesterone caproate, medroxyprogesterone acetate and megestrol acetate; estrogen such as
- antiestrogen such as tamoxifen
- androgens including testosterone propionate and fluoxymesterone/equivalents
- antiandrogens such as flutamide, gonadotropin-releasing hormone analogs and leuprolide
- non-steroidal antiandrogens such as flutamide
- Dosages of the therapeutic moiety or reagent provided are administered as a dose measured in, for example, mg/kg.
- Contemplated mg/kg doses of the disclosed therapeutics include about 1 mg/kg to about 60 mg/kg. Specific ranges of doses in mg/kg include about 1 mg/kg to about 20 mg/kg, about 5 mg/kg to about 20 mg/kg, about 10 mg/kg to about 20 mg/kg, about 25 mg/kg to about 50 mg/kg, and about 30 mg/kg to about 60 mg/kg.
- the precise effective amount for a subject will depend upon the subject's body weight, size, and health; the nature and extent of the condition; and the therapeutic or combination of therapeutics selected for administration. Therapeutically effective amounts for a given situation can be determined by routine experimentation that is within the skill and judgment of the clinician.
- Effective amount refers to an amount of a reagent of the invention sufficient to visualize the identified disease or condition, or to exhibit a detectable therapeutic or inhibitory effect. The effect is detected by, for example, an improvement in clinical condition or reduction in symptoms.
- the precise effective amount for a subject will depend upon the subject's body weight, size, and health; the nature and extent of the condition; and the therapeutic or combination of therapeutics selected for administration. Therapeutically effective amounts for a given situation can be determined by routine experimentation that is within the skill and judgment of the clinician.
- Visualization of binding to colon cells is by any means known to those of ordinary skill in the art. As discussed herein, visualization is, for example and without limitation, in vivo, in vitro, or in situ visualization.
- visualization is performed via imaging and may be performed with a wide area endoscope (Olympus Corporation, Tokyo, Japan) that is designed specifically to collect fluorescence images with high spatial resolution over large mucosal surface areas on the macroscopic scale (millimeters to centimeters). This capability is needed to rapidly screen large surface areas such as that found in the distal esophagus during endoscopy to localize regions suspicious for disease [Wang et ah, Gastrointestinal Endoscopy 1999; 49:447-55].
- This technique has been adapted for fluorescence detection, and is compatible with dye-labeled probes.
- This instrument can image in three different modes, including white light (WL), narrowband imaging (NBI), and fluorescence imaging.
- Narrow- band imaging is a new technology that represents a variation of conventional white light illumination by altering the spectrum with optical filters to restrict or narrow the range of wavelengths.
- the method enhances contrast in the endoscopic images to provide more visual details of the esophageal mucosa by tuning the light to maximize absorption of hemoglobin present in the vasculature of regions of intestinal metaplasia.
- the WL and NBI images are collected by the central objective lens, and the fluorescence image is collected by a second objective lens located near the periphery. There is a distance of approximately 3 mm between the centers of the white light and fluorescence objectives that results in only a slight misregistration of the two images. Furthermore, there is an air/water nozzle that removes debris from the objective lenses, and a 2.8 mm diameter instrument channel that can be used to deliver biopsy forceps.
- the objectives are forward viewing and have a field of view (FOV), defined by maximum angle of illumination, of 140 deg.
- the WL/NBI imaging modes have a depth of field (DOF), defined by range of distances between the distal end of the endoscope to the mucosal surface whereby the image is in focus, of 7 to 100 mm, and that for fluorescence is 5 to 100 mm.
- the transverse resolution measured at a distance of 10 mm from the mucosa for WL/NBI is 15 ⁇ and for fluorescence is 20 ⁇ .
- a xenon light source provides the illumination for all three modes, which is determined by a filter wheel located in the image processor. Illumination for all three modes of imaging is delivered through the two fiber light guides.
- the full visible spectrum 400 to 700 nm
- a filter wheel narrows the spectral bands in the red, green, and blue regime.
- a second filter wheel enters the illumination path, and provides fluorescence excitation in the 395 to 475 nm spectral band.
- illumination from 525 to 575 nm provides reflected light in the green spectral regime centered at 550 nm.
- the fluorescence image is collected by the peripherally located CCD detector that has a 490- 625 nm band pass filter for blocking the excitation light.
- Normal mucosa emits bright autofluorescence, thus the composite color appears as bright green. Because the increased vasculature in neoplastic mucosa absorbs autofluorescence, it appears with decreased intensity.
- This medical endoscope can be used to collect images after reagent administration and incubation from colon with 1) white light, 2) narrow band, and fluorescence. After entering the colon, a 5 second video is collected and digitized in the white light and narrow band imaging modes. The imaging in this mode is used to assess the spatial extent of the intestinal metaplasia for comprehensive evaluation of polypeptide binding. Then, approximately 3 ml of the fluorescence-labeled peptide is administered topically at a concentration of 10 ⁇ to the colon using a mist spray catheter being careful to cover the full extent of the mucosa. Amounts of reagent of the invention can be determined by one of ordinary skill in the art.
- the radiolabel is detected by nuclear imaging.
- Nuclear imaging is understood in the art to be a method of producing images by detecting radiation from different parts of the body after a radioactive tracer material is administered. The images are recorded on computer and on film.
- tissue sample is selected from the group consisting of a tissue or organ of said patient.
- compositions of the invention are formulated with
- compositions are generally formulated to achieve a physiologically compatible pH, and range from a pH of about 3 to a pH of about 11, about pH 3 to about pH 7, depending on the formulation and route of administration. In alternative embodiments, the pH is adjusted to a range from about pH 5.0 to about pH 8. In various aspects, the compositions comprise a therapeutically effective amount of at least one compound as described herein, together with one or more pharmaceutically acceptable excipients.
- compositions comprises a combination of the compounds described herein, or may include a second active ingredient useful in the treatment or prevention of bacterial growth (for example and without limitation, anti-bacterial or anti-microbial agents), or may include a combination of reagents of the invention.
- Suitable excipients include, for example, carrier molecules that include large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and inactive virus particles.
- Other exemplary excipients include antioxidants (for example and without limitation, ascorbic acid), chelating agents (for example and without limitation, EDTA), carbohydrates (for example and without limitation, dextrin, hydroxyalkylcellulose, and hydroxyalkylmethylcellulose), stearic acid, liquids (for example and without limitation, oils, water, saline, glycerol and ethanol) wetting or emulsifying agents, pH buffering substances, and the like.
- Fig. 2 Multi- spectral scanning fiber endoscope.
- FIG. 3 Chemical structures of molecular probes.
- B) AKP- monomer, and C) trilysine core, R indicates either Cy5.5 or FITC label.
- components include peptide binding motif, linker, and fluorescent dye.
- CPC:Apc One type of genetically engineered mice
- mice used for peptide screening as described in Example 2 below are the Cre positive progeny of mice containing Cre recombinase under the control of the Cdx2 promoter (CDX2P-9.5NLS-Cre) and mice with a floxed allele of the Ape gene as described in Hinoi et ah, Cancer Res., 67(20): 9721-9730 (2007).
- This somatic mutation in an Ape allele which leads to a truncated Ape protein, causes the development of adenomas in the distal colon as early as 10 weeks.
- mice exhibiting hyperplastic colon epithelium were generated by breeding mice with mutant Kras allele whose transcription is flanked by LoxP recombination sites with transgenic mice expressing Cre throughout the terminal ileum, cecum and colon (CDX2P9.5-G22Cre).
- mutant Kras allele whose transcription is flanked by LoxP recombination sites with transgenic mice expressing Cre throughout the terminal ileum, cecum and colon (CDX2P9.5-G22Cre).
- Kras LSL'G12d/+ mice were crossed to previously described CDX2p9.5-G22Cre (G22Cre) transgenic mice with mosaic expression of Cre in epithelial cells of the terminal ileum, cecum and colon (Akyol et ah, Nature Methods 5, 231-3 (2008).
- mice were cared for under the approval of the University Committee on the Use and Care of Animals, University of Michigan. All mice were housed in specific pathogen- free conditions and supplied water ad libitum throughout the study.
- a T7 library was constructed with the T7Select 10-3b vector as reported in the T7Select System Manual (Novagen, Gibbstown, NJ). Briefly, random oligonucleotide insert DNA for the XI 8 library was synthesized as follows: 5'-AAC TGC AAG CTT TTA- (MNN) 18 -ACC ACC ACC AGA ATT CGG ATC CCC GAG CAT-3' (where N represents an equi-molar ratio of each nucleotide and M is an equi-molar ratio of adenine and cytosine) (SEQ ID NO: 15). The amino acid translation of the complementary nucleotide sequence is: MLGDPNSGGGX 18 (SEQ ID NO: 16). The insert DNA was incubated with a
- deoxyribonucleotide triphosphates (Novagen) to form the complementary DNA strand. This was digested with EcoRl and Hindil restriction endonucleases (New England Biolabs). Following phenol/chloroform extraction and ethanol precipitation, the purified fragments were ligated into predigested T7Select 10-3b vector by T4 DNA ligase (Novagen). The ligation reaction was incubated at 16°C, subjected to in vitro packaging, and titered to determine the number of plaque forming units (pfu). The remaining solution was amplified in isopropyl 3-D-l-thiogalactopyranoside (IPTG)-induced BLT5615 until lysis. The lysate was titered and stored at -80°C in glycerol.
- IPTG isopropyl 3-D-l-thiogalactopyranoside
- a 9 month old CPC;Apc mouse was injected via tail vein with lxl0 u pfu of the parent T7-18mer library.
- the library was allowed to circulate for 10 minutes, after which the mouse was euthanized and organs were harvested and kept on ice.
- the bound phages were recovered by homogenizing each tissue or organ (colon polyps, normal colonic mucosa) (Bio-gen Pro 200) in DMEM-PI (Dulbecco's Modified Eagle Medium plus protease inhibitors: 1 mM phenylmethanesulfonylfluoride (PMSF), 20 ⁇ g/mL aprotinin, and 1 ⁇ g/mL leupeptin).
- PMSF phenylmethanesulfonylfluoride
- tissue samples were washed 3x with ice-cold washing medium (DMEM-PI containing 1% bovine serum albumin), centrifuging for 5 minutes at 3000 rpm between each wash. After the last wash, freshly starved bacteria were added to each tissue homogenate and incubated for 30 minutes at room temperature (RT). Pre-warmed Luria-Bertani (LB) medium with carbenicillin (50 ⁇ g/mL) was then added to the bacteria-homogenate solution and incubated another 30 minutes at RT. The supernatant was recovered after centrifugation and titered to determine the number of bound phage within each tissue tested. This procedure constituted one round of panning.
- DMEM-PI containing 1% bovine serum albumin
- the recovered phage that bound to the colon polyps was cleared twice: once against a homogenized tissue cocktail consisting of colon, kidney, liver and heart and a second time against normal murine colon.
- a total of four rounds of phage panning were performed, with amplification of the recovered eluate after each panning round.
- the input phage number (lxlO 11 pfu) was kept constant for each round of panning.
- the number of phages bound to each organ or tissue was calculated as the output pfu/(input pfu x tissue mass).
- the INFO value for the three candidate phages were calculated against a pool of phages from the initial T7 library [Mandava et ah, Proteomics, 4: 1439-1460 (2004)].
- the INFO scores for the SEQ ID NO: 3 peptide, the SEQ ID NO: 4 peptide, and Peptide 1 were 41.6, 45.2, and 49.1, respectively.
- a higher INFO score suggests a greater probability that the phage clone identified was not by chance. From this data, the Peptide 1 phage was shown to be the most unique clone of the three and was synthesized for further testing.
- Peptide 1 was synthesized using Fmoc-chemistry by solid phase peptide synthesis according to the literature procedure as described in Fields & Noble, Int. J. Pept. Protein Res, 35: 161-214 (1990). To ensure the phage and synthetic peptide expressed the same
- Peptide 1 was synthesized with 5'-Fluorescein isothiocyanate attached to the amino terminus of the peptide via amino hexanoic acid linker. Deprotection and cleavage of the peptides were achieved by treatment with a cleavage cocktail of trifluoroacetic acid (TFA)/Tri-isopropylsilane/Water (9.5/0.25/0.25/0.25, v/v/v/v/v) at RT for 3-4 hours.
- TFA trifluoroacetic acid
- Water 9.5/0.25/0.25/0.25, v/v/v/v/v/v
- the peptides were purified by preparative-HPLC using a water (0.1% TFA)-acetonitrile (0.1%TFA) gradient (2-33% acetonitrile over 31 minutes) (Waters Breeze HPLC, Milford, MA).
- the peptides were characterized by an ESI mass spectrometer (Micromass LCT Time-of-Flight mass spectrometer with Electrospray, FITC- Peptide 1 ( mass calc. 1451.89, Obs. 1451.7 [M+H]+)). The purity (>95%) of the compound was confirmed by analytical HPLC on a CI 8 column.
- Control peptide 1 As the side chains of amino acids can have significant roles in binding with their receptors, a control peptide containing Gly and Ala (GGGAGGGA) (SEQ ID NO: 18) (hereafter "Control peptide 1"), which does not have any functional groups on the amino acid side chains, was synthesized using same methods [mass (Calc. 1004.08 Obs. 1004.4 [M+H]+)]. All peptides were reconstituted in lx phosphate buffered saline (PBS) at 500 ⁇ and further diluted in lx PBS as necessary.
- PBS lx phosphate buffered saline
- the colon Prior to peptide administration, the colon was prepped using a tap water lavage. Using a small animal endoscope (Karl Storz Veterinary Endoscopy, Goleta, CA) with an instrument channel for performing biopsy, polyps suitable for peptide administration were located and the colon was rinsed with water until all mucous was removed. FITC-labeled Peptide 1 and Control peptide 1 were delivered in lx PBS through the instrument channel. The peptides were allowed to incubate for 5 minutes after which the colon was cleansed 3x with a tap water to remove the unbound peptide. Prior to imaging, the colon was inspected for residual peptide solution, and when clean, the colon was insufflated with air and imaged.
- a small animal endoscope Karl Storz Veterinary Endoscopy, Goleta, CA
- Fluorescence excitation produced with a 450-475 nm passband filter that can be manually switched to the optical path of a 175 W Nova Xenon light source was delivered to the endoscope via a 3 mm diameter fluid light cable (250cm length). Fluorescence images were collected with a 510 nm long-pass barrier filter to block the excitation light and detected with a 3-chip color camera with an integrated parfocal zoom lens. Real time video was recorded via firewire connected to a personal computer.
- Hyperplastic Kras mice because these mice were devoid of polyps.
- FITC-Peptide 1 bound to the colonic adenomas and provided greater fluorescent signal when compared to the Control peptide 1. Furthermore, FITC-Peptide 1 showed minimal background binding to adjacent colon tissue, also clearly evident during endoscopy. Still, the FITC-Peptide 1 did not bind to colonic mucosa in littermate mice that tested negative for Cre recombinase (control mice without polyps). Furthermore, FITC-Peptide 1 did not show preferential binding to hyperplastic colonic epithelial tissue in the Hyperplastic Kras mouse cohort tested.
- FITC-Peptide 1 (T/B: 2.17+0.61) binds 2-fold greater to the colonic adenomas when compared to the FITC-Control peptide 1 (T/B: 1.14+0.15).
- FITC-Peptide 1 binds in significantly greater amounts to the adenomas than FITC-Control peptide 1, p ⁇ 001.
- T/B calculations for the FITC-Peptide 1 binding to the control mice was not possible, because an average grey scale value could only be obtained for the adjacent normal tissue.
- Polyps were grossly imaged using the small animal endoscope to view binding to the polyp as a whole. Pairs of polyps (one candidate, one control) were imaged at a time to allow for the calculation of a candidate peptide to Control peptide 1 binding ratio for each pair analyzed. An average binding ratio was calculated + one standard deviation. A similar procedure to determine mean grey scale values for image analysis was followed for the ex vivo polyps as described above for the in vivo polyps.
- Peptide 1 displayed enhanced binding to whole polyps ex vivo. Gross analysis of peptide binding revealed that the FITC-Peptide 1 bound to the excised polyps in greater quantity than the FITC-Control peptide 1. Comparison of between FITC-Peptide 1 and FITC- Control peptide 1 binding showed Peptide 1 bound 2.51+0.59 times greater than the Control peptide 1 for the whole polyp pairs analyzed.
- Polyps were fixed in phosphate-buffered formalin for 24 hours, paraffin-embedded and sectioned into 10 ⁇ thin slices and stained with hematoxylin and eosin. Histological images were captured using an Axioskop2 upright microscope (Carl Zeiss, Inc.).
- Histology of the all polyps showed dysplasia, characterized by enlarged nuclei, hyperchromaticity, and distorted crypts.
- the sectioned tissues were air dried and washed with PBS IX. Sections were incubated with FITC labeled peptides (10 ⁇ ) for 15 min at RT. The sections were washed three times each for 1 min in PBS and fixed with 4 % paraformaldehyde for 10 min. After fixing, the sections were washed again (IX) and mounted with ProLong® Gold reagent with DAPI (Invitrogen, Carlsbad, CA). The sections were imaged under a confocal microscope (Leica Microsystems GMBH, Wetzlar, 35578 Germany). All surgical specimens were obtained from the tissue procurement core of University of Michigan with approval from the Institutional Review Board (IRB).
- the human colorectal adenocarcinoma cell line HT29 and non-malignant intestinal cell line Hs738.St/Int. were obtained from the American Type Culture Collection (ATCC, Manassas, VA).
- the HT29 cells were cultured in McCoy's medium (Gibco, CA, USA) containing 10% fetal bovine serum (FBS, Gibco, CA, USA) and 1% penicillin/streptomycin (Invitrogen Corp. USA).
- the Hs738.St/Int. cells were cultured in DMEM (Gibco, CA, USA) containing 10% FBS, 1% penicillin/streptomycin and 1% glutamax. Both cell lines were cultured at 37 deg C in 5% C0 2 . The cells were passaged using 0.25% EDTA containing trypsin (Mediatech Inc. Manssas, VA).
- Peptide selection was performed using a technique of phage display (Ph.D. -7, New England Biolabs, Beverly, MA) and a biopanning strategy based on a subtractive whole-cell approach Kelly, et al. Cancer Res. 64: 6247-6251 (2004); and Zhao et al., Clin Cancer Res 13: 6049-5055 (2007).
- HT29 and Hs738.St/Int. cells were grown to log-phase, detached either with cell dissociation buffer (Invitrogen, Carlsbad, CA) or Trypsin with 0.25% EDTA (Mediatech Inc.
- the cells were washed three times with cold PBST.
- the bound phage were then eluted with 1 mL of 0.2 M glycine (pH 2.2) containing 0.1% BSA for 8 min, and immediately neutralized with 150 of 1 M Tris (pH 9.2).
- the eluted phage was amplified, precipitated and titered according to manufacturer instructions.
- the resulting phage (2xl0 n pfu) was used to perform further 4 additional rounds of biopanning for positive selection against the HT29 cells, to enrich the pool of candidate phage.
- 60 plaques were randomly selected and their sequences were analyzed with an ABI Automatic DNA Analyzer.
- a primer 5'-CCC TCATAG TTA GCG TAA CG-3' (SEQ ID NO: 19) (-96 gill sequencing primer, provided in the phage display peptide library kit, New England Biolabs) corresponding to the pill gene sequence of the Ml 3 phage was used for sequencing.
- Preferential binding of the candidate phage to target cells was validated by bound phage counts.
- the candidate phages and non-insert wild-type (WT) phage (M13KE, New England Biolabs, Beverly, MA) were amplified, precipitated and titered per manufacturer's instruction.
- HT29 and Hs738.St/Int. ( ⁇ 5xl0 6 ) cells were grown to log-phase, detached, and blocked, as described above. A total of 2xl0 u pfu of either the candidate or wild-type phages were incubated with these cells for 15 min with continuous gentle agitation at room temperature.
- the bound phages were eluted from the cells with 0.2 M glycine (pH 2.2) containing 0.1% BSA buffer for 8 min and titered with E. coli. The number of plaques was counted, and the number of candidate phages that bound to the target cells was compared with that found for the non-target cells and for no-insert wild type phage.
- the candidate phage pool was enriched by 78 fold
- HT29 and Hs738.St/Int. (2xl0 5 ) cells were detached and blocked as mentioned above and incubated with 2xl0 n pfu of either the Peptide 2 or wild- type phage for 20 min at RT in triplicate. After washing 3 times with PBS/0.2% Tween-20, cells were incubated with anti-M13 antibody (IgG) conjugated to horseradish peroxidase (HRP, 1:2000 dil.) (Amersham, Piscataway, NJ) for 60 min at RT with continuous agitation.
- IgG anti-M13 antibody conjugated to horseradish peroxidase
- Peptide 2 peptide and a control peptide GGGAGGGAGGGK (FITQ-NH2 (SEQ ID NO: 21) (hereafter "Control peptide 2") were synthesized by solid phase synthesis with Fmoc chemistry. Fmoc protected L-amino acids were used and synthesis was assembled on rink amide MBHA resin using PS3 (Protein Technologies, Inc. AZ) automatic peptide synthesizer. The FITC was labeled at the C-terminus on the side chain of lysine residue via GGGSK linker (SEQ ID NO: 14). The glycine residues provide a spacer function which prevents stearic hindrance between the binding motif and fluorescent label.
- linker residue provides the same orientation of the peptide relative to the fluorescence label as that for the phage.
- this spacer has the same amino acid sequence as that on the pill coat protein of the M13 bacteriophage.
- Control peptide 2 was designed with multiple glycines and alanines to have different structure and properties in terms of net charge and side chains and with the same number of amino acids as that for the target peptide.
- the crude product was purified by prep-HPLC with a C18 column (Waters, city, state) using a water (0.1% TFA)-acetonitrile (0.1% TFA) gradient to give sufficient amount of the desired products.
- the successful synthesis was confirmed by LC/ESI mass spectrometry (Platform II, micromass, Manchester, UK) and its homogeneity (>95%) was confirmed by reverse phase analytical HPLC (2489 Breeze system, Waters Inc, MA) using a CI 8 column.
- FITC-Peptide 2 Preferential binding of FITC-Peptide 2 to target cells was validated using flow cytometry.
- HT29 and Hs738.St/Int. (-2x105) cells were grown, detached, and blocked as described above. These cells were incubated with the FITC-Peptide 2 or -Control peptide 2 (10 ⁇ ) for 60 min at 4°C with continuous agitation. The cells were then washed (3X) with cold PBST followed by immediate fixing for 10 min. with 4% paraformaldehyde. The cells were washed again (lx) with PBS and resuspended in 1 mL of PBS. Flow cytometry was performed using FACSDiVa (BD® LSRII, BD Biosciences, San Jose, CA) and analyzed using Flowjo analysis program (Tree Star Inc., Ashland, OR).
- FACSDiVa BD® LSRII, BD Biosciences, San Jose, CA
- FITC-Peptide 2 and FITC-Control peptide 2 were also validated via fluorescence microscopy.
- HT29 and Hs738.St/Int. cells were grown in 22 mm2 cover slips with ⁇ 80% confluence. Blocking of non-specific binding was performed by adding PBS/0.5% BSA for 30 min. The cells were then incubated with 10 ⁇ of FITC-Peptide 2 or FITC-Control peptide 2 either at 4 or 37 °C for 15 min followed by 1 ⁇ g/mL Hoechst dye (Sigma Aldrich, St. Louis, MO) along with the peptide.
- Hoechst dye Sigma Aldrich, St. Louis, MO
- the cells were washed with PBS for 3 times and fixed with 4% paraformaldehyde at room temperature for 10 min. After fixation, the cells were washed again with PBS (IX) and mounted with ProLong® Gold reagent (Invitrogen, Carlsbad, CA) and the fluorescence images were acquired with Leica Confocal system. (Leica Microsystems GMBH, Wetzlar, 35578 Germany)
- FITC-Peptide 2 binds to the surface of the HT29 but not the surface of the
- FrfC-Control peptide 2 did not bind to either the target or control cells.
- FITC-Peptide 2 peptide was tested.
- HT29 cells were incubated for 15 min. at either 4°C or 37°C in the presence of 10 ⁇ FITC-Peptide 2.
- FITC-Peptide 2 peptide was incubated with 4°C, most of the peptide binding appears to be confined to the cell surface as revealed by the overlay image stained with 4', 6-diamidino-2-phenylindole.
- the spatial extent of the cell nuclei showed affinity binding of FITC-Peptide 2 to the plasma membrane of the HT29 cells.
- incubating HT29 cells with FITC-Peptide 2 at 37°C revealed the presence of diffuse staining throughout the cells. Determination of binding constant
- the binding affinity of FITC-Peptide 2 to HT29 cells was determined using various concentrations of the peptide.
- the fluorescence intensity of the peptide bound to the HT29 cells was measured at saturation.
- the FITC-labeled peptide was serially diluted in PBS at concentrations that varied from 0 to 70 ⁇ /L and incubated with lxlO 5 HT29 cells at 4°C for 1 hr. After washing 3 times with cold PBS/0.2% Tween 20 solution, the unbound peptide was rinsed off.
- the cells were resuspended in 200 ⁇ ⁇ PBS and transferred to a 96 well plate.
- the fluorescence intensity I was measured at 525 nm using 485 nm as the excitation wavelength on a multi-well plate reader (CytoFluor Series 4000; Applied
- Frozen or fixed non-neoplastic or neoplastic human colon tissue sections were cut with 10 ⁇ thickness.
- the fixed sections were heated at 60°C to melt out the wax followed by deparaffinization with xylene and ethanol.
- the antigen retrieval was performed using Tris- EDTA buffer (10 mM Tris base, 1 mM EDTA, 0.05% Tween-20, pH 9.0) at 95°C for 10 min. Then the sections were washed with PBS (IX) and used for further staining. The fresh frozen sections were used directly without further processing.
- the sections were air-dried on slides, rinsed twice with PBS and then fixed with 4% paraformaldehyde for 10 min.
- the sections were rinsed-off with PBS and blocked with 1% BSA for one hour at RT. Tissue sections were stained with hematoxylin following the standard protocol for localizing the nucleus. Then, sections were incubated with targeted phages or non-insert wild type phages (2xl0 n pfu) for 15 min at RT. Slides were then rinsed 3 times with PBS for 1 min each and blocked for 10 min with 3% hydrogen peroxide. Slides were again rinsed 2 times for 1 min each with PBS, and staining with HRP-conjugated anti-M13 monoclonal phage antibody (1:200 dilutions) for 1 hr at RT.
- H & E staining from the serial sections was also assessed for diagnosis.
- the frozen sections of human specimens were fixed with 4% paraformaldehyde for 10 min at RT. Then the sections were stained with H&E following the standard protocol. Histopathologic interpretation of each section was performed by a gastrointestinal pathologist (HA) and classified as (1) normal mucosa, (2) dysplasia and (3) adenocarcinoma for comparison with the average fluorescence intensity from the serial sections.
- HA gastrointestinal pathologist
- the Peptide 2 phage was found to localize in dysplastic adenomas and carcinoma sections, that stained dark brown distinctly, indicated the positive binding region of the phage to these pre-malignant and malignant lesions.
- the dysplastic adenoma and carcinoma tissue sections stained with insert less wild type phage clone showed negative staining.
- the normal colonic mucosa did not stain either with Peptide 2 or with insert less phage. It is thus clear that Peptide 2 phage was able to bind specifically to adenoma and carcinoma cells.
- the representative H & E sections are shown as gold standard for comparison with staining. Binding of synthetic peptides to human surgical specimens of colon cancer
- Fresh frozen sections from human surgical specimens were cryosectioned with 10 ⁇ thickness and used to localize peptide binding.
- the sectioned tissues were air dried and washed with PBS IX.
- Sections were incubated with FITC labeled peptides (10 ⁇ ) for 15 min at RT.
- the sections were washed three times each for 1 min in PBS and fixed with 4 % paraformaldehyde for 10 min. After fixing, the sections were washed again (IX) and mounted with Pro Long® Gold reagent with DAPI (Invitrogen, Carlsbad, CA).
- the sections were imaged under a confocal microscope (Leica model no, city, state).
- FITC-Peptide 2 differentially stained the surgical specimens from human colon adenocarcinoma as opposed to normal colonic mucosa.
- FITC-Control peptide 2 was not able to bind with any of the specimens classified from normal to carcinoma. The representative H and E sections are shown as gold standard for comparison with staining.
- T/B ratio for FITC-Peptide 2 vs. FITC-Control peptide 2 was 6, 3 and 1 for carcinoma, adenoma and normal mucosa respectively.
- This example describes the_design, construction, and validation of a near-infrared (NIR) labeled peptide and matching wide-field instrument with sub-cellular resolution that were used to visualize individual pre-malignant (dysplastic) crypts in real time in vivo.
- NIR near-infrared
- This methodology can be used longitudinally to evaluate molecular expression in small animal models, and can also be directly translated into the clinic for early cancer detection.
- Octapeptide QPIHPNNM (Peptide 1; SEQ ID NO: l) was conjugated with Cy5.5 (Lumiprobe, LLC, Hallandale Beach, FL) on the N-terminus via an amino-hexanoic acid linker using NHS activation chemistry.
- the peptide was prepared using solid-phase synthesis by applying standard Fmoc chemistry on Rink amide MBHA amide resin (Anaspec, CA). Cy5.5-NHS ester was conjugated to the N-terminus of the peptide in mixed DCM/DMF (1:3) at pH 9 adjusted with diisopropylethylamine (DIEA) overnight.
- DIEA diisopropylethylamine
- the YTT-Cy5.5 (control) peptide did not stain any of the specimens, including normal, dysplasia, and adenocarcinoma.
- the QPI-Cy5.5 peptide was found to selectively stain dysplasia in 6/8 and adenocarcinoma in 8/10 sections of human specimens.
- the QPI-Cy5.5 peptide did not stain any of the 7 sections of normal colonic mucosa.
- YTT-Cy5.5 did not stain either normal or dysplasia, and was found to bind minimally to 5/10 adenocarcinoma sections.
- the mean NIR fluorescence intensities on immunohistochemistry for QPI-Cy5.5 peptide binding to normal, dysplasia and adenocarcinoma were 1.5+1.0, 10.7+3.3 and 9.8+2.4 AU, respectively.
- the resulting intensity ratio for dysplasia and adenocarcinoma was 7.1 (p ⁇ 0.0049) and 6.5 (p ⁇ 0.0168) relative to that for normal colonic mucosa.
- FIG. la A schematic of the NIR endoscopic imaging system is shown in Fig. la.
- a custom polymer housing contains a filter wheel to provide both reflectance and fluorescence images, and has a handle for holding the instrument (Fig. lc).
- a resolution of 9.8 ⁇ (group 6, element 5) was measured at a distance of 2.5 mm, a typical dimension used for in vivo imaging, resulting in a FOV with diameter of 3.6 mm (Fig. Id).
- the intensity is tunable over a range from 1 to 100 mW.
- This pediatric urethroscope (Karl Storz Veterinary Endoscopy, Goleta, CA) has a ⁇ 3 mm outer diameter and a 3 Fr instrument channel. Fluorescence images collected by the endoscope are transmitted by a set of relay lenses onto a CCD detector that has dimensions of 8.7x6.9 mm and 1388x1040 pixels (Carl Zeiss Microimaging, LLC, Thornwood, NY). A zoom lens system (NT58-440, Edmund Optics Inc., Barrington, NJ) with a tunable focal length of 20-100 mm, F#1.6-16 aperture was used to magnify the image to fill the dimensions of the CCD. The resolution of this system was measured using a standard target (USAF-1951, Newport Corporation, Irvine, CA).
- Each frame was collected in 100 ms (10 Hz), and transferred to the computer by firewire.
- the optics and detector were contained within a custom housing made of light weight polymer.
- a filter wheel was incorporated into the handle of the housing to quickly switch between collection of reflectance and fluorescence images.
- a band pass filter that transmits NIR fluorescence from em 696 to 736 nm (FFO 1-716/40-25, Semrock, Inc., Rochester, NY) was used.
- mice were cared for under the approval of the University Committee on the Use and Care of Animals (UCUCA) at the University of Michigan.
- the CPC;Apc mice are genetically engineered with a Cre recombinase under the control of the Cdx2 promoter (CDX2P-9.5NLS-Cre) and a floxed allele of the APC gene.
- This Cre-regulated somatic mutation in one of the Ape alleles causes dysplasia to develop spontaneously in the distal colon of the mouse, allowing for minimally invasive imaging to be performed. All mice were housed in specific pathogen-free conditions and supplied water ad libitum throughout the study. Animals ranged in age from 6 to 9 months.
- the peptides were allowed to incubate for 5 minutes, and then the colon was cleansed 3 times with a tap water to remove any unbound peptide. Prior to imaging, the colon was inspected for residual peptide solution, and when clean, the colon was insufflated with air for imaging. Fluorescence images were collected using Axiovision 4.8.1 software.
- the corresponding histology revealed the features of dysplasia, including elongated nuclei, disorganized crypt structure, hyperchromaticity, and crowed lamina intestinal, similar to that found in human disease.
- the fluorescence images from the same region of mucosa with administration of the control peptide YTT-Cy5.5 and with no peptide reveal negligible signal.
- This method for performing targeted in vivo optical imaging that integrates a highly-specific peptide with a wide-field NIR fluorescence endoscope achieved a sub-cellular system resolution of ⁇ 10 ⁇ , representing a significant improvement over previous NIR instruments, and was able to visualize individual dysplastic crypts with well-defined features and sharp lesion borders in real time.
- NIR fluorescence has advantages over that of visible for performing in vivo imaging since less background is observed.
- the resolution is far better than that of NIR endoscopes that use a fiber-optic bundle, which are limited by pixilation artifact.
- NIR systems have also been developed for intra- operative imaging, but these instruments are large and not minimally invasive.
- NIR tomography has been used to image hollow organs, but this approach is limited by light penetration depth and multiple air-tissue interfaces. In addition to the colon, this imaging system can be used to study other hollow organs in small animal models of disease, such as the esophagus and oropharynx.
- the instrument can be easily adapted to image multiple spectral bands with the addition of appropriate lasers, optics, and filters. Furthermore, this technology can be translated to the clinic to perform high resolution molecular imaging in hollow organs. Some of the unique advantages of this integrated platform can also realized by imaging the deep red region of the visible spectrum and by using other targeting molecules and optical reporters (fluorescent proteins expressed by genetically-engineered mice).
- Pre-malignant colonic lesions that have non-polypoid (flat and depressed) morphology are indistinguishable on colonoscopy and may confer a high risk for malignancy.
- a peptide specific for flat dysplasia was identified by phage display technology with HT29 and Hs738.st/int. cells as the positive and negative biopanning substrates, respectively.
- Bound phage counts, ELISA, flow cytometry, competitive inhibition, binding affinity and fluorescence microscopy were performed to validate specific candidate binding on cultured cells. Confocal and stereomicroscopy was performed on biopsy and endoscopic mucosal resected specimens, respectively, to validate specific peptide binding to dysplastic human colonic mucosa.
- the human colorectal adenocarcinoma (HT29) and non-malignant intestinal cells (Hs738.St/Int.) were obtained from the American Type Culture Collection (ATCC, Manassas, VA).
- the HT29 cells were cultured in McCoy's medium (Gibco, CA, USA) containing 10% fetal bovine serum (FBS, Gibco, CA, USA) and 1% penicillin/streptomycin (Invitrogen Corp. USA).
- Hs738.St/Int. cells used as controls were cultured in DMEM (Gibco, CA, USA) containing 10% FBS, 1% penicillin/streptomycin and 1% glutamax. Both cells were cultured at 37°C in 5% C0 2 . The cells were passaged using 0.25% EDTA containing trypsin
- Peptide selection was performed using phage display technology (Ph.D. -7,
- HT29 and Hs738.St/Int. cells were grown to log-phase, detached either with cell dissociation buffer (Invitrogen, Carlsbad, CA) or trypsin with 0.25% EDTA (Mediatech Inc. Mansas, VA), and immersed in blocking buffer, PBS with 1% bovine serum albumin (BSA), for 30 min at 4°C with continuous agitation. Then 3 rounds for clearing of non-specific binders were performed by incubating ⁇ 10 6 Hs738.St/Int. cells with a total of ⁇ 10 9 plaque-forming units (pfu) for 30 min at 4°C. The cleared phages in the supernatant were amplified and titered per manufacturer instructions. The amplified titer
- the resulting phages (2xl0 n pfu) were used to perform 4 additional rounds of biopanning for positive selection against HT29 cells, enriching the pool of candidate phage.
- 60 plaques were randomly selected in each round and their sequences were analyzed with an ABI Automatic DNA Analyzer.
- a primer 5'-CCC TCATAG TTA GCG TAA CG-3' (SEQ ID NO: 28) (-96 gill sequencing primer, New England Biolabs) corresponding to the pill gene sequence of the M13 phage was used for sequencing.
- KCCFPAQ SEQ ID NO: 2 phages that bound to the HT29 cells was found to be ⁇ 7-fold higher as compared to Hs738.St/Int. (4.3xl0 6 +2.8xl0 5 versus 6.8xl0 5 +6.0xl0 4 ) and 143 times higher when compared to that for non-insert WT phage (3.0xl0 4 +2.5xl0 3 ), p-value ⁇ 0.001. Based on this result, the KCCFPAQ (SEQ ID NO: 2) peptide was selected for further studies. The other sequences did not provide a significant difference in binding between HT29 and Hs738.St/Int. cell and were not used further.
- This peptide sequence were analyzed with the National Center of Biotechnology Information BLAST (Basic Local Alignment Search Tool). While complete homology for the entire sequence was not found, this peptide has partial homology (KCCF***) to the extracellular domain of ErbB-2 protein which may function as a mimic of a CCY/F motif present in EGF like domain of ErbB family member ligands.
- HT29 and Hs738.St/Int. (2xl0 5 ) cells were detached and blocked, as described above, and incubated with 2xl0 n pfu of either the candidate or WT phages for 20 min at RT in triplicate. After washing 3X with PBS/0.2% Tween-20, the cells were incubated with anti-M13 antibody (IgG) conjugated to horseradish peroxidase (HRP, 1:2000 dil.) (Amersham, Piscataway, NJ) for 60 min at RT with continuous agitation.
- IgG anti-M13 antibody conjugated to horseradish peroxidase
- TMB tetramethylbenzidine
- the candidate and control peptides were produced by solid phase synthesis with Fmoc chemistry. Fmoc protected L-amino acids were used, and synthesis was assembled on rink amide MBHA resin using a PS3 (Protein Technologies, Inc. AZ) automatic peptide synthesizer. Isomer I of fluorescein isothiocyanate (5-FITC) was labeled at the C-terminus on the side chain of the lysine residue via a GGGSK linker (SEQ ID NO: 14). The glycine residues provide a spacer function that prevents stearic hindrance between the binding motif and the fluorescent label.
- the GGGS (amino acids 1-4 of SEQ ID NO: 14) residue provides the same orientation of the peptide relative to the fluorescence label as that for the phage.
- this spacer has the same amino acid sequence as that on the pill coat protein of the Ml 3 bacteriophage.
- the unlabeled peptides were also synthesized for the competitive binding study. Cleavage of the peptides from the resin was achieved by treatment with a mixture of 3 ml TFA: TIS: H 2 0 (95:2.5:2.5 v/v/v) at RT for 4 hr (Sigma Aldrich, St. Louis, MO). After filtration and washing of the resin by TFA, a gentle stream of nitrogen was used to remove the excess TFA. The crude peptide was triturated with diethyl ether chilled at -20°C and then centrifuged at 3,000 rpm for 10 min at 4°C. The crude product was purified by prep-HPLC with a Ci 8 column (Waters Inc.
- HT29 and Hs738.St/Int. ( ⁇ 2xl0 5 ) cells were grown, detached, and blocked, as described above. These cells were incubated with the 5-FITC labeled candidate or control peptide (10 ⁇ ) for 60 min at 4°C with continuous agitation. The cells were then washed 3X with cold PBST followed by immediate fixation for 10 min with 4% paraformaldehyde. The cells were washed again with PBS and resuspended in 1 mL of PBS. Flow cytometry was performed using FACSDiVa (BD ® LSRII, BD Biosciences, San Jose, CA) and analyzed using Flowjo analysis program (Tree Star Inc. Ashland, OR).
- FACSDiVa BD ® LSRII, BD Biosciences, San Jose, CA
- the KCCFPAQ (SEQ ID NO: 2) peptide bound to 97% of the total HT29 cell population compared to 2.3% for a control peptide. Furthermore, both the candidate and control peptides bound minimally to the Hs738.St/Int. cells.
- the control peptide (GGGAGGGAGGGK) (SEQ ID NO: 21) was designed with multiple glycines and alanines to have different structure and properties in terms of net charge and side chains from the target peptide.
- the control peptide is labeled with the same 5'-FITC fluorophore, and has the same number of amino acids as that of the target peptide.
- FITC-labeled candidate and control peptides were further validated via fluorescence microscopy.
- HT29 and Hs738.St/Int. cells were grown on cover slips to -80% confluence. Blocking of non-specific binding was performed by adding PBS/0.5% BSA for 30 min. The cells were then incubated with 10 ⁇ of 5-FITC-labeled candidate or control peptide at either 4 or 37 °C for 15 min followed by staining with 1 ⁇ g/mL Hoechst dye (Sigma Aldrich, St. Louis, MO) along with the peptide.
- Hoechst dye Sigma Aldrich, St. Louis, MO
- the cells were washed 3X with PBS and fixed with 4% paraformaldehyde at RT for 10 min. After fixation, the cells were washed again with PBS and mounted with ProLong Gold reagent (Invitrogen, Carlsbad, CA) and fluorescence images were collected with confocal microscopy (Leica TCS SP5 Microsystems, Bannockburn, IL).
- the fluorescent-labeled peptide KCCFPAQ (SEQ ID NO: 2) binds to the surface of the HT29 cells at 4°C on fluorescence microscopy. Binding of this peptide is confined to the plasma membrane of the HT29 cells, as revealed by the overlay image of the cells stained with 4',6-diamidino-2-phenylindole. No binding is seen to the Hs738.St/Int. cells. The fluorescent-labeled control peptide did not bind to either the HT29 or Hs738.St/Int. cells.
- the ability of the KCCFPAQ (SEQ ID NO: 2) peptide to internalize at 37°C is demonstrated by the presence of diffuse peptide staining throughout the cells on the images collected at 15 and 30 min. Competitive inhibition assay
- Bound phage counts were performed to observe the competitive inhibition effect of the synthetic candidate heptapeptide with its representative phage counterpart in triplicate.
- HT29 cells (5xl0 6 ) were detached with enzyme free cell dissociation buffer and blocked with 1% BSA containing PBS for 30 min at 4°C. The cells were washed and incubated with phage (2xl0 n ) for 15 min. Then, the cells were washed with PBS and immediately incubated with different concentrations of unlabeled peptide ranging from 10 to 200 ⁇ for an additional 15 min. Cells were washed 3X and the bound phages were recovered as described above in bound phage counts.
- the bound phages were then tittered and counted, and the relative inhibition rate was calculated.
- the inhibition activity of no-insert WT phage by synthetic candidate peptide and phage with unrelated synthetic control peptide were used as negative controls.
- KCCFPAQ (SEQ ID NO: 2) peptide in concentrations from 0 to 200 ⁇ reduced binding of KCCFPAQ (SEQ ID NO: 2) phage to HT29 cells in a dose-dependent manner
- KCCFPAQ (SEQ ID NO: 2) phage to the surface of HT29 cells depends on the specific insert peptide sequence rather than other phage coat proteins.
- the concentration of the 5-FITC-labeled peptide incubated with the HT29 cells (lxlO 5 ) until saturation of fluorescence intensity was achieved (24).
- the FITC-labeled peptide was serially diluted in PBS at concentrations that varied from 0 to 70 ⁇ and incubated with the HT29 cells at 4°C for 1 hr.
- the unbound peptide was rinsed off the cells by washing 3X with cold PBS/0.2% Tween-20 solution.
- the cells were resuspended in 200 ⁇ ⁇ of PBS and transferred to a 96 well plate.
- I[X] (Io+I max K a [X])/ (Io+ K a [X]).
- I 0 and I max are the initial and maximum fluorescence intensities, corresponding to no peptide and at saturation,
- [X] represents the concentration of the bound peptide.
- Origin 6.1 data analysis software (Origin Lab Corp, Northampton, MA) was used to perform a non-linear least square fit of the data.
- the sections were imaged under a confocal microscope (Leica TCS SP5 Microsystems, Bannockburn, IL). Adjacent sections were sent for routine histology. The intensity for each image was calculated using Matlab (Mathworks, Natick, MA).
- the FITC-labeled KCCFPAQ (SEQ ID NO: 2) peptide selectively stains dysplasia and adenocarcinoma in comparison to normal colonic mucosa on sections of freshly resected human specimens.
- the FITC-labeled control (GGG) peptide did not stain any of the specimens, including normal, dysplasia, and adenocarcinoma.
- Binding of the candidate or control peptide to the dysplasia on freshly resected human specimens via endoscopic mucosal resection (EMR) was validated on fluorescence stereomicroscopy. Patients with previously diagnosed polypoid and non-polypoid dysplasia who were referred for EMR were recruited. Institutional review board approval was obtained from the VA Palo Alto Health Care System, and informed consent was acquired. After resection, the specimens were rinsed in PBS 3X to remove debris and mucous. An autofluorescence image was acquired before incubating with the peptide.
- specimens were incubated with either the FITC-labeled candidate or control peptide at a concentration of 10 ⁇ /L for 5 min.
- the unbound peptide was rinsed off with PBS 3X.
- the mucosal surface of the specimen was oriented face up, and a dab of ink was applied to the upper border as a landmark to register the white light and fluorescence images with histology.
- a white light image was collected from the specimen with and without an overlying transparent grid that contains squares with dimensions of 1 x 1 mm .
- Fluorescence images were collected at 500 milliseconds per frame (with the overlying grid removed) using a stereomicro scope (Olympus SZX-16 equipped with Rolera camera; Olympus Corp, Tokyo, Japan) using 477 to 500 nm excitation and 500 to 630 nm emission.
- a correction to the fluorescence images was performed because the intensity at the center of the image is greater than that in the periphery due to differences in distance.
- a fluorescence image was collected from a solution of 10 ⁇ FITC in a plate to provide a uniform target for calibration, allowing for quantitative analysis over the entire field of view. After the fluorescence intensities were corrected, lines along the length of the specimen spaced by 2-mm intervals in each image were identified using the grid from the white light image.
- the mean intensity from each l x l mm interval along this length of tissue was calculated using Matlab and compared with histology. Histopathologic interpretation was performed by a gastrointestinal pathologist (HA) who classified the specimens stained with H&E as normal colonic mucosa, dysplasia, or adenocarcinoma. The histopathologic evaluation of the EMR specimens was conducted at VA Palo Alto Health Care System (AM) and classified as either dysplasia or normal mucosa.
- HA gastrointestinal pathologist
- adenocarcinoma (31.5+6.0 AU) compared to normal mucosa (10.1+3.6 AU), p ⁇ 0.001 and 1.5 fold higher than dysplasia (21.1+3.8 AU), p ⁇ 0.001.
- the target-to-background (T/B) ratio for the KCCFPAQ (SEQ ID NO: 2) peptide vs. control peptide was 3.6, 3.1, and 2.0 for adenocarcinoma, dysplasia and normal mucosa, respectively on frozen sections.
- the T/B of KCCFPAQ (SEQ ID NO: 2) peptide for flat adenoma to adjacent normal mucosa was found to be higher by -2.0 fold whereas T/B for polypoid adenoma to adjacent normal mucosa was 1.8.
- the peptide sequence KCCFPAQ (SEQ ID NO: 2) binds specifically to pre- malignant human colonic mucosa with non-polypoid morphology and can be fluorescent- labeled to target these lesions on endoscopic imaging in patients. This peptide can therefore be used as a targeted contrast agent for enhancing diagnostic specificity on endoscopy.
- Fluorescent- labeled peptides such as KCCFPAQ (SEQ ID NO: 2) are thus contemplated for use, for example, in targeting pre-malignant and malignant lesions during colonoscopy for guiding tissue biopsy, identifying flat and depressed lesions, and localizing tumor margins in patients at increased risk for developing adenocarcinoma.
- fluorescent-labeled peptides can also be used to visualize flat and depressed lesions that occur in the setting of ulcerative colitis, as molecular targets associated with cancer progression are frequently preserved in different disease processes.
- Gastrointestinal cancers are heterogeneous and can over-express several gene targets that can be imaged simultaneously on endoscopy using multiple molecular probes.
- a multi- spectral scanning fiber endoscope was developed for wide-field fluorescence detection of colonic dysplasia. Excitation at 440, 532 and 635 nm was delivered into a single spiral scanning fiber, and fluorescence was collected by a ring of light-collecting optical fibers placed around the instrument periphery. Specific-binding peptides were selected with phage display technology using the CPC;Apc mouse model of spontaneous colonic dysplasia. Validation of peptide specificity was performed on flow cytometry and in vivo endoscopy.
- the peptides KCCFPAQ (SEQ ID NO: 2), AKPGYLS (SEQ ID NO: 25), and LTTHYKL (SEQ ID NO: 26) were selected and labeled with 7-Diethylaminocoumarin-3-carboxylic acid (DEAC), 5-Carboxytetramethylrhodamine (TAMRA), and CF633, respectively.
- DEAC 7-Diethylaminocoumarin-3-carboxylic acid
- TAMRA 5-Carboxytetramethylrhodamine
- CF633 7-Diethylaminocoumarin-3-carboxylic acid
- TAMRA 5-Carboxytetramethylrhodamine
- CF633 7-Diethylaminocoumarin-3-carboxylic acid
- TAMRA 5-Carboxytetramethylrhodamine
- CF633 7-Diethylaminocoumarin-3-carboxylic acid
- TAMRA 5-Carboxytetramethyl
- a scanning fiber endoscope system was adapted for fluorescence detection in three channels (RGB) using excitation at 440 (NDHB510APA, Nichia, Tokyo, Japan), 532 (FTEC532-V10TA0, Blue Sky Research, Milpitas, CA) and 635 (FMXL635-017TA0B, Blue Sky Research) nm using an RGB coupler (OZ Optics, Ottawa, Canada).
- the three laser sources are delivered simultaneously into the scanning fiber, and focused to the same point on the illumination plane using a custom lens assembly, as shown in the schematic in Fig. 2A.
- the laser power coming out of the distal tip of the endoscope is ⁇ 2 mW for each channel, a level consistent with a non- significant risk (NSR) determination by the U.S. Food and Drug Administration (FDA, 21 CFR 812) for future human clinical studies.
- the amplitude of the spiral scanner was reduced to achieve a divergence angle of 70 deg (max 100 deg) to minimize noise in the periphery of the image.
- Fluorescence is collected by a ring of 12 step-index plastic optical fibers (POF) with numerical aperture (N.A.) of 0.63 and outer diameter of 250 ⁇ (Toray Industries Inc, Tokyo, Japan).
- An additive RGB set of dichroics (XR,G,B, part# 52-546, Edmund Optics Inc) is used to filter the individual fluorescence beams, which are focused onto separate PMT (H7826-01, Hamamatsu Corp, Hamamatsu City, Japan) detectors using an objective lens
- the PMT signals are sampled at 25 MHz to generate video rate (30 Hz) images.
- the distal tip of the flexible multi- spectral endoscope had a 1.6 mm outer diameter).
- the distal end of the single illumination optical fiber was scanned in 250 circles in a growing spiral pattern at approximately 11.5 kHz.
- Real-time zooming to the diffraction limit of the optics can be performed by reducing the scan angle while capturing the same number of pixels over the FOV.
- the sub-millimeter lens assembly seals the distal tip of the instrument and extends the waist of the laser beam to define a depth of focus that ranges between 2 to 50 mm.
- a spatial resolution of ⁇ 15 ⁇ was achieved at a distance of 3 mm from the distal tip to the illumination plane and ⁇ 1 mm at the maximum depth of focus.
- Cell culture reagents were purchased from Invitrogen (Carlsbad, CA). Chemical reagents were purchased from Sigma- Aldrich (St. Louis, MO) unless otherwise noted. Mice were cared for under the approval of the University Committee on the Use and Care of Animals (UCUCA) at the University of Michigan. Five- to seven-month old CPC;Apc mice that have a Cre-regulated somatic mutation in one Ape allele, causing adenomas to develop spontaneously in the distal colon at approximately 3 months of age, were used. This mutation is commonly found in sporadic human colorectal cancer. All mice were housed in specific pathogen-free conditions and supplied water ad libitum throughout the study.
- UUCA University Committee on the Use and Care of Animals
- Peptide selection was performed with in vivo phage display technology using this mouse as the biopanning substrate.
- phenylmethanesulfonylfluoride 20 ⁇ g/mL aprotinin, and 1 ⁇ g/mL leupeptin.
- the tissue samples were washed 3x with ice-cold washing medium (DMEM-PI containing 1% bovine serum albumin (BSA)), centrifuging for 5 min at 3000 rpm between each wash. After the last wash, freshly starved Escherichia coli (ER2738) were added to each tissue homogenate and incubated for 30 min at room temperature (RT). Pre-warmed Luria-Bertani (LB) medium was then added to the bacteria-homogenate solution and incubated for an additional 30 min at RT.
- DMEM-PI containing 1% bovine serum albumin (BSA)
- the supernatant was recovered after centrifugation and tittered to determine the number of bound phage within each tissue tested. This procedure constituted one round of biopanning. A total of 3 rounds of phage biopanning were performed, with amplification of the recovered eluate after each biopanning round. The input phage number (2xl0 n pfu) was kept constant for each round of biopanning. Tittering was performed with appropriate serial dilutions for both eluted phage and amplified phage after each round of biopanning.
- Agar plates treated with IPTG (isopropyl-b-D-thiogalactosidase) and Xgal (5- bromo-4-chloro-3-indoyl-b-D-thiogalactosidase) were able to visually identify plaques using blue/white screening.
- Amplified phages from selected phage plaques were purified by PEG/NaCl (polyethylene glycol/sodium chloride) precipitation.
- All Ml 3 DNA were sequenced after isolating single stranded DNA using an iodide buffer extraction via dideoxy chain termination using a DNA sequencer (Applied Biosystems, 3730XL DNA Analyzer, UM DNA Core) with the NEB-96 gill sequencing primer provided by New England Biolabs (# S1259S). The number of phages bound to each organ or tissue was calculated as the output pfu/(input pfu x tissue mass).
- Binding to isolated colonic epithelial cells from adenomas for each phage clone was analyzed using flow cytometry.
- a common 7-mer phage that expresses the sequence HAIYPRH (SEQ ID NO: 29) is a known contaminant, and was run (labeled # in Supplementary Fig. IB) to ensure the validity of the assay.
- HAIYPRH was found to be 1.10+0.08, indicating minimal binding from a non-specific clone, as expected.
- Six phage clones with a T/B ratio (target to wild-type phage) >1.9 were identified as ALTPTPP (SEQ ID NO: 30), NLVNLLP (SEQ ID NO: 31), ANYPREP (SEQ ID NO: 32), ATTVPAS (SEQ ID NO: 33), LTTHYKL (SEQ ID NO: 26), and AKPGYLS (SEQ ID NO: 25).
- the KCCFPAQ SEQ ID NO: 2 peptide had been previously found to bind to human HT29 cells.
- the 7 peptides were synthesized and conjugated to 5'-FITC for evaluation of in vivo binding.
- the GGGAGGG (SEQ ID NO: 34) peptide used as a control.
- the target and control peptides were prepared using solid phase synthesis with standard Fmoc chemistry. Fmoc protected L-amino acids were used, and synthesis was assembled on rink amide MBHA resin using a PS3 (Protein Technologies, Inc. AZ) automatic peptide synthesizer.
- the candidate peptides for the validation study were labeled with 5'-FITC (Anaspec, Fremont, CA) at the C-terminus on the side chain of a lysine residue via a GGGSK linker (SEQ ID NO: 14).
- the candidate peptides for the multi- spectral study were labeled with three different organic fhiorophores.
- 7-Diethylaminocoumarin-3-carboxylic acid (DEAC, Sigma- Aldrich, St. Louis, MO) has a peak absorption and emission at 432 and 472 nm, respectively.
- 5-Carboxytetramethylrhodamine (TAMRA, Chempep, Wellington, FL) has a peak absorption and emission at 541 and 568 nm, respectively.
- CF633 Biotium Inc., Hay ward, CA has a peak absorption and emission at 630 and 650 nm, respectively. These dyes have peak absorption that approximately match the laser sources.
- the peptide has a peak absorption that approximately match the laser sources.
- GGGAGGGAGGGK (SEQ ID NO: 21) was used as a control.
- LTTHYKL (SEQ ID NO: 26) exhibited the highest T/B ratio for binding to colonic adenomas in vivo, shown in Table 1.
- Table 1 Summary of imaging results. The average T/B ratios for in vivo imaging of colonic adenomas in CPC;Apc mice are shown for candidate peptides labeled with FITC for validation of specific binding using a non-scanning endoscope and for target peptides labeled with DEAC and TAMRA using the multi- spectral scanning fiber endoscope.
- GGGAGGG-FITC 3 13 1.05 ⁇ 0.05
- GGGAGGG-TAMRA 2 4 1.32 ⁇ 0.10 [00161]
- the three peptides were subsequently conjugated to 7-Diethylaminocoumarin-3- carboxylic acid (DEAC), 5-Carboxytetramethylrhodamine (TAMRA), and CF633, respectively, for in vivo imaging with the multi- spectral scanning fiber endoscope.
- the control peptides GGGAGGGAGGGK (DEAC)-NH 2 and GGGAGGGAGGGK (5-TAMRA)- NH 2 were also synthesized.
- a fiber-coupled spectrophotometer (Ocean Optics, Dundin, FL) was used to validate the excitation and emission spectra of the fluorescent-labeled peptides. Droplets of each fluorescent-labeled peptide at 1 ⁇ concentration were analyzed individually. The optical collection fibers of the multi- spectral scanning fiber endoscope were disconnected from the base station and connected to the spectrophotometer. Directed data collection was performed by stopping the motion of the scanning fiber and aiming the illumination spot at the droplet. Readings were then acquired using a 3 ms integration time with Ocean Optics Spectra Suite software.
- spectrophotometer The spectra were collected from the labeled peptides both with and without use of the respective dichroic (bandpass) filters Excitation at 440 nm and peak emission at 486 nm were observed for the KCCFPAQ-DEAC peptide. Excitation at 532 nm and peak emission at 577 nm were observed for the AKPGYLS -TAMRA peptide.
- the CP C; Ape mice were first imaged with white light using a non- scanning endoscope (Karl Storz Veterinary Endoscopy, Goleta, CA) to assess for the presence of colonic adenomas that have a size between -0.5 to 4 mm in diameter. Any adenomas were rinsed of debris including stool and mucous, by delivering tap water through a 3 Fr instrument channel. Then, the fluorescent-labeled peptides were delivered topically at a concentration of 100 ⁇ in lx PBS in a volume of 1 mL to the distal 4 cm of the colon and rectum.
- a non- scanning endoscope Karl Storz Veterinary Endoscopy, Goleta, CA
- the peptides were incubated for 5 minutes and then the unbound peptides were rinsed away with tap water 3 times. The colon was inspected for any residual peptide, and when clean, the colon was insufflated with air and imaged with the multi- spectral scanning fiber endoscope. Cre-recombinase negative littermates that do not express colonic adenomas were used as controls.
- the average T/B ratios of peptide binding to dysplasia versus normal appearing adjacent colonic mucosa were 1.71 ⁇ 0.19 (range 1.50 - 2.06) and 1.67 ⁇ 0.12 (1.50 - 1.78) for KCCFPAQ-DEAC and AKPGYLS-TAMRA, respectively (Table 1), while that for LTTHYKL-CF633 was not measured because of low signal level.
- H&E histology
- Specific binding of two or more peptides can be distinguished in vivo using the multi- spectral endoscope described herein to localize colonic dysplasia on real-time wide-field imaging.
- the ultrathin dimensions and flexibility of this multi- spectral endoscope allow for seamless integration with standard instrument channels of conventional medical endoscopes.
- the lasers, detectors and data acquisition system are conveniently contained within a portable cart that can be easily transported around a procedure room.
- NIR near-infrared
- HT29, SW480 Human colorectal adenocarcinoma (HT29, SW480) and non-malignant intestinal (CCD841Con) cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA).
- the HT29, SW480, and CCD841Con cells were cultured in McCoy's Medium, Dulbecco's Modified Eagle Medium, Eagle's Minimal Essential Medium, and Roswell Park Memorial Institute medium, respectively. All cells were cultured at 37°C in 5% C0 2 , and supplemented with 10% fetal bovine serum (FBS), 1% penicillin/streptomycin, and 1% glutamax.
- FBS fetal bovine serum
- penicillin/streptomycin 1% glutamax.
- the cells were passaged using 0.25% EDTA containing trypsin (Mediatech Inc, Mansas, VA). The cell number was determined using a hemocytometer.
- Peptide synthesis reagents were obtained from Anaspec (Anaspec, Fremont, CA) or AAPPTEC (AAPPTEC, Louisville, KY) and were of the highest grade available (>99 % purity) and used without further purification. Solvents and other chemical reagents were purchased from Sigma Aldrich (St. Louis, MO) unless otherwise mentioned.
- mice were cared for under the approval of the University Committee on the Use and Care of Animals, University of Michigan (UCUCA). All mice were housed in specific pathogen-free conditions and supplied water ad libitum under controlled conditions of humidity (50+10%), light (12/12 hr light/dark cycle) and temperature (25°C) throughout the study.
- the peptides used in this study were prepared using standard Fmoc-mediated solid-phase peptide synthesis on Rink amide MBHA resin. Fmoc and Boc protected L-amino acids were used and synthesis was assembled on rink amide MBHA resin.
- the peptides synthesized were: 1) AKPGYLSGGGSK-CONH 2 (AKP-monomer), 2) tetrameric version of AKPGYLS anchored on a trilysine core (AKP-multimer), and 3) trilysine core alone
- the monomer peptide was synthesized on a PS3 automatic synthesizer (Protein Technologies Inc., Arlington, AZ).
- the C-terminal lysine was incorporated as Fmoc-Lys (ivDde)-OH and the N-terminal Ala was incorporated as Boc-Ala-OH to avoid unwanted Fmoc removal during deprotection of the ivDde moiety prior to dye labeling.
- the resin was transferred to a reaction vessel for manual labeling with dye.
- the ivDde side chain protecting group was removed with 5% hydrazine in DMF (3x10 min) with continuous shaking at room temperature (RT).
- the resin was washed with Dimethylformamide (DMF) and dichloromethane (DCM) 3 times each for 1 min.
- DMF Dimethylformamide
- DCM dichloromethane
- the protected resin-bound peptide was incubated overnight either with 5-FITC (Anaspec, Fremont, CA) or Cy5.5-NHS ester (Lumiprobe LLC, Hallandale Beach, FL) with DIEA and the completion of the reaction was monitored by a qualitative Ninhydrin test.
- the peptide was cleaved from the resin using TFA: TIS: H20
- the AKP-multimer was synthesized manually on a trilysine-core which has 4-reactive sites for peptide coupling.
- the C-terminus Fmoc-Lys-(ivDde)-OH was conjugated on the resin for specific labeling of the dye followed by deprotection of Fmoc group with 20% piperidine.
- two consecutive coupling steps were performed with Fmoc-Lys (Fmoc)-OH.
- Fmoc-OH Fmoc-OH
- the deprotection of Fmoc-group provided the 4-arms for assembling the peptide sequences in a tetrameric form.
- stepwise solid phase synthesis was performed.
- the Boc-Ala-OH was used at the N-terminus. All other steps after complete assembly were repeated similarly as for monomer peptide synthesis.
- the experimental m/z (mass units) measured for the AKP-monomer-FITC, AKP-multimer-FITC, trilysine-FITC, AKP-monomer-Cy5.5, AKP-multimer-Cy5.5, and trilysine-Cy5.5 was 1510.0, 3786.0, 919.5, 1727.97, 4003.3, and 1136.7, respectively. These values agree with the expected molecular mass of 1509.8, 3785.9, 919.8, 1726.97, 4002.3, and 1136.7, respectively.
- the colon Prior to applying the peptides, the colon was prepped using a tap water lavage.
- the adenomas were viewed endoscopically, and videos were recorded using white light with a small animal endoscope (Karl Storz Veterinary Endoscopy, Goleta, CA).
- the colon was rinsed with water until all mucous and other debris was removed.
- the Cy5.5-labeled peptides were delivered at a concentration of 100 ⁇ in PBS containing 2.5% DMSO (dimethyl sulfoxide) through the instrument channel of the endoscope. During peptide administration, 1.5 mL of peptide was delivered to the distal colon in each mouse. The peptide was allowed to incubate for 5 min after which the colon was cleansed 3X with a tap water to remove the unbound peptide. Prior to imaging, the colon was inspected for residual peptide solution, and when clean, the colon was insufflated with air and imaged with the wide field endoscope which provides excitation at 671 nm. Fluorescence and reflectance videos were collected using Axiovision 4.8.1 software.
- Fluorescence videos were collected at 100 ms/frame (10 Hz), and transferred to the computer for storage by a firewire connection.
- a filter wheel was incorporated into the handle of the housing to quickly switch between collection of reflectance and fluorescence images.
- the CPC;Apc mice imaged ranged in age from 3 to 6 months. Fluorescence images were exported as videos in zvi format (16 bit digital resolution) using Lab View software.
- Peptides labeled with 5-FITC were used for the validation assays of cell binding. Preferential binding of the multimer peptide, monomer peptide, and trilysine to different human colorectal cancer (SW480, and HT29) and control cells (CCD841-Con) was validated on flow cytometry. A total of 5xl0 5 cells were used with each probe. The confluent cells were detached using enzyme free cell dissociation buffer (Invitrogen, Carlsbad, CA) or trypsin with 0.25% EDTA (Mediatech Inc, Manassa, VA) and immersed in blocking buffer, PBS with 1% bovine serum albumin (BSA), for 30 min at 4°C with continuous agitation.
- enzyme free cell dissociation buffer Invitrogen, Carlsbad, CA
- trypsin with 0.25% EDTA Mediatech Inc, Manassa, VA
- BSA bovine serum albumin
- FACSDiVa (BD ® LSRII, BD Biosciences, San Jose, CA) and analyzed using Flowjo analysis program (Tree Star Inc, Ashland, OR). The gain was kept constant for all experiments.
- AKP-multimer peptide bound specifically to the plasma membrane of the SW480 and HT29 cells but not to CCD-841Con cells, as shown by an overlay of the FITC and DAPI images.
- the same concentration of AKP-monomer peptide revealed a lower fluorescence intensity at the cell surface.
- the trilysine core did not stain any of the cells.
- the binding affinity of multimer and monomer peptide was measured by varying the concentration of the 5 -FITC-labeled peptides and trilysine incubated with the target cells (lxlO 5 ) until saturation of fluorscence intensity was achieved [16].
- the FITC-labeled peptide was serially diluted in PBS at concentrations that varied from 0 to 10 ⁇ and incubated with the target cells at 4°C for 1 hr.
- the unbound peptide was rinsed off the cells by washing 3X with cold PBS/0.2% Tween-20 solution.
- the cells were fixed with 4% PFA, as mentioned above, washed IX with PBS, and resuspended in lmL of PBS.
- the binding kinetics for AKP-monomer and AKP-multimer peptide was further evaluated on the target cells in the presence of 10 ⁇ peptide concentration.
- the target cells (5 X10 5 ) were detached and blocked as mentioned earlier and incubated with both monomer and multimer peptides at 4°C over time from 0-60 min. After completing the incubation for each time course, the samples were prepared for flow cytometry, as mentioned above.
- the kinetics of peptide binding with the cell surface was determined by measuring the shift in the intensity of FITC-channel as a function of time.
- the multimer demonstrated increased fluorescence intensity from binding to colonic adenomas in vivo with a target/background ratio (TBR) of 3.84+0.26 compared to 2.21+0.13 for the monomer and 1.56+0.12 for the trilysine core, p ⁇ 0.001.
- TBR target/background ratio
- the near-infrared (NIR) labeled multimer peptide can be used longitudinally to evaluate molecular expression in small animal models, and can also be directly translated into the clinic for early cancer detection.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention is directed to peptide reagents, methods for detecting colon pre-cancer (dysplasia with non-polypoid or polypoid morphology) or cancer using the peptide reagents, and methods for targeting pre-cancerous or cancerous colon cells using the peptide reagents.
Description
PEPTIDE REAGENTS AND METHODS
FOR DETECTION OF COLON DYSPLASIA
[0001] This application claims the benefit of U.S. Provisional Patent Application No. 61/425,062 filed December 20, 2010. The provisional application is hereby incorporated by reference in its entirety.
Statement of Government Interest
[0002] This invention was made with government support under U54 CA 136429 and R01 CA142750 awarded by the National Institutes of Health. The government has certain rights in the invention.
Incorporation By Reference Of Material Submitted Electronically
[0003] Incorporated by reference in its entirety is a computer-readable nucleotide/amino acid sequence listing submitted concurrently herewith and identified as follows: 12 kilobytes ACII (Text) file named "45776A_SeqListing.txt," created on December 14, 2011.
Field of the Invention
[0004] The present invention is directed to peptide reagents, methods for detecting colon pre-cancer (dysplasia with non-polypoid or polypoid morphology) or cancer using the peptide reagents, and methods for targeting pre-cancerous or cancerous colon cells using the peptide reagents.
Background
[0005] Colorectal cancer (CRC) is one of the most common causes of cancer-related deaths in the world. In 2009, there were more than 146,000 new cases of colorectal cancer diagnosed, and colorectal cancer was the cause of nearly one out of every five cancer-related deaths in the United States. Jemal et al, CA Cancer J Clin, 59:225-49 (2009). White light colonoscopy is currently the primary method for performing colorectal cancer screening. This technique is sensitive to morphological changes in the mucosa, such as polyps and masses. However, this method is not sensitive to the detection of flat and depressed lesions, and the polyp miss rates can be as high as 22%. van Rijn et al., Am J Gastroenterol.
101:343-50 (2006). Adenomatous polyps, or adenomas, appear to be major precursors to CRC, even though only a fraction of adenomas progress to CRC. The transformation from pre-malignant mucosa to carcinoma occurs over a period of many years, thus providing
window of opportunity for early detection. Furthermore, the presence of flat dysplastic lesions in the setting of chronic ulcerative colitis presents a significantly increased risk for the development of frank carcinoma.
[0006] Pre-clinical mouse models of disease provide an important tool for studying mechanisms of disease development. It has been established that mutations in the
adenomatous polyposis coli (APC) gene are likely to be critical events in the initiation of the majority of adenomas and CRC. Previously-reported genetically engineered mouse models that mimic human APC gene mutations mainly develop adenomas in the small intestine (e.g., APCMin model> Su gt al > Science 256(5057):668-670 (1992)), not the distal colon, making it difficult to image the polyps and their progression in vivo using currently available small animal endoscopy tools. Hinoi et al., Cancer Res., 67(20): 9721-9730 (2007) describes genetically engineered mice (termed CPC:Apc mice) in which a somatic mutation in an Ape allele leads to a truncated Ape protein and causes the development of adenomas in the distal colon as early as 10 weeks. Others have developed mouse models that grow tumors in the distal colon using implantation of cancerous cells [Alencar et al., Radiology, 244: 232-238 (2007)] or adenovirus activated mutations [Hung et al., Proc. Natl. Acad. Sci. USA, 107: 1565-1570 (2010)] and report binding of cathepsin B smart probes, but surgical intervention was needed to generate polyps and the ensuing response to injury may have resulted in target alteration.
[0007] Endoscopic imaging with use of exogenous fluorescent-labeled probes, is a promising method for achieving greater specificity in the detection of neoplastic lesions by identifying the expression of unique molecular targets. Imaging provides precise
localization, and fluorescence provides improved contrast. Previously, several diagnostic molecules have been used as targeted agents, including antibodies and antibody fragments, for the detection of pre-malignant and malignant lesions in various types of cancer. However, the use of antibodies and antibody fragments is limited by immunogenicity, cost of production and long plasma half-life. Small molecules, RNA aptamers, and activatable probes have also been used. Peptides represent a new class of imaging agent that is compatible with clinical use in the digestive tract, in particular with topical administration.
[0008] Phage display is a powerful combinatorial technique for peptide discovery that uses methods of recombinant DNA technology to generate a complex library of peptides, often expressing up to 107-109 unique sequences, that can bind to cell surface antigens. The DNA of candidate phages can be recovered and sequenced, elucidating positive binding peptides that can then be synthetically fabricated. Phage display identified peptide binders to high
grade dysplasia in Barrett's esophagus [Li et al., Gastroenterology, 139: 1472-80 (2010)] and human colonic dysplasia [Hsiung et al., Nat. Med., 14: 454-458 (2008)] using the
commercially available NEB Ml 3 phage system. The T7 system has proven effective in in vivo panning experiments identifying peptides specific to pancreatic islet vasculature [Joyce et al., Cancer Cell, 4: 393-403 (2003)], breast vasculature [Essler and Ruoslahti, Proc. Natl. Acad. Sci. USA, 99: 2252-2257 (2002)] , bladder tumor cells [Lee et al., Mol. Cancer Res., 5(1): 11-19 (2007)], and liver tissue [Ludtke et al., Drug Deliv., 14: 357-369 (2007)] .
Panning with intact tissue presents additional relevant cell targets while accounting for subtle features in the tissue microenvironment that may affect binding.
[0009] Improved animal models for CRC and new products and methods for early detection of dysplasia are needed in the art. New products and methods for early detection would have important clinical applications for increasing the survival rate for CRC and reducing the healthcare costs.
Description
[0010] Transformed cells and tissues express molecular changes well in advance of gross morphological changes, thus providing a unique opportunity for the early detection of cancer. Peptides that bind to pre-cancerous colorectal lesions have the potential to guide tissue biopsy for lesions that are endoscopically "invisible," and such peptides can be isolated using combinatorial phage display screening. Peptides have in vivo advantages in the
gastrointestinal tract because they can be delivered topically to identify early molecular changes on the surface of epithelial cells located on the most superficial layer of mucosa where cancer originates. In addition, they can exhibit rapid binding kinetics and also diffuse into diseased mucosa.
[0011] In one aspect, the invention provides peptides that bind to dysplastic colon cells and/or cancerous colon cells. Examples of peptides provided are
NGTTSSNNQLINENNIQN (SEQ ID NO: 3), EHMYNTPHTYHTTMKNNK (SEQ ID NO: 4), QPIHPNNM (SEQ ID NO: 1), NKLAAALE (SEQ ID NO: 5), KNYKN (SEQ ID NO: 6), TNTHN (SEQ ID NO: 7) and KHTNN (SEQ ID NO: 8). Still other examples are SILPYPY (SEQ ID NO: 9), KCCFPAQ (SEQ ID NO: 2), YRAPWPP (SEQ ID NO: 10), QPWPTSI (SEQ ID NO: 11), WPTPPYA (SEQ ID NO: 12), MHAPPFY (SEQ ID NO: 13), VRPTLPM (SEQ ID NO: 22, NFMES LPRLGMH (SEQ ID NO: 23), HYKL (SEQ ID NO: 24),
AKPGYLS (SEQ ID NO: 25), and LTTHKYL (SEQ ID NO: 26). Accordingly, a reagent is provided comprising a peptide consisting of an amino acid sequence selected from
NGTTSSNNQLINENNIQN (SEQ ID NO: 3), EHMYNTPHTYHTTMKNNK (SEQ ID NO: 4), QPIHPNNM (SEQ ID NO: 1), NKLAAALE (SEQ ID NO: 5), KNYKN (SEQ ID NO: 6), TNTHN (SEQ ID NO: 7), KHTNN (SEQ ID NO: 8), SILPYPY (SEQ ID NO: 9), KCCFPAQ (SEQ ID NO: 2), YRAPWPP (SEQ ID NO: 10), QPWPTSI (SEQ ID NO: 11), WPTPPYA (SEQ ID NO: 12), MHAPPFY (SEQ ID NO: 13), VRPTLPM (SEQ ID NO: 22,
NFMES LPRLGMH (SEQ ID NO: 23), HYKL (SEQ ID NO: 24), AKPGYLS (SEQ ID NO: 25), and LTTHKYL (SEQ ID NO: 26). The disclosure further provides a peptide consisting of an amino acid sequence selected from NGTTSSNNQLINENNIQN (SEQ ID NO: 3), EHMYNTPHTYHTTMKNNK (SEQ ID NO: 4), QPIHPNNM (SEQ ID NO: 1),
NKLAAALE (SEQ ID NO: 5), KNYKN (SEQ ID NO: 6), TNTHN (SEQ ID NO: 7), KHTNN (SEQ ID NO: 8), SILPYPY (SEQ ID NO: 9), KCCFPAQ (SEQ ID NO: 2), YRAPWPP (SEQ ID NO: 10), QPWPTSI (SEQ ID NO: 11), WPTPPYA (SEQ ID NO: 12), MHAPPFY (SEQ ID NO: 13), VRPTLPM (SEQ ID NO: 22, NFMESLPRLGMH (SEQ ID NO: 23), HYKL (SEQ ID NO: 24), AKPGYLS (SEQ ID NO: 25), and LTTHKYL (SEQ ID NO: 26). Also provided is a reagent comprising a peptide consisting essentially of an amino acid sequence selected from NGTTSSNNQLINENNIQN (SEQ ID NO: 3),
EHMYNTPHTYHTTMKNNK (SEQ ID NO: 4), QPIHPNNM (SEQ ID NO: 1),
NKLAAALE (SEQ ID NO: 5), KNYKN (SEQ ID NO: 6), TNTHN (SEQ ID NO: 7), KHTNN (SEQ ID NO: 8), SILPYPY (SEQ ID NO: 9), KCCFPAQ (SEQ ID NO: 2), YRAPWPP (SEQ ID NO: 10), QPWPTSI (SEQ ID NO: 11), WPTPPYA (SEQ ID NO: 12), MHAPPFY (SEQ ID NO: 13), VRPTLPM (SEQ ID NO: 22, NFMESLPRLGMH (SEQ ID NO: 23), HYKL (SEQ ID NO: 24), AKPGYLS (SEQ ID NO: 25), and LTTHKYL (SEQ ID NO: 26). A peptide is also provided consisting essentially of an amino acid sequence selected from NGTTSSNNQLINENNIQN (SEQ ID NO: 3), EHMYNTPHTYHTTMKNNK (SEQ ID NO: 4), QPIHPNNM (SEQ ID NO: 1), NKLAAALE (SEQ ID NO: 5), KNYKN (SEQ ID NO: 6), TNTHN (SEQ ID NO: 7), KHTNN (SEQ ID NO: 8), SILPYPY (SEQ ID NO: 9), KCCFPAQ (SEQ ID NO: 2), YRAPWPP (SEQ ID NO: 10), QPWPTSI (SEQ ID NO: 11), WPTPPYA (SEQ ID NO: 12), MHAPPFY (SEQ ID NO: 13), VRPTLPM (SEQ ID NO: 22, NFMESLPRLGMH (SEQ ID NO: 23), HYKL (SEQ ID NO: 24), AKPGYLS (SEQ ID NO: 25), and LTTHKYL (SEQ ID NO: 26). Further a reagent is provided comprising a peptide comprising an amino acid sequence selected from NGTTSSNNQLINENNIQN (SEQ ID NO: 3), EHMYNTPHTYHTTMKNNK (SEQ ID NO: 4), QPIHPNNM (SEQ ID NO: 1), NKLAAALE (SEQ ID NO: 5), KNYKN (SEQ ID NO: 6), TNTHN (SEQ ID NO: 7), KHTNN (SEQ ID NO: 8), SILPYPY (SEQ ID NO: 9), KCCFPAQ (SEQ ID NO: 2), YRAPWPP (SEQ ID NO: 10), QPWPTSI (SEQ ID NO: 11), WPTPPYA (SEQ ID NO: 12),
MHAPPFY (SEQ ID NO: 13), VRPTLPM (SEQ ID NO: 22, NFMESLPRLGMH (SEQ ID NO: 23), HYKL (SEQ ID NO: 24), AKPGYLS (SEQ ID NO: 25), and LTTHKYL (SEQ ID NO: 26). In still another aspect, a peptide is provided comprising an amino acid sequence selected from NGTTSSNNQLINENNIQN (SEQ ID NO: 3), EHMYNTPHTYHTTMKNNK (SEQ ID NO: 4), QPIHPNNM (SEQ ID NO: 1), NKLAAALE (SEQ ID NO: 5), KNYKN (SEQ ID NO: 6), TNTHN (SEQ ID NO: 7), KHTNN (SEQ ID NO: 8), SILPYPY (SEQ ID NO: 9), KCCFPAQ (SEQ ID NO: 2), YRAPWPP (SEQ ID NO: 10), QPWPTSI (SEQ ID NO: 11), WPTPPYA (SEQ ID NO: 12), MHAPPFY (SEQ ID NO: 13), VRPTLPM (SEQ ID NO: 22, NFMESLPRLGMH (SEQ ID NO: 23), HYKL (SEQ ID NO: 24), AKPGYLS (SEQ ID NO: 25), and LTTHKYL (SEQ ID NO: 26).
[0012] In a further aspect, the invention provides reagents comprising a peptide of the invention.
[0013] In some embodiments, the reagents comprise a detectable label attached to a peptide of the invention. The detectable label may be detectable, for example, by
microscopy, ultrasound, PET, SPECT, or magnetic resonance imaging. In some
embodiments the label detectable by microscopy is fluorescein isothiocyanate (FITC), 7- diethylaminocoumarin-3-carboxylic acid (DEAC), CF-633 or 5- carboxytetramethylrhodamine (TAMRA) .
[0014] In some embodiments, a detectable label is attached to a peptide of the invention by a peptide linker. The terminal amino acid of the linker by be a lysine such as in the exemplary linker GGGSK (SEQ ID NO: 14). In certain aspects, the linker is an Ahx linker, an amino terminal linker comprising 6-amino hexanoic acid.
[0015] In other embodiments, the reagents comprise a therapeutic moiety attached to a peptide of the invention. The therapeutic moiety may be a chemopreventative or
chemotherapeutic agent. In certain embodiments, the therapeutic moiety is celecoxib, 5- fluorouracil, and/or chlorambucil.
[0016] In yet a further aspect, the invention provides a composition comprising a reagent of the invention and a pharmaceutically acceptable excipient.
[0017] In still a further aspect, the invention provides a method for detecting colon dysplasia in a patient comprising the steps of administering a reagent comprising a peptide of the invention attached to a detectable label to the colon of the patient and detecting binding of the reagent to dysplastic cells. In some embodiments, the detectable binding takes place in vivo. In others, the detectable binding takes places in vitro. In still others, the detectable
binding takes place in situ. In the colon, the transformation from pre-malignant mucosa to carcinoma involves the development of flat and depressed (non-polypoid) lesions, adenomatous polyps (polypoid lesions) and then frank carcinoma (colon cancer cells).
Detecting colon dysplasia (i.e., dysplastic cells) according to the invention includes detecting binding to flat and depressed lesions, adenomatous polyps and/or cancer cells. In some embodiments, a reagent of the invention specifically detects cells of flat and depressed lesions. In some embodiments, a reagent of the invention specifically detects cells of adenomatous polyps. In some embodiments, a reagent of the invention specifically detects colon cancer cells. In some embodiments, a reagent of the invention may specifically detect two or more of cells of flat and depressed lesions, cells of adenomatous polyps and colon cancer cells. The phrase "specifically detects" means that the reagent binds to and is detected in association with a type of cell, and the reagent does not bind to and is not detected in association with another type of cell at the level of sensitivity at which the method is carried out. Flat dysplastic lesions are also observed in the setting of chronic ulcerative colitis and are also contemplated to be detectable by methods of the invention.
[0018] In an additional aspect, the invention provides a method of determining the effectiveness of a treatment for colon cancer and/or cancer metastasis, or recurrence of cancer in a patient comprising the step of administering a reagent comprising a peptide of the invention attached to a detectable label to the colon of the patient, visualizing a first amount of cells labeled with the reagent, and comparing the first amount to a previously- visualized second amount of cells labeled with the reagent, wherein a decrease in the first amount cells labeled relative to the previously- visualized second amount of cells labeled is indicative of effective treatment. In some embodiments, a decrease of 5% is indicative of effective treatment. In other embodiments, a decrease of about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95% or more is indicative of effective treatment. In some embodiments, the method further comprises obtaining a biopsy of the cells labeled by the reagent.
[0019] In another aspect, the invention provides a method for delivering a therapeutic agent to dysplastic colon cells of a patient comprising the step of administering a reagent comprising a peptide of the invention attached to a therapeutic moiety to the patient.
[0020] In yet another aspect, the invention provides a method for delivering a therapeutic agent to colon cancer cells of a patient comprising the step of administering a reagent comprising a peptide of the invention attached to a therapeutic moiety to the patient.
[0021] In still another aspect, the invention provides a kit for administering a composition of the invention to a patient in need thereof, where the kit comprises a composition of invention, instructions for use of the composition and a device for administering the composition to the patient.
Linkers, Peptides and Peptide Analogs
[0022] As used herein, a "linker" is a sequence of amino acids, generally uncharged, located at a terminus of a polypeptide of the disclosure. In some embodiments, the linker sequence terminates with a lysine residue. Uncharged amino acids contemplated by the present disclosure include, but are not limited to, glycine, serine, cysteine, threonine, histidine, tyrosine, asparagine, and glutamine.
[0023] In some embodiments, the presence of a linker results in at least a 1% increase in detectable binding of a reagent of the invention to dysplastic colon cells or cancerous colon cells compared to the detectable binding of the reagent in the absence of the linker. In various aspects, the increase in detectable binding is at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, at least about 2-fold, at least about 3- fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 35-fold, at least about 40-fold, at least about 45-fold, at least about 50-fold, at least about 100-fold or more.
[0024] The term "peptide" refers to molecules of 2 to 50 amino acids, molecules of 3 to 20 amino acids, and those of 6 to 15 amino acids. Peptides and linkers as contemplated by the invention may be 5 amino acids in length. In various aspects, a polypeptide or linker may be 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or more amino acids in length.
[0025] Exemplary peptides are, in various aspects, randomly generated by methods known in the art, carried in a polypeptide library (for example and without limitation, a phage display library), derived by digestion of proteins, or chemically synthesized. Peptides
exemplified in the present disclosure have been developed using techniques of phage display, a powerful combinatorial method that uses recombinant DNA technology to generate a complex library of polypeptides for selection by preferential binding to cell surface targets [Scott et al., Science, 249:386-390 (1990)]. The protein coat of bacteriophage, such as the filamentous M13 or icosahedral T7, is genetically engineered to express a very large number (>109) of different polypeptides with unique sequences to achieve affinity binding [Cwirla et al, Proc. Natl. Acad. Sci. USA, 87:6378-6382 (1990)]. Selection is then performed by biopanning the phage library against cultured cells and tissues that over express the target. The DNA sequences of these candidate phage are then recovered and used to synthesize the polypeptide [Pasqualini et al., Nature, 380:364-366 (1996)]. The polypeptides that preferentially bind to dysplastic mucosa are optionally labeled with fluorescence dyes, including but not limited to, FITC, Cy 5.5, Cy 7, and Li-Cor. These polypeptide-dye reagents have been developed and have demonstrated preferential binding to colon cancer (HT29) cells in culture and to pre-clinical xenograft models [Kelly et al., Cancer Res., (54:6247-51 (2004)].
[0026] Peptides include D and L forms, either purified or in a mixture of the two forms. Also contemplated by the present disclosure are peptides that compete with peptides of the invention for binding to colon cells.
[0027] In some embodiments, a peptide of a reagent of the invention is presented in multimer form. Various scaffolds are known in the art upon which multiple peptides can be presented. In one exemplary embodiment herein, peptide AKPGYLS (SEQ ID NO: 25) is presented in multimer form on a trilysine dendritic wedge. Other scaffolds known in the art include, but are not limited to, other dendrimers and polymeric (e.g., PEG) scaffolds.
[0028] It will be understood that peptides and linkers of the invention optionally incorporate modifications known in the art and that the location and number of such modifications are varied to achieve an optimal effect.
[0029] In some embodiments, the compound is a peptide analog having a structure based on one of the peptides disclosed herein (the "parent peptide") but differs from the parent peptide in one or more respects. Accordingly, as appreciated by one of ordinary skill in the art, the teachings regarding the parent peptides provided herein may also be applicable the peptide analogs.
[0030] In some embodiments, the peptide analog comprises the structure of a parent peptide, except that the peptide analog comprises one or more non-peptide bonds in place of
peptide bond(s). In some embodiments, the peptide analog comprises in place of a peptide bond, an ester bond, an ether bond, a thioether bond, an amide bond, and the like. In some embodiments, the peptide analog is a depsipeptide comprising an ester linkage in place of a peptide bond.
[0031] In some embodiments, the peptide analog comprises the structure of a parent peptide described herein, except that the peptide analog comprises one or more amino acid substitutions, e.g., one or more conservative amino acid substitutions. Conservative amino acid substitutions are known in the art, and include amino acid substitutions in which one amino acid having certain physical and/or chemical properties is exchanged for another amino acid that has the same chemical or physical properties. For instance, the conservative ammo acid substitution may be an acidic amino acid substituted for another acidic amino acid (e.g., Asp or Glu), an amino acid with a nonpolar side chain substituted for another amino acid with a nonpolar side chain (e.g., Ala, Gly, Val, He, Leu, Met, Phe, Pro, Trp, Val, etc.), a basic amino acid substituted for another basic amino acid (Lys, Arg, etc.), an amino acid with a polar side chain substituted for another amino acid with a polar side chain (Asn, Cys, Gin, Ser, Thr, Tyr, etc.), etc.
[0032] In some aspects, the peptide analog comprises one or more synthetic amino acids, e.g., an amino acid non-native to a mammal. Synthetic amino acids include β-alanine (β- Ala), N-a-methyl- alanine (Me-Ala), aminobutyric acid (Abu), γ-aminobutyric acid (γ-Abu), aminohexanoic acid (ε-Ahx), aminoisobutyric acid (Aib), aminomethylpyrrole carboxylic acid, aminopiperidinecarboxylic acid, aminoserine (Ams), aminotetrahydropyran-4- carboxylic acid, arginine N-methoxy-N-methyl amide, β-aspartic acid (β-Asp), azetidine carboxylic acid, 3-(2-benzothiazolyl)alanine, cc-iert-butylglycine, 2-amino-5-ureido-n-valeric acid (citrulline, Cit), β-Cyclohexylalanine (Cha), acetamidomethyl-cysteine, diaminobutanoic acid (Dab), diaminopropionic acid (Dpr), dihydroxyphenylalanine (DOPA),
dimethylthiazolidine (DMTA), γ-Glutamic acid (γ-Glu), homoserine (Hse), hydroxyproline (Hyp), isoleucine N-methoxy-N-methyl amide, methyl-isoleucine (Melle), isonipecotic acid (Isn), methyl-leucine (MeLeu), methyl-lysine, dimethyl-lysine, trimethyl-lysine,
methanoproline, methionine- sulfoxide (Met(O)), methionine- sulf one (Met(02)), norleucine (Nle), methyl-norleucine (Me-Nle), norvaline (Nva), ornithine (Orn), para-aminobenzoic acid (PABA), penicillamine (Pen), methylphenylalanine (MePhe), 4-Chlorophenylalanine (Phe(4- Cl)), 4-fluorophenylalanine (Phe(4-F)), 4-nitrophenylalanine (Phe(4-N02)), 4- cyanophenylalanine ((Phe(4-CN)), phenylglycine (Phg), piperidinylalanine,
piperidinylglycine, 3,4-dehydroproline, pyrrolidinylalanine, sarcosine (Sar), selenocysteine
(Sec), O-Benzyl-phosphoserine, 4-amino-3-hydroxy-6-methylheptanoic acid (Sta), 4-amino- 5-cyclohexyl-3-hydroxypentanoic acid (ACHPA), 4-amino-3-hydroxy-5-phenylpentanoic acid (AHPPA), l,2,3,4,-tetrahydro-isoquinoline-3-carboxylic acid (Tic),
tetrahydropyranglycine, thienylalanine (Thi) , O-benzyl-phosphotyrosine, O- Phosphotyrosine, methoxytyrosine, ethoxytyrosine, O-(bis-dimethylamino-phosphono)- tyrosine, tyrosine sulfate tetrabutylamine, methyl-valine (MeVal), and alkylated 3- mercaptopropionic acid.
[0033] In some embodiments, the peptide analog comprises one or more non-conservative amino acid substitutions and the peptide analog still functions to a similar extent, the same extent, or an improved extent as the parent peptide. In certain embodiments, the peptide analog comprising one or more non-conservative amino acid substitutions exhibits about the same or greater binding to the colon cell in comparison to the parent peptide.
[0034] In some embodiments, the peptide analog comprises one or more amino acid insertions or deletions, in comparison to the parent peptide described herein. In some embodiments, the peptide analog comprises an insertion of one or more amino acids in comparison to the parent peptide. In some embodiments, the peptide analog comprises a deletion of one or more amino acids in comparison to the parent peptide. In some
embodiments, the peptide analog comprises an insertion of one or more amino acids at the N- or C-terminus in comparison to the parent peptide. In some embodiments, the peptide analog comprises a deletion of one or more amino acids at the N- or C-terminus in comparison to the parent peptide. In these embodiments, the peptide analog still exhibits about the same or greater binding to colon cells in comparison to the parent peptide.
Detectable markers
[0035] As used herein, a "detectable marker" is any label that can be used to identify the binding of a composition of the disclosure to colon tissue. Non-limiting examples of detectable markers are fluorophores, chemical or protein tags that enable the visualization of a polypeptide. Visualization in certain aspects is carried out with the naked eye, or a device (for example and without limitation, an endoscope) and may also involve an alternate light or energy source.
[0036] Fluorophores, chemical and protein tags that are contemplated for use in the invention include, but are not limited to, FITC, Cy 5.5, Cy 7, Li-Cor, a radiolabel, biotin, luciferase, 1,8-ANS (l-Anilinonaphthalene-8-sulfonic acid), l-Anilinonaphthalene-8-sulfonic acid (1,8-ANS), 5-(and-6)-Carboxy-2', 7'-dichlorofluorescein pH 9.0, 5-FAM pH 9.0, 5-ROX
(5-Carboxy-X-rhodamine, triethylammonium salt), 5-ROX pH 7.0, 5-TAMRA, 5 -T AMR A pH 7.0, 5-TAMRA-MeOH, 6 JOE, 6,8-Difluoro-7-hydroxy-4-methylcoumarin pH 9.0, 6- Carboxyrhodamine 6G pH 7.0, 6-Carboxyrhodamine 6G, hydrochloride, 6-HEX, SE pH 9.0, 6-TET, SE pH 9.0, 7-Amino-4-methylcoumarin pH 7.0, 7-Hydroxy-4-methylcoumarin, 7- Hydroxy-4-methylcoumarin pH 9.0, Alexa 350, Alexa 405, Alexa 430, Alexa 488, Alexa 532, Alexa 546, Alexa 555, Alexa 568, Alexa 594, Alexa 647, Alexa 660, Alexa 680, Alexa 700, Alexa Fluor 430 antibody conjugate pH 7.2, Alexa Fluor 488 antibody conjugate pH 8.0, Alexa Fluor 488 hydrazide-water, Alexa Fluor 532 antibody conjugate pH 7.2, Alexa Fluor 555 antibody conjugate pH 7.2, Alexa Fluor 568 antibody conjugate pH 7.2, Alexa Fluor 610 R-phycoerythrin streptavidin pH 7.2, Alexa Fluor 647 antibody conjugate pH 7.2, Alexa Fluor 647 R-phycoerythrin streptavidin pH 7.2, Alexa Fluor 660 antibody conjugate pH 7.2, Alexa Fluor 680 antibody conjugate pH 7.2, Alexa Fluor 700 antibody conjugate pH 7.2, Allophycocyanin pH 7.5, AMCA conjugate, Amino Coumarin, APC (allophycocyanin) ,Atto 647, BCECF pH 5.5, BCECF pH 9.0, BFP (Blue Fluorescent Protein), Calcein, Calcein pH 9.0, Calcium Crimson, Calcium Crimson Ca2+, Calcium Green, Calcium Green- 1 Ca2+, Calcium Orange, Calcium Orange Ca2+, Carboxynaphthofluorescein pH 10.0, Cascade Blue, Cascade Blue BSA pH 7.0, Cascade Yellow, Cascade Yellow antibody conjugate pH 8.0, CFDA, CFP (Cyan Fluorescent Protein), CI-NERF pH 2.5, CI-NERF pH 6.0, Citrine, Coumarin, Cy 2, Cy 3, Cy 3.5, Cy 5, CyQUANT GR-DNA, Dansyl Cadaverine, Dansyl Cadaverine, MeOH, DAPI, DAPI-DNA, Dapoxyl (2-aminoethyl) sulfonamide, DDAO pH 9.0, Di-8 ANEPPS, Di-8-ANEPPS-lipid, Dil, DiO, DM-NERF pH 4.0, DM-NERF pH 7.0, DsRed, DTAF, dTomato, eCFP (Enhanced Cyan Fluorescent Protein), eGFP (Enhanced Green Fluorescent Protein), Eosin, Eosin antibody conjugate pH 8.0, Erythrosin-5- isothiocyanate pH 9.0, eYFP (Enhanced Yellow Fluorescent Protein), FDA, FITC antibody conjugate pH 8.0, FlAsH, Fluo-3, Fluo-3 Ca2+, Fluo-4, Fluor-Ruby, Fluorescein, Fluorescein 0.1 M NaOH, Fluorescein antibody conjugate pH 8.0, Fluorescein dextran pH 8.0,
Fluorescein pH 9.0, Fluoro-Emerald, FM 1-43, FM 1-43 lipid, FM 4-64, FM 4-64, 2%
CHAPS, Fura Red Ca2+, Fura Red, high Ca, Fura Red, low Ca, Fura-2 Ca2+, Fura-2, Fura-2, GFP (S65T), HcRed, Indo-1 Ca2+, Indo-1, Ca free, Indo-1, Ca saturated, JC-1, JC-1 pH 8.2, Lissamine rhodamine, Lucifer Yellow, CH, Magnesium Green, Magnesium Green Mg2+, Magnesium Orange, Marina Blue, mBanana, mCherry, mHoneydew, mOrange, mPlum, mRFP, mStrawberry, mTangerine, NBD-X, NBD-X, MeOH, NeuroTrace 500/525, green fluorescent Nissl stain-RNA, Nile Blue, Nile Red, Nile Red-lipid, Nissl, Oregon Green 488, Oregon Green 488 antibody conjugate pH 8.0, Oregon Green 514, Oregon Green 514 antibody conjugate pH 8.0, Pacific Blue, Pacific Blue antibody conjugate pH 8.0,
Phycoerythrin, R-Phycoerythrin pH 7.5, ReAsH, Resorufin, Resorufin pH 9.0, Rhod-2, Rhod- 2 Ca2+, Rhodamine, Rhodamine 110, Rhodamine 110 pH 7.0, Rhodamine 123, MeOH, Rhodamine Green, Rhodamine phalloidin pH 7.0, Rhodamine Red-X antibody conjugate pH 8.0, Rhodamine Green pH 7.0, Rhodol Green antibody conjugate pH 8.0, Sapphire, SBFI- Na+, Sodium Green Na+, Sulforhodamine 101, Tetramethylrhodamine antibody conjugate pH 8.0, Tetramethylrhodamine dextran pH 7.0, and Texas Red-X antibody conjugate pH 7.2.
[0037] Non-limiting examples of chemical tags contemplated by the invention include radiolabels. For example and without limitation, radiolabels that contemplated in the compositions and methods of the present disclosure include 11 C, 13 N, 15 O, 18 F, 32 P, 52 Fe , 62Cu, ^Cu, 67Cu, 67Ga, 68Ga, 86Y, 89Zr, 90Y, 94mTc, 94Tc, 95Tc, "mTc, 103Pd, 105Rh, 109Pd, mAg, mIn, 123I, 124I, 125I, 131I, 140La, 149Pm, 153Sm, 154"159Gd, 165Dy, 166Dy, 166Ho, 169Yb, 175Yb, 175Lu, 177Lu, 186Re, 188Re, 192Ir, 198Au, 199Au, and 212Bi.
[0038] A worker of ordinary skill in the art will appreciate that there are many such detectable markers that can be used to visualize a composition of the disclosure, in vitro, in vivo or ex vivo.
Therapeutic moieties
[0039] Therapeutic moieties contemplated by the invention include, but are not limited to polypeptides or peptides, small molecules, therapeutic agents, chemotherapeutic agents, or combinations thereof.
[0040] The term "small molecule", as used herein, refers to a chemical compound, for instance a peptidometic or oligonucleotide that may optionally be derivatized, or any other low molecular weight organic compound, either natural or synthetic.
[0041] By "low molecular weight" is meant compounds having a molecular weight of less than 1000 Daltons, typically between 300 and 700 Daltons. Low molecular weight compounds, in various aspects, are about 100, about 150, about 200, about 250, about 300, about 350, about 400, about 450, about 500, about 550, about 600, about 650, about 700, about 750, about 800, about 850, about 900, about 1000 or more Daltons.
[0042] In some aspects, the therapeutic moiety is a protein therapeutic. Protein
therapeutics include, without limitation, cellular or circulating proteins as well as fragments and derivatives thereof. Still other therapeutic moieties include polynucleotides, including without limitation, protein coding polynucleotides, polynucleotides encoding regulatory polynucleotides, and/or polynucleotides which are regulatory in themselves. Optionally, the compositions comprise a combination of the compounds described herein.
[0043] In various aspects, protein therapeutics include cytokines or hematopoietic factors including without limitation IL-1 alpha, IL-1 beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-11, colony stimulating factor- 1 (CSF-1), M-CSF, SCF, GM-CSF, granulocyte colony stimulating factor (G-CSF), EPO, interferon- alpha (IFN-alpha), consensus interferon, IFN-beta, IFN-gamma, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, thrombopoietin (TPO), angiopoietins, for example Ang-1, Ang-2, Ang-4, Ang-Y, the human angiopoietin- like polypeptide, vascular endothelial growth factor (VEGF), angiogenin, bone morphogenic protein- 1, bone morphogenic protein-2, bone morphogenic protein-3, bone morphogenic protein-4, bone morphogenic protein-5, bone morphogenic protein-6, bone morphogenic protein-7, bone morphogenic protein-8, bone morphogenic protein-9, bone morphogenic protein-10, bone morphogenic protein-11, bone morphogenic protein-12, bone morphogenic protein- 13, bone morphogenic protein- 14, bone morphogenic protein- 15, bone morphogenic protein receptor IA, bone morphogenic protein receptor IB, brain derived neurotrophic factor, ciliary neutrophic factor, ciliary neutrophic factor receptor, cytokine-induced neutrophil chemotactic factor 1, cytokine-induced neutrophil, chemotactic factor 2a, cytokine-induced neutrophil chemotactic factor 2β, β endothelial cell growth factor, endothelin 1, epidermal growth factor, epithelial-derived neutrophil attractant, fibroblast growth factor 4, fibroblast growth factor 5, fibroblast growth factor 6, fibroblast growth factor 7, fibroblast growth factor 8, fibroblast growth factor 8b, fibroblast growth factor 8c, fibroblast growth factor 9, fibroblast growth factor 10, fibroblast growth factor acidic, fibroblast growth factor basic, glial cell line-derived neutrophic factor receptor al, glial cell line-derived neutrophic factor receptor a2, growth related protein, growth related protein a, growth related protein β, growth related protein γ, heparin binding epidermal growth factor, hepatocyte growth factor, hepatocyte growth factor receptor, insulin-like growth factor I, insulin-like growth factor receptor, insulin-like growth factor II, insulin-like growth factor binding protein, keratinocyte growth factor, leukemia inhibitory factor, leukemia inhibitory factor receptor a, nerve growth factor nerve growth factor receptor, neurotrophin-3, neurotrophin-4, placenta growth factor, placenta growth factor 2, platelet-derived endothelial cell growth factor, platelet derived growth factor, platelet derived growth factor A chain, platelet derived growth factor AA, platelet derived growth factor AB, platelet derived growth factor B chain, platelet derived growth factor BB, platelet derived growth factor receptor a, platelet derived growth factor receptor β, pre-B cell growth stimulating factor, stem cell factor receptor, TNF, including TNF0, TNF1, TNF2, transforming growth factor a, transforming growth factor β,
transforming growth factor βΐ, transforming growth factor βΐ.2, transforming growth factor β2, transforming growth factor β3, transforming growth factor β5, latent transforming growth
factor βΐ, transforming growth factor β binding protein I, transforming growth factor β binding protein II, transforming growth factor β binding protein III, tumor necrosis factor receptor type I, tumor necrosis factor receptor type II, urokinase-type plasminogen activator receptor, vascular endothelial growth factor, and chimeric proteins and biologically or immunologically active fragments thereof.
[0044] Therapeutic moieties also include, as one embodiment, chemotherapeutic agents. A chemotherapeutic agent contemplated for use in a reagent of the invention includes, without limitation, alkylating agents including: nitrogen mustards, such as mechlor-ethamine, cyclophosphamide, ifosfamide, melphalan and chlorambucil; nitrosoureas, such as carmustine (BCNU), lomustine (CCNU), and semustine (methyl-CCNU);
ethylenimines/methylmelamine such as thriethylenemelamine (TEM), triethylene, thiophosphoramide (thiotepa), hexamethylmelamine (HMM, altretamine); alkyl sulfonates such as busulfan; triazines such as dacarbazine (DTIC); antimetabolites including folic acid analogs such as methotrexate and trimetrexate, pyrimidine analogs such as 5-fluorouracil, fluorodeoxyuridine, gemcitabine, cytosine arabinoside (AraC, cytarabine), 5-azacytidine, 2,2'-difluorodeoxycytidine, purine analogs such as 6-mercaptopurine, 6-thioguanine, azathioprine, 2'-deoxycoformycin (pento statin), erythrohydroxynonyladenine (EHNA), fludarabine phosphate, and 2-chlorodeoxyadenosine (cladribine, 2-CdA); natural products including antimitotic drugs such as paclitaxel, vinca alkaloids including vinblastine (VLB), vincristine, and vinorelbine, taxotere, estramustine, and estramustine phosphate;
epipodophylotoxins such as etoposide and teniposide; antibiotics such as actimomycin D, daunomycin (rubidomycin), doxorubicin, mitoxantrone, idarubicin, bleomycins, plicamycin (mithramycin), mitomycinC, and actinomycin; enzymes such as L-asparaginase; biological response modifiers such as interferon-alpha, IL-2, G-CSF and GM-CSF; miscellaneous agents including platinium coordination complexes such as cisplatin and carboplatin, anthracenediones such as mitoxantrone, substituted urea such as hydroxyurea,
methylhydrazine derivatives including N-methylhydrazine (MIH) and procarbazine, adrenocortical suppressants such as mitotane (ο,ρ'-DDD) and aminoglutethimide; hormones and antagonists including adrenocortico steroid antagonists such as prednisone and equivalents, dexamethasone and aminoglutethimide; progestin such as hydroxyprogesterone caproate, medroxyprogesterone acetate and megestrol acetate; estrogen such as
diethylstilbestrol and ethinyl estradiol equivalents; antiestrogen such as tamoxifen; androgens including testosterone propionate and fluoxymesterone/equivalents; antiandrogens such as
flutamide, gonadotropin-releasing hormone analogs and leuprolide; and non-steroidal antiandrogens such as flutamide.
[0045] Dosages of the therapeutic moiety or reagent provided are administered as a dose measured in, for example, mg/kg. Contemplated mg/kg doses of the disclosed therapeutics include about 1 mg/kg to about 60 mg/kg. Specific ranges of doses in mg/kg include about 1 mg/kg to about 20 mg/kg, about 5 mg/kg to about 20 mg/kg, about 10 mg/kg to about 20 mg/kg, about 25 mg/kg to about 50 mg/kg, and about 30 mg/kg to about 60 mg/kg. The precise effective amount for a subject will depend upon the subject's body weight, size, and health; the nature and extent of the condition; and the therapeutic or combination of therapeutics selected for administration. Therapeutically effective amounts for a given situation can be determined by routine experimentation that is within the skill and judgment of the clinician.
[0046] "Effective amount" as used herein refers to an amount of a reagent of the invention sufficient to visualize the identified disease or condition, or to exhibit a detectable therapeutic or inhibitory effect. The effect is detected by, for example, an improvement in clinical condition or reduction in symptoms. The precise effective amount for a subject will depend upon the subject's body weight, size, and health; the nature and extent of the condition; and the therapeutic or combination of therapeutics selected for administration. Therapeutically effective amounts for a given situation can be determined by routine experimentation that is within the skill and judgment of the clinician.
Visualization of reagents
[0047] Visualization of binding to colon cells is by any means known to those of ordinary skill in the art. As discussed herein, visualization is, for example and without limitation, in vivo, in vitro, or in situ visualization.
[0048] In one embodiment, visualization is performed via imaging and may be performed with a wide area endoscope (Olympus Corporation, Tokyo, Japan) that is designed specifically to collect fluorescence images with high spatial resolution over large mucosal surface areas on the macroscopic scale (millimeters to centimeters). This capability is needed to rapidly screen large surface areas such as that found in the distal esophagus during endoscopy to localize regions suspicious for disease [Wang et ah, Gastrointestinal Endoscopy 1999; 49:447-55]. This technique has been adapted for fluorescence detection, and is compatible with dye-labeled probes. This instrument can image in three different modes, including white light (WL), narrowband imaging (NBI), and fluorescence imaging. Narrow-
band imaging is a new technology that represents a variation of conventional white light illumination by altering the spectrum with optical filters to restrict or narrow the range of wavelengths.
[0049] The method enhances contrast in the endoscopic images to provide more visual details of the esophageal mucosa by tuning the light to maximize absorption of hemoglobin present in the vasculature of regions of intestinal metaplasia. The WL and NBI images are collected by the central objective lens, and the fluorescence image is collected by a second objective lens located near the periphery. There is a distance of approximately 3 mm between the centers of the white light and fluorescence objectives that results in only a slight misregistration of the two images. Furthermore, there is an air/water nozzle that removes debris from the objective lenses, and a 2.8 mm diameter instrument channel that can be used to deliver biopsy forceps. The objectives are forward viewing and have a field of view (FOV), defined by maximum angle of illumination, of 140 deg. The WL/NBI imaging modes have a depth of field (DOF), defined by range of distances between the distal end of the endoscope to the mucosal surface whereby the image is in focus, of 7 to 100 mm, and that for fluorescence is 5 to 100 mm. The transverse resolution measured at a distance of 10 mm from the mucosa for WL/NBI is 15 μιη and for fluorescence is 20 μιη. A xenon light source provides the illumination for all three modes, which is determined by a filter wheel located in the image processor. Illumination for all three modes of imaging is delivered through the two fiber light guides. In the WL mode, the full visible spectrum (400 to 700 nm) is provided, while in the NBI mode, a filter wheel narrows the spectral bands in the red, green, and blue regime. In the fluorescence mode, a second filter wheel enters the illumination path, and provides fluorescence excitation in the 395 to 475 nm spectral band. In addition, illumination from 525 to 575 nm provides reflected light in the green spectral regime centered at 550 nm. The fluorescence image is collected by the peripherally located CCD detector that has a 490- 625 nm band pass filter for blocking the excitation light. Normal mucosa emits bright autofluorescence, thus the composite color appears as bright green. Because the increased vasculature in neoplastic mucosa absorbs autofluorescence, it appears with decreased intensity.
[0050] This medical endoscope can be used to collect images after reagent administration and incubation from colon with 1) white light, 2) narrow band, and fluorescence. After entering the colon, a 5 second video is collected and digitized in the white light and narrow band imaging modes. The imaging in this mode is used to assess the spatial extent of the intestinal metaplasia for comprehensive evaluation of polypeptide binding. Then,
approximately 3 ml of the fluorescence-labeled peptide is administered topically at a concentration of 10 μΜ to the colon using a mist spray catheter being careful to cover the full extent of the mucosa. Amounts of reagent of the invention can be determined by one of ordinary skill in the art.
[0051] In some embodiments where the detectable label is a radiolabel, the radiolabel is detected by nuclear imaging. Nuclear imaging is understood in the art to be a method of producing images by detecting radiation from different parts of the body after a radioactive tracer material is administered. The images are recorded on computer and on film.
[0052] Other methods of the invention involve the acquisition of a tissue sample from a patient. The tissue sample is selected from the group consisting of a tissue or organ of said patient.
Formulations
[0053] In various aspects, compositions of the invention are formulated with
pharmaceutically acceptable excipients such as carriers, solvents, stabilizers, adjuvants, diluents, etc., depending upon the particular mode of administration and dosage form. The compositions are generally formulated to achieve a physiologically compatible pH, and range from a pH of about 3 to a pH of about 11, about pH 3 to about pH 7, depending on the formulation and route of administration. In alternative embodiments, the pH is adjusted to a range from about pH 5.0 to about pH 8. In various aspects, the compositions comprise a therapeutically effective amount of at least one compound as described herein, together with one or more pharmaceutically acceptable excipients. Optionally, the compositions comprises a combination of the compounds described herein, or may include a second active ingredient useful in the treatment or prevention of bacterial growth (for example and without limitation, anti-bacterial or anti-microbial agents), or may include a combination of reagents of the invention.
[0054] Suitable excipients include, for example, carrier molecules that include large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and inactive virus particles. Other exemplary excipients include antioxidants (for example and without limitation, ascorbic acid), chelating agents (for example and without limitation, EDTA), carbohydrates (for example and without limitation, dextrin, hydroxyalkylcellulose, and hydroxyalkylmethylcellulose), stearic acid, liquids (for example and without limitation, oils,
water, saline, glycerol and ethanol) wetting or emulsifying agents, pH buffering substances, and the like.
Brief Description of the Drawing
[0055] Fig. 1 - NIR fluorescence imaging system, a) system schematic, details in text, b) 671 nm excitation is delivered from distal end of (~3 mm diameter) endoscope, c) custom polymer housing contains filter wheel to provide reflectance and fluorescence images, d) image of standard target demonstrates resolution of 9.8 μιη and FOV of 3.6 mm at imaging distance of d = 2.5 mm.
[0056] Fig. 2 - Multi- spectral scanning fiber endoscope. A) Optical design. RGB laser excitation (440, 532, and 635 nm) is delivered into a single-mode optical fiber that is scanned in a spiral pattern by a piezo tube actuator and focused onto the tissue (illumination plane) by a lens assembly. Fluorescence is collected by a ring of 12 collection fibers mounted around the periphery of the scanner housing, protected by an outer sheath. B) Fluorescence detection. Reflectance from RGB laser excitation is removed using a combination of long pass (λπ> = 450 nm) and notch (λΝ1 = 532 nm and λΝ2 = 632.8 nm) filters. Fluorescence is deflected into individual RGB channels using dichroic mirrors DM1 (λο = 460 nm) and DM2 (λο = 550 nm) and an additive dichroic filter set ( R, G, and λβ) prior to detection with PMTs.
[0057] Fig. 3 - Chemical structures of molecular probes. A) AKP-multimer, B) AKP- monomer, and C) trilysine core, R indicates either Cy5.5 or FITC label. Different
components include peptide binding motif, linker, and fluorescent dye. D) Fluorescence emission spectra of molecular probes labeled with Cy5.5 using
excitation.
Examples
[0058] The invention will be more fully understood by reference to the following examples which detail exemplary embodiments of the invention.
Example 1
Mouse Models
[0059] One type of genetically engineered mice (termed CPC:Apc) producing
adenomatous polyps, the mice used for peptide screening as described in Example 2 below, are the Cre positive progeny of mice containing Cre recombinase under the control of the Cdx2 promoter (CDX2P-9.5NLS-Cre) and mice with a floxed allele of the Ape gene as
described in Hinoi et ah, Cancer Res., 67(20): 9721-9730 (2007). This somatic mutation in an Ape allele, which leads to a truncated Ape protein, causes the development of adenomas in the distal colon as early as 10 weeks.
[0060] Another type of genetically engineered mice, mice exhibiting hyperplastic colon epithelium (termed Hyperplastic Kras), were generated by breeding mice with mutant Kras allele whose transcription is flanked by LoxP recombination sites with transgenic mice expressing Cre throughout the terminal ileum, cecum and colon (CDX2P9.5-G22Cre). To activate the mutant Kras allele in the mouse intestinal tract, KrasLSL'G12d/+ mice were crossed to previously described CDX2p9.5-G22Cre (G22Cre) transgenic mice with mosaic expression of Cre in epithelial cells of the terminal ileum, cecum and colon (Akyol et ah, Nature Methods 5, 231-3 (2008).
[0061] Mice were cared for under the approval of the University Committee on the Use and Care of Animals, University of Michigan. All mice were housed in specific pathogen- free conditions and supplied water ad libitum throughout the study.
Example 2
[0062] Sequences of peptides that bind to dysplastic colon mucosa in the CPCApc mice described in Example 1 were identified by phage display and peptides having the sequences were synthesized for further testing.
Phage Display
[0063] A T7 library was constructed with the T7Select 10-3b vector as reported in the T7Select System Manual (Novagen, Gibbstown, NJ). Briefly, random oligonucleotide insert DNA for the XI 8 library was synthesized as follows: 5'-AAC TGC AAG CTT TTA- (MNN)18-ACC ACC ACC AGA ATT CGG ATC CCC GAG CAT-3' (where N represents an equi-molar ratio of each nucleotide and M is an equi-molar ratio of adenine and cytosine) (SEQ ID NO: 15). The amino acid translation of the complementary nucleotide sequence is: MLGDPNSGGGX18 (SEQ ID NO: 16). The insert DNA was incubated with a
complementary extension primer (5'-ATG CTC GGG GAT CCG AAT TCTGGT-3') (SEQ ID NO: 17), Klenow enzyme (New England Biolabs, Beverly, MA), and
deoxyribonucleotide triphosphates (Novagen) to form the complementary DNA strand. This was digested with EcoRl and Hindil restriction endonucleases (New England Biolabs). Following phenol/chloroform extraction and ethanol precipitation, the purified fragments were ligated into predigested T7Select 10-3b vector by T4 DNA ligase (Novagen). The ligation reaction was incubated at 16°C, subjected to in vitro packaging, and titered to
determine the number of plaque forming units (pfu). The remaining solution was amplified in isopropyl 3-D-l-thiogalactopyranoside (IPTG)-induced BLT5615 until lysis. The lysate was titered and stored at -80°C in glycerol.
In vivo phage panning procedure
[0064] A 9 month old CPC;Apc mouse was injected via tail vein with lxl0u pfu of the parent T7-18mer library. The library was allowed to circulate for 10 minutes, after which the mouse was euthanized and organs were harvested and kept on ice. The bound phages were recovered by homogenizing each tissue or organ (colon polyps, normal colonic mucosa) (Bio-gen Pro 200) in DMEM-PI (Dulbecco's Modified Eagle Medium plus protease inhibitors: 1 mM phenylmethanesulfonylfluoride (PMSF), 20 μg/mL aprotinin, and 1 μg/mL leupeptin). The tissue samples were washed 3x with ice-cold washing medium (DMEM-PI containing 1% bovine serum albumin), centrifuging for 5 minutes at 3000 rpm between each wash. After the last wash, freshly starved bacteria were added to each tissue homogenate and incubated for 30 minutes at room temperature (RT). Pre-warmed Luria-Bertani (LB) medium with carbenicillin (50 μg/mL) was then added to the bacteria-homogenate solution and incubated another 30 minutes at RT. The supernatant was recovered after centrifugation and titered to determine the number of bound phage within each tissue tested. This procedure constituted one round of panning. After two rounds of panning, the recovered phage that bound to the colon polyps was cleared twice: once against a homogenized tissue cocktail consisting of colon, kidney, liver and heart and a second time against normal murine colon. A total of four rounds of phage panning were performed, with amplification of the recovered eluate after each panning round. The input phage number (lxlO11 pfu) was kept constant for each round of panning. The number of phages bound to each organ or tissue was calculated as the output pfu/(input pfu x tissue mass).
[0065] After the first two rounds of in vivo panning, the number of phages bound to the colonic adenomas was approximately the same as that for the adjacent normal colon tissue. However, after clearing against normal colon and other organs, the third round showed a 9- fold increase in the number of bound phages to the adenomas over adjacent normal colon tissue. This trend continued after the fourth round of panning. Fifty phages were selected from rounds three and four and the DNA was sequenced. Three entire sequences were repeated twice NGTTSSNNQLINENNIQN (SEQ ID NO: 3), EHMYNTPHTYHTTMKNNK (SEQ ID NO: 4) and QPIHPNNM (SEQ ID NO: 1) (hereafter "Phage 1" or "Peptide 1"), and four partial sequences were repeated twice NKLAAALE (SEQ ID NO: 5), KNYKN (SEQ ID NO: 6), TNTHN (SEQ ID NO: 7) and KHTNN (SEQ ID NO: 8). One of the three repeated
phages was less than eighteen amino acids because of the presence of a stop codon within the sequence.
[0066] Using the RELIC software, the INFO value for the three candidate phages were calculated against a pool of phages from the initial T7 library [Mandava et ah, Proteomics, 4: 1439-1460 (2004)]. The INFO scores for the SEQ ID NO: 3 peptide, the SEQ ID NO: 4 peptide, and Peptide 1 were 41.6, 45.2, and 49.1, respectively. A higher INFO score suggests a greater probability that the phage clone identified was not by chance. From this data, the Peptide 1 phage was shown to be the most unique clone of the three and was synthesized for further testing.
Peptide synthesis
[0067] Peptide 1 was synthesized using Fmoc-chemistry by solid phase peptide synthesis according to the literature procedure as described in Fields & Noble, Int. J. Pept. Protein Res, 35: 161-214 (1990). To ensure the phage and synthetic peptide expressed the same
orientation, Peptide 1 was synthesized with 5'-Fluorescein isothiocyanate attached to the amino terminus of the peptide via amino hexanoic acid linker. Deprotection and cleavage of the peptides were achieved by treatment with a cleavage cocktail of trifluoroacetic acid (TFA)/Tri-isopropylsilane/Water (9.5/0.25/0.25/0.25, v/v/v/v) at RT for 3-4 hours. After cleavage of the product from the resin, the peptides were purified by preparative-HPLC using a water (0.1% TFA)-acetonitrile (0.1%TFA) gradient (2-33% acetonitrile over 31 minutes) (Waters Breeze HPLC, Milford, MA). The peptides were characterized by an ESI mass spectrometer (Micromass LCT Time-of-Flight mass spectrometer with Electrospray, FITC- Peptide 1 ( mass calc. 1451.89, Obs. 1451.7 [M+H]+)). The purity (>95%) of the compound was confirmed by analytical HPLC on a CI 8 column. As the side chains of amino acids can have significant roles in binding with their receptors, a control peptide containing Gly and Ala (GGGAGGGA) (SEQ ID NO: 18) (hereafter "Control peptide 1"), which does not have any functional groups on the amino acid side chains, was synthesized using same methods [mass (Calc. 1004.08 Obs. 1004.4 [M+H]+)]. All peptides were reconstituted in lx phosphate buffered saline (PBS) at 500 μΜ and further diluted in lx PBS as necessary.
Example 3
[0068] The fluorescein-labeled Peptide 1 synthesized in Example 2 was used in endoscopic analysis.
Small Animal Endoscopy and Peptide Administration
[0069] Prior to peptide administration, the colon was prepped using a tap water lavage. Using a small animal endoscope (Karl Storz Veterinary Endoscopy, Goleta, CA) with an instrument channel for performing biopsy, polyps suitable for peptide administration were located and the colon was rinsed with water until all mucous was removed. FITC-labeled Peptide 1 and Control peptide 1 were delivered in lx PBS through the instrument channel. The peptides were allowed to incubate for 5 minutes after which the colon was cleansed 3x with a tap water to remove the unbound peptide. Prior to imaging, the colon was inspected for residual peptide solution, and when clean, the colon was insufflated with air and imaged. Fluorescence excitation produced with a 450-475 nm passband filter that can be manually switched to the optical path of a 175 W Nova Xenon light source was delivered to the endoscope via a 3 mm diameter fluid light cable (250cm length). Fluorescence images were collected with a 510 nm long-pass barrier filter to block the excitation light and detected with a 3-chip color camera with an integrated parfocal zoom lens. Real time video was recorded via firewire connected to a personal computer. Polyps in CPC;Apc mice developing distal colonic adenomas (Peptide 1, n=6 mice, n=18 polyps; Control peptide 1, n=4 mice, n=7 polyps) in addition to Cre recombinase negative littermate controls (Peptide 1, n=2 mice) and Hyperplastic Kras mice (Peptide 1, n=3 mice) were imaged using both white light and fluorescence endoscopy. The CPC;Apc mice imaged using fluorescence endoscopy ranged in age from 3-5 months.
Fluorescent Image Analysis
[0070] Videos collected via firewire during endoscopy were exported as .avi video files and converted into sequential .png images using Apple QuickTime. Consecutive white light and fluorescent images for each polyp analyzed were imported into NIH Image J. The white light image was utilized to draw a region of interest (ROI) around the polyp or adjacent normal appearing colonic mucosa which was then superimposed onto the fluorescent image. In experiments herein, a comparison of the difference in the mean findings between two groups was performed using a 2-sided independent samples t-test (a = 0.05). All data are presented as mean + SD. A p value less than 0.05 was considered as significantly different. Mean grey scale values were calculated for each ROI and a polyp/normal colon, or a target to background ratio (T/B), value was then calculated for each polyp. Target to background ratios were not calculated for Cre recombinase negative littermate control mice or
Hyperplastic Kras mice, because these mice were devoid of polyps.
[0071] The in vivo endoscopy images revealed that FITC-Peptide 1 bound to the colonic adenomas and provided greater fluorescent signal when compared to the Control peptide 1.
Furthermore, FITC-Peptide 1 showed minimal background binding to adjacent colon tissue, also clearly evident during endoscopy. Still, the FITC-Peptide 1 did not bind to colonic mucosa in littermate mice that tested negative for Cre recombinase (control mice without polyps). Furthermore, FITC-Peptide 1 did not show preferential binding to hyperplastic colonic epithelial tissue in the Hyperplastic Kras mouse cohort tested. Lack of binding to the hyperplastic colon epithelium in the Hyperplastic Kras mice, illustrated that Peptide 1 is specific to dysplasic adenomas in the colon. Adenomatous polyps are thought to be precursors to CRC where hyperplastic polyps are not, suggesting that the Peptide 1 could be binding to a cell surface target unique to dysplastic and/or cancerous cells.
Quantitative Analysis
[0072] Quantitative analysis of peptide adsorption to distal colonic adenomas revealed FITC-Peptide 1 (T/B: 2.17+0.61) binds 2-fold greater to the colonic adenomas when compared to the FITC-Control peptide 1 (T/B: 1.14+0.15). Independent samples t-test statistical analysis indicated that FITC-Peptide 1 binds in significantly greater amounts to the adenomas than FITC-Control peptide 1, p<001. T/B calculations for the FITC-Peptide 1 binding to the control mice was not possible, because an average grey scale value could only be obtained for the adjacent normal tissue.
Confocal Fluorescence Imaging
[0073] Preferential binding of Peptide compared to the Control peptide 1 on the adenomatous polyps was confirmed with confocal microscopy. A polyp biopsy was taken after 5'-FITC-labeled peptide administration in vivo, incubated in 1 μg/mL Hoechst dye for 5 minutes to stain living nuclei, rinsed 3x with lx PBS and imaged on a Leica Confocal Microscope (Leica Microsystems, Bannockburn, IL).
[0074] Confocal microscopy images of biopsied polyps collected subsequent to peptide administration showed evidence that Peptide 1 bound more to adenomas than the Control peptide 1.
Example 4
[0075] Binding of peptides to excised polyps was also tested.
Ex vivo Peptide Binding
[0076] Polyps from CPC;Apc mice (n=3 mice, 5 polyp pairs) were excised and washed 3x in PBS. The polyps were incubated in 100 μΜ peptide solution for 5 minutes and
subsequently washed 3x with lx PBS. Polyps were grossly imaged using the small animal endoscope to view binding to the polyp as a whole. Pairs of polyps (one candidate, one control) were imaged at a time to allow for the calculation of a candidate peptide to Control
peptide 1 binding ratio for each pair analyzed. An average binding ratio was calculated + one standard deviation. A similar procedure to determine mean grey scale values for image analysis was followed for the ex vivo polyps as described above for the in vivo polyps.
[0077] This study showed a similar 2-fold increase in binding of Peptide 1 compared to the Control peptide 1.
Confocal Fluorescence Imaging of ex vivo Binding
[0078] Preferential binding of the Peptide 1 compared to the Control peptide 1 on the adenomatous polyps was again confirmed with confocal microscopy. After peptide incubation, excised polyps were incubated ex vivo in 1 μg/mL Hoechst dye for 5 min to stain living nuclei, rinsed 3x with lx PBS and imaged on an Olympus Confocal Microscope (Olympus, Tokyo, Japan).
[0079] Peptide 1 displayed enhanced binding to whole polyps ex vivo. Gross analysis of peptide binding revealed that the FITC-Peptide 1 bound to the excised polyps in greater quantity than the FITC-Control peptide 1. Comparison of between FITC-Peptide 1 and FITC- Control peptide 1 binding showed Peptide 1 bound 2.51+0.59 times greater than the Control peptide 1 for the whole polyp pairs analyzed.
[0080] From the ex vivo peptide binding experiment, confocal microscopic imaging revealed that the FITC-Peptide 1 showed increased binding to the dysplastic crypts when compared to the FITC-Control peptide 1. When the Hoechst nuclear stain is overlaid with the FITC-labeled peptide binding, it is evident that the Peptide 1 is binding dysplastic
colonocytes. Minimal to no binding was found for the FITC-Control peptide 1.
Example 5
[0081] Histological examination of the polyps from phage panning, in vivo peptide administration, ex vivo peptide administration, and biopsies was performed.
Histology
[0082] Polyps were fixed in phosphate-buffered formalin for 24 hours, paraffin-embedded and sectioned into 10 μιη thin slices and stained with hematoxylin and eosin. Histological images were captured using an Axioskop2 upright microscope (Carl Zeiss, Inc.).
[0083] Histology of the all polyps showed dysplasia, characterized by enlarged nuclei, hyperchromaticity, and distorted crypts.
Example 6
[0084] Experiments were carried out to determine binding of the synthetic peptides to human surgical specimens of colon cancer. In brief, frozen or fixed non-neoplastic or neoplastic human colon tissue sections were cut with 10 μΜ thickness. The fixed sections were heated at 60°C to melt out the wax followed by deparaffinization with xylene and ethanol. The antigen retrieval was performed using Tris-EDTA buffer (10 mM Tris base, 1 mM EDTA, 0.05% Tween-20, pH 9.0) at 95°C for 10 min. The sections were then washed with PBS (IX) and used for further staining. The fresh frozen sections were used directly after cut without any further process to localize peptide binding. The sectioned tissues were air dried and washed with PBS IX. Sections were incubated with FITC labeled peptides (10 μΜ) for 15 min at RT. The sections were washed three times each for 1 min in PBS and fixed with 4 % paraformaldehyde for 10 min. After fixing, the sections were washed again (IX) and mounted with ProLong® Gold reagent with DAPI (Invitrogen, Carlsbad, CA). The sections were imaged under a confocal microscope (Leica Microsystems GMBH, Wetzlar, 35578 Germany). All surgical specimens were obtained from the tissue procurement core of University of Michigan with approval from the Institutional Review Board (IRB).
Example 7
[0085] Sequences of peptides that bind to a human colorectal adenocarcinoma cell line were identified by phage display and peptides having the sequences were synthesized for further testing.
Cell lines and cultures
[0086] The human colorectal adenocarcinoma cell line HT29 and non-malignant intestinal cell line Hs738.St/Int. were obtained from the American Type Culture Collection (ATCC, Manassas, VA). The HT29 cells were cultured in McCoy's medium (Gibco, CA, USA) containing 10% fetal bovine serum (FBS, Gibco, CA, USA) and 1% penicillin/streptomycin (Invitrogen Corp. USA). The Hs738.St/Int. cells were cultured in DMEM (Gibco, CA, USA) containing 10% FBS, 1% penicillin/streptomycin and 1% glutamax. Both cell lines were cultured at 37 deg C in 5% C02 . The cells were passaged using 0.25% EDTA containing trypsin (Mediatech Inc. Manssas, VA).
In vitro panning procedure
[0087] Peptide selection was performed using a technique of phage display (Ph.D. -7, New England Biolabs, Beverly, MA) and a biopanning strategy based on a subtractive whole-cell approach Kelly, et al. Cancer Res. 64: 6247-6251 (2004); and Zhao et al., Clin Cancer Res 13: 6049-5055 (2007). HT29 and Hs738.St/Int. cells were grown to log-phase, detached
either with cell dissociation buffer (Invitrogen, Carlsbad, CA) or Trypsin with 0.25% EDTA (Mediatech Inc. Mansas, VA) and immersed in blocking buffer, PBS with 1% bovine serum albumin (BSA), for 30 min at 4°C with continuous agitation. Three rounds of clearing were performed by incubating ~106 Hs738.St/Int. cells with a total of ~109 plaque-forming units (pfu) of the phage library for 30 min at 4°C. The cleared phage in the supernatant was amplified and titered with E. coli (ER 2738). The amplified titer (2xl0n) was used for further positive selection against HT29 cells (-107) in PBS containing 0.2% Tween-20 (PBST) for 60 min at 4°C. The cells were washed three times with cold PBST. The bound phage were then eluted with 1 mL of 0.2 M glycine (pH 2.2) containing 0.1% BSA for 8 min, and immediately neutralized with 150
of 1 M Tris (pH 9.2). The eluted phage was amplified, precipitated and titered according to manufacturer instructions. The resulting phage (2xl0n pfu) was used to perform further 4 additional rounds of biopanning for positive selection against the HT29 cells, to enrich the pool of candidate phage. After three rounds of in vitro panning, 60 plaques were randomly selected and their sequences were analyzed with an ABI Automatic DNA Analyzer. A primer 5'-CCC TCATAG TTA GCG TAA CG-3' (SEQ ID NO: 19) (-96 gill sequencing primer, provided in the phage display peptide library kit, New England Biolabs) corresponding to the pill gene sequence of the Ml 3 phage was used for sequencing.
[0088] Preferential binding of the candidate phage to target cells was validated by bound phage counts. The candidate phages and non-insert wild-type (WT) phage (M13KE, New England Biolabs, Beverly, MA) were amplified, precipitated and titered per manufacturer's instruction. HT29 and Hs738.St/Int. (~5xl06) cells were grown to log-phase, detached, and blocked, as described above. A total of 2xl0u pfu of either the candidate or wild-type phages were incubated with these cells for 15 min with continuous gentle agitation at room temperature. After three rounds of washing with PBS/0.2% Tween-20, the bound phages were eluted from the cells with 0.2 M glycine (pH 2.2) containing 0.1% BSA buffer for 8 min and titered with E. coli. The number of plaques was counted, and the number of candidate phages that bound to the target cells was compared with that found for the non-target cells and for no-insert wild type phage.
[0089] After five rounds of positive selection with HT29 and three rounds of negative selection with Hs738.St/Int. cells, the candidate phage pool was enriched by 78 fold
[10χ102/μ1 (first round) vs. 78χ103/μ1 (5th round)] in 5th round in comparison to first round, which indicates the enough specificity of phage pool for HT29 cells. A total of 60 clones from 5th rounds yielded the following amino acid sequences multiple times: SILPYPY (SEQ
ID NO: 9) (4 times), KCCFPAQ (SEQ ID NO: 2) (hereafter "Peptide 2" or "Peptide 2 phage") (13 times), YRAPWPP (SEQ ID NO: 10) (3 times), QPWPTSI (SEQ ID NO: 11) (3 times), WPTPPYA (SEQ ID NO: 12) (1 time), MHAPPFY (SEQ ID NO: 13) (1 time), VRPTLPM (SEQ ID NO: 22) (2 times) and NFMESLPRLGMH (SEQ ID NO: 23) (4 times). Multiple sequence alignment analysis did not reveal any strong homology among these repeated sequences. Only some short motifs such as PP, FP and WP were found. These sequences were further tested with HT29 and Hs738.St/Int. cell lines and bound phages were recovered in triplicate and titered with E. coli ER 2738. The Peptide 2 phage bound with the HT29 cell displayed 7-fold higher binding as compared to Hs738.St/Int. (4293333+279886 Ht29 vs.682323+59013 Hs738.St/Int.) and 145 times (29666+2516 wt) than non-insert wild type phage with P value <0.001. This result indicates that the Peptide 2 phage binds with high specificity to the HT29 cells.
[0090] Based on this result, the Peptide 2 phage and a synthetic peptide corresponding to the Peptide 2 amino acid sequence were used for further studies. The sequences of this peptide were analyzed with the National Center of Biotechnology Information BLAST (Basic Local Alignment Search Tool). While complete homology for the entire sequence was not found, this peptide does have partial homology to the ubiquitin protein ligases (5 of 7 amino acids, /KCCFP) (SEQ ID NO: 20), which is involved in tumor generation, development and metastasis in gastric, colonic and liver tumors by ubiquitin-proteasome pathway. Mani, et ah, Cancer; J Clin Oncol, 23,:4776-4789 (2005); Voutsadakis, Biochim Biophys Acta, 1782:800 - 808 (2008).
Cell-based ELISA with phage
[0091] Preferential binding of the Peptide 2 phage to HT29 cells was also validated by cell based ELISA. HT29 and Hs738.St/Int. (2xl05) cells were detached and blocked as mentioned above and incubated with 2xl0n pfu of either the Peptide 2 or wild- type phage for 20 min at RT in triplicate. After washing 3 times with PBS/0.2% Tween-20, cells were incubated with anti-M13 antibody (IgG) conjugated to horseradish peroxidase (HRP, 1:2000 dil.) (Amersham, Piscataway, NJ) for 60 min at RT with continuous agitation. After washing 2 times with PBST; tetramethylbenzidine (TMB) substrate (Sigma, Saint Louis, MO) was added to the cells and color was developed for 3 min at RT. The reaction was quenched with the IN H2S04 and incubated further for 30 min to observe the final end point at RT. The optical density (absorbance) was measured at 450 nm. Untreated cells with phages were used as controls and subtracted from the binding with Peptide 2 phage.
[0092] Results indicated that Peptide 2 phage clone could bind effectively to HT29 cell compared with Hs738.St/Int. and non-insert wild type phage by 5 fold and p-value < 0.002. Synthesis of Peptides
[0093] Peptide 2 peptide and a control peptide GGGAGGGAGGGK (FITQ-NH2 (SEQ ID NO: 21) (hereafter "Control peptide 2") were synthesized by solid phase synthesis with Fmoc chemistry. Fmoc protected L-amino acids were used and synthesis was assembled on rink amide MBHA resin using PS3 (Protein Technologies, Inc. AZ) automatic peptide synthesizer. The FITC was labeled at the C-terminus on the side chain of lysine residue via GGGSK linker (SEQ ID NO: 14). The glycine residues provide a spacer function which prevents stearic hindrance between the binding motif and fluorescent label. Also, the linker residue provides the same orientation of the peptide relative to the fluorescence label as that for the phage. Moreover, this spacer has the same amino acid sequence as that on the pill coat protein of the M13 bacteriophage. Control peptide 2 was designed with multiple glycines and alanines to have different structure and properties in terms of net charge and side chains and with the same number of amino acids as that for the target peptide.
[0094] Unlabeled peptides were also synthesized for a competitive binding study.
Cleavage of the peptides from the resin was achieved by treatment with a mixture of 3 mL TFA: TIS: H20 (95:2.5:2.5 v/v/v) at RT for 4 hr (Sigma Aldrich, St. Louis, MO). After filtration and washing of the resin by TFA, a gentle stream of nitrogen was used to remove the excess TFA. The crude peptide was triturated with diethyl ether chilled at -20°C and then centrifuged at 3,000 rpm for 10 min at 4°C. The crude product was purified by prep-HPLC with a C18 column (Waters, city, state) using a water (0.1% TFA)-acetonitrile (0.1% TFA) gradient to give sufficient amount of the desired products. The successful synthesis was confirmed by LC/ESI mass spectrometry (Platform II, micromass, Manchester, UK) and its homogeneity (>95%) was confirmed by reverse phase analytical HPLC (2489 Breeze system, Waters Inc, MA) using a CI 8 column.
Example 8
[0095] Binding of FITC-Peptide 2 to target cells was validated in multiple experiments. Flow Cytometry Analysis
[0096] Preferential binding of FITC-Peptide 2 to target cells was validated using flow cytometry. HT29 and Hs738.St/Int. (-2x105) cells were grown, detached, and blocked as described above. These cells were incubated with the FITC-Peptide 2 or -Control peptide 2
(10 μΜ) for 60 min at 4°C with continuous agitation. The cells were then washed (3X) with cold PBST followed by immediate fixing for 10 min. with 4% paraformaldehyde. The cells were washed again (lx) with PBS and resuspended in 1 mL of PBS. Flow cytometry was performed using FACSDiVa (BD® LSRII, BD Biosciences, San Jose, CA) and analyzed using Flowjo analysis program (Tree Star Inc., Ashland, OR).
[0097] About 97% of the total HT29 cell population was bound with FITC-Peptide 2 when gated for positive binding through FITC channel compared to 18.6% for FITC-Control peptide 2. Furthermore, both the FITC-Peptide 2 and FITC-Control peptide 2 bound minimally to the Hs738.St/Int cells.
Fluorescence Microscopy
[0098] Preferential binding of the FITC-Peptide 2 and FITC-Control peptide 2 to target and non-target cells was also validated via fluorescence microscopy. HT29 and Hs738.St/Int. cells were grown in 22 mm2 cover slips with ~ 80% confluence. Blocking of non-specific binding was performed by adding PBS/0.5% BSA for 30 min. The cells were then incubated with 10 μΜ of FITC-Peptide 2 or FITC-Control peptide 2 either at 4 or 37 °C for 15 min followed by 1 μg/mL Hoechst dye (Sigma Aldrich, St. Louis, MO) along with the peptide. The cells were washed with PBS for 3 times and fixed with 4% paraformaldehyde at room temperature for 10 min. After fixation, the cells were washed again with PBS (IX) and mounted with ProLong® Gold reagent (Invitrogen, Carlsbad, CA) and the fluorescence images were acquired with Leica Confocal system. (Leica Microsystems GMBH, Wetzlar, 35578 Germany)
[0099] FITC-Peptide 2 binds to the surface of the HT29 but not the surface of the
Hs738.St/Int cells. As expected, FrfC-Control peptide 2 did not bind to either the target or control cells.
[00100] In addition, the ability of the FITC-Peptide 2 peptide to internalize within the HT29 cells was tested. HT29 cells were incubated for 15 min. at either 4°C or 37°C in the presence of 10 μΜ FITC-Peptide 2. When HT29 cells were incubated with FITC-Peptide 2 peptide at 4 °C, most of the peptide binding appears to be confined to the cell surface as revealed by the overlay image stained with 4', 6-diamidino-2-phenylindole. The spatial extent of the cell nuclei showed affinity binding of FITC-Peptide 2 to the plasma membrane of the HT29 cells. In contrast, incubating HT29 cells with FITC-Peptide 2 at 37°C revealed the presence of diffuse staining throughout the cells.
Determination of binding constant
[00101] The binding affinity of FITC-Peptide 2 to HT29 cells ( 1 x 105) was determined using various concentrations of the peptide. The fluorescence intensity of the peptide bound to the HT29 cells was measured at saturation. Then, the FITC-labeled peptide was serially diluted in PBS at concentrations that varied from 0 to 70 μιηοΙ/L and incubated with lxlO5 HT29 cells at 4°C for 1 hr. After washing 3 times with cold PBS/0.2% Tween 20 solution, the unbound peptide was rinsed off. The cells were resuspended in 200 μΐ^ PBS and transferred to a 96 well plate. The fluorescence intensity I was measured at 525 nm using 485 nm as the excitation wavelength on a multi-well plate reader (CytoFluor Series 4000; Applied
Biosystems Inc, Foster City, CA). Binding of the peptide to the cells was calculated using the peptide emission intensity with the same concentration without the cells present. The peptide equilibrium dissociation constant ¾ = 1/Ka was calculated by performing a least squares fit of the data to the non-linear equation 1= (Io+ImaxKa[X])/ (Io+ Ka[X]). I0 and Imax are the initial and maximum fluorescence intensities, corresponding to no peptide and at saturation, respectively, and [X] represents the concentration of the bound peptide. Origin 6.1 data analysis software (Origin Lab Corp, Northampton, MA) was used to fit the equation for nonlinear least square fitting.
[00102] With respect to the relative fluorescence intensity at 525 nm as a function of the concentration of the FITC-Peptide 2 bound to the HT29 cells, a non-linear increase in intensity until it reaches to the saturation was fitted with the equation and yielded the ¾ value of 65 nM/L (R2 = 0.988).
Example 9
[00103] Binding of Peptide 2 phage as well as Peptide 2 itself to human colon tissue was examined.
Immunohistochemistry with phage
[00104] Frozen or fixed non-neoplastic or neoplastic human colon tissue sections were cut with 10μΜ thickness. The fixed sections were heated at 60°C to melt out the wax followed by deparaffinization with xylene and ethanol. The antigen retrieval was performed using Tris- EDTA buffer (10 mM Tris base, 1 mM EDTA, 0.05% Tween-20, pH 9.0) at 95°C for 10 min. Then the sections were washed with PBS (IX) and used for further staining. The fresh frozen sections were used directly without further processing. The sections were air-dried on slides, rinsed twice with PBS and then fixed with 4% paraformaldehyde for 10 min. The sections were rinsed-off with PBS and blocked with 1% BSA for one hour at RT. Tissue sections were
stained with hematoxylin following the standard protocol for localizing the nucleus. Then, sections were incubated with targeted phages or non-insert wild type phages (2xl0n pfu) for 15 min at RT. Slides were then rinsed 3 times with PBS for 1 min each and blocked for 10 min with 3% hydrogen peroxide. Slides were again rinsed 2 times for 1 min each with PBS, and staining with HRP-conjugated anti-M13 monoclonal phage antibody (1:200 dilutions) for 1 hr at RT. Slides were rinsed 2 times for 1 min each with PBS and developed with diaminobenzidine; DAB (Sigma, St Louis, MO) solution for 3 min. Finally, slides were rinsed in PBST 3 times for 1 min each and imaged under a fluorescence microscope (Carl Zeiss Microimaging GmbH, Gottingen, Germany). The non-insert wild type and only HRP stained sections were used as negative controls.
[00105] To correlate the binding of Peptide 2 phage between diseased and healthy tissue sections, H & E staining from the serial sections was also assessed for diagnosis. The frozen sections of human specimens were fixed with 4% paraformaldehyde for 10 min at RT. Then the sections were stained with H&E following the standard protocol. Histopathologic interpretation of each section was performed by a gastrointestinal pathologist (HA) and classified as (1) normal mucosa, (2) dysplasia and (3) adenocarcinoma for comparison with the average fluorescence intensity from the serial sections.
[00106] The Peptide 2 phage was found to localize in dysplastic adenomas and carcinoma sections, that stained dark brown distinctly, indicated the positive binding region of the phage to these pre-malignant and malignant lesions. The dysplastic adenoma and carcinoma tissue sections stained with insert less wild type phage clone showed negative staining. The normal colonic mucosa did not stain either with Peptide 2 or with insert less phage. It is thus clear that Peptide 2 phage was able to bind specifically to adenoma and carcinoma cells. The representative H & E sections are shown as gold standard for comparison with staining. Binding of synthetic peptides to human surgical specimens of colon cancer
[00107] Fresh frozen sections from human surgical specimens were cryosectioned with 10 μΜ thickness and used to localize peptide binding. The sectioned tissues were air dried and washed with PBS IX. Sections were incubated with FITC labeled peptides (10 μΜ) for 15 min at RT. The sections were washed three times each for 1 min in PBS and fixed with 4 % paraformaldehyde for 10 min. After fixing, the sections were washed again (IX) and mounted with Pro Long® Gold reagent with DAPI (Invitrogen, Carlsbad, CA). The sections were imaged under a confocal microscope (Leica model no, city, state). All surgical specimens were obtained from the tissue procurement core of University of Michigan with approval from the Institutional Review Board (IRB).
[00108] FITC-Peptide 2 differentially stained the surgical specimens from human colon adenocarcinoma as opposed to normal colonic mucosa. FITC-Peptide 2 stained consistently with pre-malignant lesions (dysplastic adenomas, n =4) and malignant lesions (carcinoma, n=6) from 10 different patients; whereas, no binding was observed the normal mucosa (n=10). FITC-Control peptide 2 was not able to bind with any of the specimens classified from normal to carcinoma. The representative H and E sections are shown as gold standard for comparison with staining. Statistical evaluation indicated that the FITC-Peptide 2 binds more strongly with carcinoma (T/B = 7) compared to normal mucosa and 1.5-fold higher than dysplastic adenomas. The T/B ratio for FITC-Peptide 2 vs. FITC-Control peptide 2 was 6, 3 and 1 for carcinoma, adenoma and normal mucosa respectively. These results suggested that Peptide 2 binds avidly with pre-malignant and malignant lesions of colonic neoplasia.
Example 10
[00109] This example describes the_design, construction, and validation of a near-infrared (NIR) labeled peptide and matching wide-field instrument with sub-cellular resolution that were used to visualize individual pre-malignant (dysplastic) crypts in real time in vivo. This methodology can be used longitudinally to evaluate molecular expression in small animal models, and can also be directly translated into the clinic for early cancer detection.
NIR-labeled fluorescent peptides
[00110] Octapeptide QPIHPNNM (Peptide 1; SEQ ID NO: l)was conjugated with Cy5.5 (Lumiprobe, LLC, Hallandale Beach, FL) on the N-terminus via an amino-hexanoic acid linker using NHS activation chemistry. The peptide was prepared using solid-phase synthesis by applying standard Fmoc chemistry on Rink amide MBHA amide resin (Anaspec, CA). Cy5.5-NHS ester was conjugated to the N-terminus of the peptide in mixed DCM/DMF (1:3) at pH 9 adjusted with diisopropylethylamine (DIEA) overnight. Side-chain protecting groups were removed with a mixture containing trifluoroacetic acid (TFA)/triisopropylsilane (TIS)/ water (95:2.5:2.5, V/V/V). The crude product was purified using semi-preparative HPLC (C- 18, Waters) with water-acetonitrile gradient mobile phase containing 0.1% TFA. The products were analyzed with HPLC System (Waters Breeze, 2489) using a C-18 analytical column and Q-TOF mass spectrometer (Agilent Technologies, Inc.; Santa Clara CA). To investigate the specificity of the target peptide, an unrelated peptide YTTNKH (SEQ ID NO: 27) was selected randomly for use as a control. This peptide was synthesized, labeled with Cy5.5, purified and analyzed.
[00111] On mass spec, the experimental m/z (mass units) measured for the peptides were found to agree with their expected molecular masses: QPI-Cy5.5, expected = 1668.91 and experimental = 1668.91; YTT-Cy5.5, expected = 1755.95 and experimental = 1756.8, respectively. The purity of the final synthesized products was >95 each. The peak fluorescence emission occurs at em = 709 nm and 708 nm for QPI-Cy5.5 and YTT-Cy5.5, respectively, at a concentration of 10 μΜ in IX PBS, and has a spectral range of
approximately 680 to 900 nm.
Specificity of the conjugated peptide for human colonic neoplasia
[00112] All specimens were obtained with approval from the University of Michigan Institutional Review Board (IRB). Freshly resected specimens of human colonic mucosa were frozen in OCT and sectioned with 10 μιη thickness using Microm-HM-550 Microtome (EquipNet, Inc. Canton, MA). The sections were then air dried, washed with PBS IX, and incubated with the Cy5.5-labeled peptides at a concentration of 10 μΜ for 15 min at RT. The sections were washed 3X for 1 min in PBS and fixed with 4% paraformaldehyde for 10 min. After fixation, the sections were washed again (IX) and mounted with Pro Long Gold reagent with DAPI (Invitrogen, Carlsbad, CA). The sections were imaged under a confocal microscope (Leica TCS SP5 Microsystems, Bannockburn, IL). Adjacent sections were sent for routine histology. The average intensity from the entire field-of-view of each image was calculated using Matlab (Mathworks, Natick, MA).
[00113] For the ex-vivo peptide immunohistochemistry, the nonparametric Kruskal- Wallis test was used to determine if observed differences are statistically significant among all three pathological classifications. The nonparametric Mann-Whitney test was used for comparisons between two independent samples, and differences with p<0.05 were considered significant.
[00114] The QPI-CY5.5 peptide demonstrated no binding to normal colonic mucosa (n = 7), but consistently stained dysplasia (n = 8), shown in Supplementary Fig. 2B, and adenocarcinoma (n = 10). The YTT-Cy5.5 (control) peptide did not stain any of the specimens, including normal, dysplasia, and adenocarcinoma. In total, the QPI-Cy5.5 peptide was found to selectively stain dysplasia in 6/8 and adenocarcinoma in 8/10 sections of human specimens. The QPI-Cy5.5 peptide did not stain any of the 7 sections of normal colonic mucosa. YTT-Cy5.5 did not stain either normal or dysplasia, and was found to bind minimally to 5/10 adenocarcinoma sections. The mean NIR fluorescence intensities on immunohistochemistry for QPI-Cy5.5 peptide binding to normal, dysplasia and
adenocarcinoma were 1.5+1.0, 10.7+3.3 and 9.8+2.4 AU, respectively. The resulting intensity ratio for dysplasia and adenocarcinoma was 7.1 (p<0.0049) and 6.5 (p<0.0168) relative to that for normal colonic mucosa. A comparison of the mean fluorescence intensities between dysplasia and adenocarcinoma using QPI-Cy5.5 peptide was not significantly different, p<0.41. The T/B ratio for binding by the QPI-Cy5.5 peptide in comparison to the YTT-Cy5.5 peptide was 26.7, 2.9, and 1.8 for dysplasia, adenocarcinoma and normal mucosa, respectively. The average T/B ratio for QPI-Cy5.5 was 3.42±1.30 and that for YTT-Cy5.5 was 1.88±0.38. Non-parametric Mann- Whitney independent samples analysis showed that the fluorescence intensity associated with binding of the target peptide to dysplasia was greater than that of the control with significance, p = 0.007.
NIR fluorescence imaging system
A schematic of the NIR endoscopic imaging system is shown in Fig. la. The distal end of the endoscope is ~3 mm in diameter, and delivers excitation at λεχ = 671 nm (Fig. lb). A custom polymer housing contains a filter wheel to provide both reflectance and fluorescence images, and has a handle for holding the instrument (Fig. lc). Using a standard target, a resolution of 9.8 μιη (group 6, element 5) was measured at a distance of 2.5 mm, a typical dimension used for in vivo imaging, resulting in a FOV with diameter of 3.6 mm (Fig. Id). A diode-pumped solid state laser (TechnicaLaser Inc, Winter Park, Fl) with λεχ = 671 nm is used to excite the Cy5.5 labeled peptides. The intensity is tunable over a range from 1 to 100 mW. The incident beam is expanded to 3 mm in diameter by a pair of relay lenses with focal lengths of fi = 30 and f2 = 50 mm (Thorlabs Ltd., Newton, NJ) to fill the aperture of a fluid light cable that is coupled to a Hopkins® II rigid endocope (Karl Storz, Goleta, CA). This pediatric urethroscope (Karl Storz Veterinary Endoscopy, Goleta, CA) has a ~3 mm outer diameter and a 3 Fr instrument channel. Fluorescence images collected by the endoscope are transmitted by a set of relay lenses onto a CCD detector that has dimensions of 8.7x6.9 mm and 1388x1040 pixels (Carl Zeiss Microimaging, LLC, Thornwood, NY). A zoom lens system (NT58-440, Edmund Optics Inc., Barrington, NJ) with a tunable focal length of 20-100 mm, F#1.6-16 aperture was used to magnify the image to fill the dimensions of the CCD. The resolution of this system was measured using a standard target (USAF-1951, Newport Corporation, Irvine, CA). Each frame was collected in 100 ms (10 Hz), and transferred to the computer by firewire. The optics and detector were contained within a custom housing made of light weight polymer. A filter wheel was incorporated into the handle of the housing to quickly switch between collection of reflectance and fluorescence images. A band pass filter that
transmits NIR fluorescence from em = 696 to 736 nm (FFO 1-716/40-25, Semrock, Inc., Rochester, NY) was used.
CPC;Apc mouse model of colonic dysplasia
[00115] Mice were cared for under the approval of the University Committee on the Use and Care of Animals (UCUCA) at the University of Michigan. The CPC;Apc mice are genetically engineered with a Cre recombinase under the control of the Cdx2 promoter (CDX2P-9.5NLS-Cre) and a floxed allele of the APC gene. This Cre-regulated somatic mutation in one of the Ape alleles causes dysplasia to develop spontaneously in the distal colon of the mouse, allowing for minimally invasive imaging to be performed. All mice were housed in specific pathogen-free conditions and supplied water ad libitum throughout the study. Animals ranged in age from 6 to 9 months.
In vivo NIR fluorescence imaging
[00116] Anesthesia was induced and maintained with inhaled isofluorane mixed with oxygen via a nose cone at a dose of 4% and 2% at a flow rate 0.5 liter/min, respectively. Prior to peptide administration, the colon of each mouse was cleaned with a tap water lavage to remove debris. The conventional white light endoscope was used first with a color camera to identify the presence of adenomas. The colon was then rinsed with water until all of the visible mucous was removed. The Cy5.5-labeled peptides were then delivered at a concentration of 100 μΜ in IX PBS containing 2.5% DMSO (phosphate buffered saline) through the instrument channel. The peptides were allowed to incubate for 5 minutes, and then the colon was cleansed 3 times with a tap water to remove any unbound peptide. Prior to imaging, the colon was inspected for residual peptide solution, and when clean, the colon was insufflated with air for imaging. Fluorescence images were collected using Axiovision 4.8.1 software.
Fluorescence Image Analysis
[00117] Images collected during endoscopy were recorded as .zvi files and converted into .tiff images using Axiovision Lite software. Consecutive white light and fluorescence images for each adenoma were analyzed. Regions of interest (ROI) around the adenoma and adjacent normal- appearing mucosa were defined on the color and fluorescence images using Lab view®. The white light image was utilized to draw an ROI around the adenoma or adjacent normal appearing colonic mucosa which was then superimposed onto the fluorescent image. Mean gray scale values were calculated for each ROI, and an adenoma/normal colon, or a T/B ratio, value was then calculated for each adenoma. The mean fluorescence
intensities were calculated from each ROI to determine the ratio of the average intensities for the adenomas to that from adjacent normal-appearing mucosa, or T/B ratio.
Statistics
[00118] Two-tailed independent samples t-tests (significance level at cc=0.05) were used to determine statistical significance between the T/B ratio for the QPI-Cy5.5 and YTT-Cy5.5 peptides binding to colonic adenomas in the CPC;Apc mice. All statistical computations were processed either using statistical software (SPSS 15.0.; SPSS, Chicago, IL) or Minitab (Minitab Inc. State College, PA).
Summary of Results
[00119] In the NIR fluorescence images collected endoscopically in real time (10 Hz) from the colon of CPC;Apc mice in vivo, a white light image showed spontaneous colonic dysplasia on the left side. The NIR reflectance image showed amorphous surface texture from dysplasia, and several bright regions of specular reflection. The corresponding fluorescence image revealed significant contrast enhancement from binding of the QPI-Cy5.5 peptide to dysplasia but not to adjacent normal- appearing colonic mucosa. The margins between dysplasia and normal mucosa were quite sharp in comparison to that on the white light and reflectance images. On an expanded view, heterogeneous, oval structures representing individual crypts could be appreciated, magnification 4X. The corresponding histology (H&E) revealed the features of dysplasia, including elongated nuclei, disorganized crypt structure, hyperchromaticity, and crowed lamina propria, similar to that found in human disease. The fluorescence images from the same region of mucosa with administration of the control peptide YTT-Cy5.5 and with no peptide reveal negligible signal.
[00120] This method for performing targeted in vivo optical imaging that integrates a highly- specific peptide with a wide-field NIR fluorescence endoscope achieved a sub-cellular system resolution of <10 μιη, representing a significant improvement over previous NIR instruments, and was able to visualize individual dysplastic crypts with well-defined features and sharp lesion borders in real time.
[00121] The ability to attain this level of performance in hollow organs of the digestive tract is useful for visualization of drug transport. The fast binding kinetics of the peptide allows for imaging to be performed within only a few minutes after administration, a time interval that is compatible with practical laboratory and clinical use. Topical application provides local disease contrast enhancement without increased background from the probe accumulating within the circulation. Other molecular probe platforms, such as antibodies and
activatable probes, have much slower onset and longer clearance, requiring hours (or even days) to reach peak effect, limiting utility and increasing background.
[00122] The use of NIR fluorescence has advantages over that of visible for performing in vivo imaging since less background is observed. In addition, the resolution is far better than that of NIR endoscopes that use a fiber-optic bundle, which are limited by pixilation artifact. NIR systems have also been developed for intra- operative imaging, but these instruments are large and not minimally invasive. Furthermore, NIR tomography has been used to image hollow organs, but this approach is limited by light penetration depth and multiple air-tissue interfaces. In addition to the colon, this imaging system can be used to study other hollow organs in small animal models of disease, such as the esophagus and oropharynx. The instrument can be easily adapted to image multiple spectral bands with the addition of appropriate lasers, optics, and filters. Furthermore, this technology can be translated to the clinic to perform high resolution molecular imaging in hollow organs. Some of the unique advantages of this integrated platform can also realized by imaging the deep red region of the visible spectrum and by using other targeting molecules and optical reporters (fluorescent proteins expressed by genetically-engineered mice).
Example 11
[00123] Pre-malignant colonic lesions that have non-polypoid (flat and depressed) morphology are indistinguishable on colonoscopy and may confer a high risk for malignancy. A peptide specific for flat dysplasia was identified by phage display technology with HT29 and Hs738.st/int. cells as the positive and negative biopanning substrates, respectively.
Bound phage counts, ELISA, flow cytometry, competitive inhibition, binding affinity and fluorescence microscopy were performed to validate specific candidate binding on cultured cells. Confocal and stereomicroscopy was performed on biopsy and endoscopic mucosal resected specimens, respectively, to validate specific peptide binding to dysplastic human colonic mucosa.
Cell lines and cultures
[00124] The human colorectal adenocarcinoma (HT29) and non-malignant intestinal cells (Hs738.St/Int.) were obtained from the American Type Culture Collection (ATCC, Manassas, VA). The HT29 cells were cultured in McCoy's medium (Gibco, CA, USA) containing 10% fetal bovine serum (FBS, Gibco, CA, USA) and 1% penicillin/streptomycin (Invitrogen Corp. USA). Hs738.St/Int. cells used as controls were cultured in DMEM (Gibco, CA, USA)
containing 10% FBS, 1% penicillin/streptomycin and 1% glutamax. Both cells were cultured at 37°C in 5% C02. The cells were passaged using 0.25% EDTA containing trypsin
(Mediatech Inc. Mansas, VA).
Peptide selection
[00125] Peptide selection was performed using phage display technology (Ph.D. -7,
New England Biolabs, Beverly, MA), and a biopanning strategy based on a subtractive whole-cell approach (20-22). HT29 and Hs738.St/Int. cells were grown to log-phase, detached either with cell dissociation buffer (Invitrogen, Carlsbad, CA) or trypsin with 0.25% EDTA (Mediatech Inc. Mansas, VA), and immersed in blocking buffer, PBS with 1% bovine serum albumin (BSA), for 30 min at 4°C with continuous agitation. Then 3 rounds for clearing of non-specific binders were performed by incubating ~106 Hs738.St/Int. cells with a total of ~109 plaque-forming units (pfu) for 30 min at 4°C. The cleared phages in the supernatant were amplified and titered per manufacturer instructions. The amplified titer
(2X10 1111) was used for further positive selection against HT29 cells (-107 ) in PBS containing 0.2% Tween-20 (PBST) for 60 min at 4°C. The cells were washed 3X with cold PBST. The bound phages were then eluted with 1 ml of 0.2 M glycine (pH 2.2) containing 0.1% BSA for 8 min, and immediately neutralized with 150 μΐ of 1 M Tris buffer (pH 9.2). The eluted phages were amplified, precipitated and titered per manufacturer instructions. The resulting phages (2xl0n pfu) were used to perform 4 additional rounds of biopanning for positive selection against HT29 cells, enriching the pool of candidate phage. After round 3 of in vitro panning, 60 plaques were randomly selected in each round and their sequences were analyzed with an ABI Automatic DNA Analyzer. A primer 5'-CCC TCATAG TTA GCG TAA CG-3' (SEQ ID NO: 28) (-96 gill sequencing primer, New England Biolabs) corresponding to the pill gene sequence of the M13 phage was used for sequencing.
[00126] After 3 rounds of negative selection with Hs738.St/Int. and 5 rounds of positive selection with the HT29 cells, the pool of candidate phage was enriched by 78 fold
[10χ102/μ1 (1st round) vs. 78χ103/μ1 (5th round)]. A total of 60 clones from the 5th round yielded the following amino acid sequences in multiplicity: SILPYPY (4) (SEQ ID NO: 9), KCCFPAQ (13) (SEQ ID NO: 2), YRAPWPP (3) (SEQ ID NO: 10), QPWPTSI (3) (SEQ ID NO: 11), WPTPPYA (1) (SEQ ID NO: 12) and MHAPPFY (1) (SEQ ID NO: 13). These sequences were also repeated multiple times in the 3rd and 4th rounds, further suggesting enrichment. Multiple sequence alignment analysis using RELIC software did not reveal significant homology among these repeated sequences. Only some short motifs such as PP/FP/WP were found.
[00127] These sequences were further tested with HT29 and Hs738.St/Int. cells, and bound phages were recovered in triplicate and tittered. Preferential binding of the candidate phage to HT29 cells was validated by bound phage counts. The candidate and non-insert wild-type (WT) phages (M13KE, New England Biolabs) were amplified, precipitated and titered. HT29 and Hs738.St/Int. (~5xl06) cells were grown to log-phase, detached, and blocked, as described above. A total of 2xl0u pfu of either the candidate or WT phages were incubated with these cells for 15 min with continuous gentle agitation at room temperature, hereafter RT. After 3 rounds of washing with PBS/0.2% Tween-20, the bound phages were eluted from the cells with 0.2 M glycine (pH 2.2) containing 0.1% BSA buffer for 8 min and tittered. The number of plaques was counted, and the number of candidate phage that bound to the target cells was compared with that found for the control cells as well as that for no- insert WT phage.
[00128] The number of KCCFPAQ (SEQ ID NO: 2) phages that bound to the HT29 cells was found to be ~7-fold higher as compared to Hs738.St/Int. (4.3xl06+2.8xl05 versus 6.8xl05+6.0xl04) and 143 times higher when compared to that for non-insert WT phage (3.0xl04+2.5xl03), p-value <0.001. Based on this result, the KCCFPAQ (SEQ ID NO: 2) peptide was selected for further studies. The other sequences did not provide a significant difference in binding between HT29 and Hs738.St/Int. cell and were not used further. This peptide sequence were analyzed with the National Center of Biotechnology Information BLAST (Basic Local Alignment Search Tool). While complete homology for the entire sequence was not found, this peptide has partial homology (KCCF***) to the extracellular domain of ErbB-2 protein which may function as a mimic of a CCY/F motif present in EGF like domain of ErbB family member ligands.
Cell based ELISA
[00129] Preferential binding of the candidate phage to HT29 cells was also validated by cell based ELISA. HT29 and Hs738.St/Int. (2xl05) cells were detached and blocked, as described above, and incubated with 2xl0n pfu of either the candidate or WT phages for 20 min at RT in triplicate. After washing 3X with PBS/0.2% Tween-20, the cells were incubated with anti-M13 antibody (IgG) conjugated to horseradish peroxidase (HRP, 1:2000 dil.) (Amersham, Piscataway, NJ) for 60 min at RT with continuous agitation. After washing 2X with PBST; tetramethylbenzidine (TMB) substrate (Sigma, Saint Louis, MO) was added to the cells and developed for 3 min at RT. The reaction was quenched with the IN H2SO4 and incubated further for 30 min to observe the final end point at RT. The optical density
(absorbance) was measured at 450 nm. Cells that were not administered the phages were used as control and subtracted from binding with candidate phages.
[00130] On ELISA, the optical density (O.D.) at 450 nm for the KCCFPAQ (SEQ ID NO: 2) phage with HT29 cells compared to that for Hs738.St/Int. cells was 0.67+0.06 versus 0.14+0.03, p < 0.002. The ELISA result for the non-insert WT phage with HT29 cells was 0.14+0.04, p < 0.002 and 0.06+0.01, p < 0.002 for HS738.St/Int. cells
Synthesis of Peptides
[00131] The candidate and control peptides were produced by solid phase synthesis with Fmoc chemistry. Fmoc protected L-amino acids were used, and synthesis was assembled on rink amide MBHA resin using a PS3 (Protein Technologies, Inc. AZ) automatic peptide synthesizer. Isomer I of fluorescein isothiocyanate (5-FITC) was labeled at the C-terminus on the side chain of the lysine residue via a GGGSK linker (SEQ ID NO: 14). The glycine residues provide a spacer function that prevents stearic hindrance between the binding motif and the fluorescent label. Also, the GGGS (amino acids 1-4 of SEQ ID NO: 14) residue provides the same orientation of the peptide relative to the fluorescence label as that for the phage. Moreover, this spacer has the same amino acid sequence as that on the pill coat protein of the Ml 3 bacteriophage.
[00132] The unlabeled peptides were also synthesized for the competitive binding study. Cleavage of the peptides from the resin was achieved by treatment with a mixture of 3 ml TFA: TIS: H20 (95:2.5:2.5 v/v/v) at RT for 4 hr (Sigma Aldrich, St. Louis, MO). After filtration and washing of the resin by TFA, a gentle stream of nitrogen was used to remove the excess TFA. The crude peptide was triturated with diethyl ether chilled at -20°C and then centrifuged at 3,000 rpm for 10 min at 4°C. The crude product was purified by prep-HPLC with a Ci8 column (Waters Inc. Milford, MA) using a water (0.1% TFA)-acetonitrile (0.1% TFA) gradient. Successful synthesis was confirmed by Liquid Chromatography/Electro Spray Ionization mass spectrometry (Platform II, micromass, Manchester, UK) and its purity (>95%) was confirmed by reverse phase analytical HPLC (2489 Breeze system, Waters Inc.) using a C18 column.
Flow Cytometry Analysis
[00133] Preferential binding of the candidate peptide labeled with 5-FITC to the target and control cells was also validated using flow cytometry. HT29 and Hs738.St/Int. (~2xl05) cells were grown, detached, and blocked, as described above. These cells were incubated with the 5-FITC labeled candidate or control peptide (10 μΜ) for 60 min at 4°C with continuous
agitation. The cells were then washed 3X with cold PBST followed by immediate fixation for 10 min with 4% paraformaldehyde. The cells were washed again with PBS and resuspended in 1 mL of PBS. Flow cytometry was performed using FACSDiVa (BD® LSRII, BD Biosciences, San Jose, CA) and analyzed using Flowjo analysis program (Tree Star Inc. Ashland, OR).
[00134] On flow cytometry, the KCCFPAQ (SEQ ID NO: 2) peptide bound to 97% of the total HT29 cell population compared to 2.3% for a control peptide. Furthermore, both the candidate and control peptides bound minimally to the Hs738.St/Int. cells. The control peptide (GGGAGGGAGGGK) (SEQ ID NO: 21) was designed with multiple glycines and alanines to have different structure and properties in terms of net charge and side chains from the target peptide. The control peptide is labeled with the same 5'-FITC fluorophore, and has the same number of amino acids as that of the target peptide.
Fluorescence Microscopy
[00135] Preferential binding of the FITC-labeled candidate and control peptides to the target and non-target cells was further validated via fluorescence microscopy. HT29 and Hs738.St/Int. cells were grown on cover slips to -80% confluence. Blocking of non-specific binding was performed by adding PBS/0.5% BSA for 30 min. The cells were then incubated with 10 μΜ of 5-FITC-labeled candidate or control peptide at either 4 or 37 °C for 15 min followed by staining with 1 μg/mL Hoechst dye (Sigma Aldrich, St. Louis, MO) along with the peptide. The cells were washed 3X with PBS and fixed with 4% paraformaldehyde at RT for 10 min. After fixation, the cells were washed again with PBS and mounted with ProLong Gold reagent (Invitrogen, Carlsbad, CA) and fluorescence images were collected with confocal microscopy (Leica TCS SP5 Microsystems, Bannockburn, IL).
[00136] The fluorescent-labeled peptide KCCFPAQ (SEQ ID NO: 2) binds to the surface of the HT29 cells at 4°C on fluorescence microscopy. Binding of this peptide is confined to the plasma membrane of the HT29 cells, as revealed by the overlay image of the cells stained with 4',6-diamidino-2-phenylindole. No binding is seen to the Hs738.St/Int. cells. The fluorescent-labeled control peptide did not bind to either the HT29 or Hs738.St/Int. cells. The ability of the KCCFPAQ (SEQ ID NO: 2) peptide to internalize at 37°C is demonstrated by the presence of diffuse peptide staining throughout the cells on the images collected at 15 and 30 min.
Competitive inhibition assay
[00137] Bound phage counts were performed to observe the competitive inhibition effect of the synthetic candidate heptapeptide with its representative phage counterpart in triplicate. HT29 cells (5xl06) were detached with enzyme free cell dissociation buffer and blocked with 1% BSA containing PBS for 30 min at 4°C. The cells were washed and incubated with phage (2xl0n) for 15 min. Then, the cells were washed with PBS and immediately incubated with different concentrations of unlabeled peptide ranging from 10 to 200 μΜ for an additional 15 min. Cells were washed 3X and the bound phages were recovered as described above in bound phage counts. The bound phages were then tittered and counted, and the relative inhibition rate was calculated. The inhibition activity of no-insert WT phage by synthetic candidate peptide and phage with unrelated synthetic control peptide were used as negative controls.
[00138] The results of the competition assay showed that the unlabeled synthetic
KCCFPAQ (SEQ ID NO: 2) peptide in concentrations from 0 to 200 μΜ reduced binding of KCCFPAQ (SEQ ID NO: 2) phage to HT29 cells in a dose-dependent manner,
4.3xl06+2.7xl05 to 3.8xl04+6.6xl03 with p <0.001, demonstrating binding inhibition. The rate of inhibition saturated (>98 ) when the peptide concentration increased above -75 μΜ. No inhibition was observed with addition of up to 200 μΜ of the control peptide, p <0.001. Similarly, addition of the KCCFPAQ (SEQ ID NO: 2) peptide did not inhibit WT phage, 2.6xl04+2.7xl03 versus 2.5xl04+3.5xl03. These results suggest that binding of the
KCCFPAQ (SEQ ID NO: 2) phage to the surface of HT29 cells depends on the specific insert peptide sequence rather than other phage coat proteins.
Measurement of Binding Affinity
[00139] The binding affinity of candidate peptide was measured by varying the
concentration of the 5-FITC-labeled peptide incubated with the HT29 cells (lxlO5) until saturation of fluorescence intensity was achieved (24). The FITC-labeled peptide was serially diluted in PBS at concentrations that varied from 0 to 70 μΜ and incubated with the HT29 cells at 4°C for 1 hr. The unbound peptide was rinsed off the cells by washing 3X with cold PBS/0.2% Tween-20 solution. The cells were resuspended in 200 μΐ^ of PBS and transferred to a 96 well plate. Then the fluorescence intensity I was measured at 525 nm using 485 nm excitation on a multi-well plate reader (CytoFluor Series 4000). These results were compared to the fluorescence intensities from the peptide alone (no cells) at
concentrations that varied from 0 to 70 μΜ. These intensities were used to calculate the
equilibrium dissociation constant ¾ = l/Ka by performing a least squares fit of the data to the non-linear equation I[X] = (Io+ImaxKa[X])/ (Io+ Ka[X]). I0 and Imax are the initial and maximum fluorescence intensities, corresponding to no peptide and at saturation,
respectively, and [X] represents the concentration of the bound peptide. Origin 6.1 data analysis software (Origin Lab Corp, Northampton, MA) was used to perform a non-linear least square fit of the data.
[00140] The relative fluorescence intensity at 525 nm as a function of the concentration of the fluorescent-labeled KCCFPAQ (SEQ ID NO: 2) peptide bound to the HT29 cells was determined. A non-linear increase in fluorescence intensity with peptide concentration was observed until saturation was reached. A fit of the data with the model yields a K<j = 65 nM/L, R2 = 0.988.
Peptide Immunohistochemistry
[00141] All specimens were obtained with approval from the University of Michigan Institutional Review Board (IRB). Freshly resected specimens of human colonic mucosa were frozen in OCT and sectioned with 10 μιη thickness. The sections were then air dried, washed with PBS, and incubated with the FITC-labeled peptides at a concentration of 10 μΜ for 15 min at RT. The sections were washed 3X for 1 min in PBS and fixed with 4% paraformaldehyde for 10 min. After fixation, the sections were washed again and mounted with ProLong Gold reagent with DAPI (Invitrogen, Carlsbad, CA). The sections were imaged under a confocal microscope (Leica TCS SP5 Microsystems, Bannockburn, IL). Adjacent sections were sent for routine histology. The intensity for each image was calculated using Matlab (Mathworks, Natick, MA).
[00142] The FITC-labeled KCCFPAQ (SEQ ID NO: 2) peptide selectively stains dysplasia and adenocarcinoma in comparison to normal colonic mucosa on sections of freshly resected human specimens. The KCCFPAQ (SEQ ID NO: 2) peptide demonstrated no binding to normal colonic mucosa (n = 21), but consistently stains dysplasia (n = 8) and adenocarcinoma (n = 19). The FITC-labeled control (GGG) peptide did not stain any of the specimens, including normal, dysplasia, and adenocarcinoma.
Stereomicroscopic Validation on EMR Specimens
[00143] Binding of the candidate or control peptide to the dysplasia on freshly resected human specimens via endoscopic mucosal resection (EMR) was validated on fluorescence stereomicroscopy. Patients with previously diagnosed polypoid and non-polypoid dysplasia who were referred for EMR were recruited. Institutional review board approval was obtained
from the VA Palo Alto Health Care System, and informed consent was acquired. After resection, the specimens were rinsed in PBS 3X to remove debris and mucous. An autofluorescence image was acquired before incubating with the peptide. Then, specimens were incubated with either the FITC-labeled candidate or control peptide at a concentration of 10 μιηοΙ/L for 5 min. The unbound peptide was rinsed off with PBS 3X. The mucosal surface of the specimen was oriented face up, and a dab of ink was applied to the upper border as a landmark to register the white light and fluorescence images with histology. A white light image was collected from the specimen with and without an overlying transparent grid that contains squares with dimensions of 1 x 1 mm . Fluorescence images were collected at 500 milliseconds per frame (with the overlying grid removed) using a stereomicro scope (Olympus SZX-16 equipped with Rolera camera; Olympus Corp, Tokyo, Japan) using 477 to 500 nm excitation and 500 to 630 nm emission. A correction to the fluorescence images was performed because the intensity at the center of the image is greater than that in the periphery due to differences in distance. A fluorescence image was collected from a solution of 10 μΜ FITC in a plate to provide a uniform target for calibration, allowing for quantitative analysis over the entire field of view. After the fluorescence intensities were corrected, lines along the length of the specimen spaced by 2-mm intervals in each image were identified using the grid from the white light image. The mean intensity from each l x l mm interval along this length of tissue was calculated using Matlab and compared with histology. Histopathologic interpretation was performed by a gastrointestinal pathologist (HA) who classified the specimens stained with H&E as normal colonic mucosa, dysplasia, or adenocarcinoma. The histopathologic evaluation of the EMR specimens was conducted at VA Palo Alto Health Care System (AM) and classified as either dysplasia or normal mucosa.
[00144] Increased intensity from the FITC-labeled peptide binding can be observed in the region of flat dysplasia as compared to the normal mucosa in the fluorescence image. An expanded view of the histology from the surface epithelium revealed features of dysplasia, notably the flat morphology of the surface epithelium. Using the same instrument settings, there was no visually recognizable autofluorescence from the tissue prior to the peptide incubation, suggesting that the observed fluorescence is due to peptide binding alone.
[00145] Quantitative evaluation of the fluorescence intensities on immunohistochemistry showed that the KCCFPAQ (SEQ ID NO: 2) peptide binds 3.1 times greater to
adenocarcinoma (31.5+6.0 AU) compared to normal mucosa (10.1+3.6 AU), p<0.001 and 1.5 fold higher than dysplasia (21.1+3.8 AU), p <0.001. The target-to-background (T/B) ratio for
the KCCFPAQ (SEQ ID NO: 2) peptide vs. control peptide was 3.6, 3.1, and 2.0 for adenocarcinoma, dysplasia and normal mucosa, respectively on frozen sections.
[00146] The fluorescence intensities (mean+SEM) for the 3 histologic classifications from the EMR specimens associated with binding by the KCCFPAQ (SEQ ID NO: 2) and control peptides on stereomicroscopy were determined. For the candidate peptide, the results for normal mucosa (n = 15), polypoid dysplasia (n = 24) and non-polypoid dysplasia (n = 16) were 43.5+10.7, 78.6+12.8 and 85.1+19.2 AU, respectively, p <0.001. For the control peptide, the intensities for normal mucosa (n = 6), polypoid dysplasia (n=5) and non-polypoid dysplasia (n = 2) were 16.5+2.5, 14.0+3.0 and 21.8+4.1 AU, respectively. The T/B of KCCFPAQ (SEQ ID NO: 2) peptide for flat adenoma to adjacent normal mucosa was found to be higher by -2.0 fold whereas T/B for polypoid adenoma to adjacent normal mucosa was 1.8.
Statistical Analysis
[00147] To evaluate competitive binding between the candidate phage and peptide, the differences in mean phage counts were first compared using a one-way analysis of variance (ANOVA), and differences in the mean value between classifications were evaluated using Tukey's multiple comparisons of the means (cc=0.05). Similarly, differences in the mean intensity for all histopathological classifications were evaluated as described above.
Statistical significance was assessed at the 0.01 level. For all other validation experiments, a comparison of the difference in the mean findings between 2 groups was performed using a 2-sided independent samples t-test (a = 0.05). All data are presented as mean + SD unless otherwise specified. A p-value < 0.05 was considered to be significant.
Summary of Results
[00148] The 7mer sequence KCCFPAQ (SEQ ID NO: 2) was selected after 5 rounds of enrichment, and specific binding of this peptide to HT29 cells was observed in culture. A dose-dependent reduction in binding was observed on competition with unlabeled peptide, an affinity of Kd=65 nmol/L was measured, and specific binding to the plasma membrane of HT29 cells was observed on fluorescence microscopy. On biopsy specimens (n=28), the fluorescence intensity (mean+SEM) from sections classified histologically as normal mucosa (n=21), dysplasia (n=8), and adenocarcinoma (n=19), was 10.1+3.6, 21.1+3.8, and 31.5+6.0 AU, respectively, p<0.001. Similarly, a significant difference in fluorescence intensity was observed among normal mucosa (n=15, 43.5+10.7), polypoid dysplasia (n=24, 78.6+12.8) and non-polypoid dysplasia (n=16, 85.1+19.2) on human EMR specimens, p<0.001.
[00149] The peptide sequence KCCFPAQ (SEQ ID NO: 2) binds specifically to pre- malignant human colonic mucosa with non-polypoid morphology and can be fluorescent- labeled to target these lesions on endoscopic imaging in patients. This peptide can therefore be used as a targeted contrast agent for enhancing diagnostic specificity on endoscopy. These validated results support its use with novel imaging instruments, including fluorescence endoscopes and confocal endomicroscopes that are being used in the clinic. Fluorescent- labeled peptides such as KCCFPAQ (SEQ ID NO: 2) are thus contemplated for use, for example, in targeting pre-malignant and malignant lesions during colonoscopy for guiding tissue biopsy, identifying flat and depressed lesions, and localizing tumor margins in patients at increased risk for developing adenocarcinoma. Such fluorescent-labeled peptides can also be used to visualize flat and depressed lesions that occur in the setting of ulcerative colitis, as molecular targets associated with cancer progression are frequently preserved in different disease processes.
Example 12
[00150] Gastrointestinal cancers are heterogeneous and can over-express several gene targets that can be imaged simultaneously on endoscopy using multiple molecular probes. A multi- spectral scanning fiber endoscope was developed for wide-field fluorescence detection of colonic dysplasia. Excitation at 440, 532 and 635 nm was delivered into a single spiral scanning fiber, and fluorescence was collected by a ring of light-collecting optical fibers placed around the instrument periphery. Specific-binding peptides were selected with phage display technology using the CPC;Apc mouse model of spontaneous colonic dysplasia. Validation of peptide specificity was performed on flow cytometry and in vivo endoscopy. The peptides KCCFPAQ (SEQ ID NO: 2), AKPGYLS (SEQ ID NO: 25), and LTTHYKL (SEQ ID NO: 26) were selected and labeled with 7-Diethylaminocoumarin-3-carboxylic acid (DEAC), 5-Carboxytetramethylrhodamine (TAMRA), and CF633, respectively. Separate droplets of KCCFPAQ-DEAC, AKPGYLS-TAMRA, and LTTHYKL-CF633 were distinguished at concentrations of 100 and 1 μΜ. Separate application of the fluorescent- labeled peptides demonstrated specific binding to colonic adenomas.
Multi-Spectral Scanning Fiber Endoscope
[00151] A scanning fiber endoscope system was adapted for fluorescence detection in three channels (RGB) using excitation at 440 (NDHB510APA, Nichia, Tokyo, Japan), 532 (FTEC532-V10TA0, Blue Sky Research, Milpitas, CA) and 635 (FMXL635-017TA0B, Blue
Sky Research) nm using an RGB coupler (OZ Optics, Ottawa, Canada). The three laser sources are delivered simultaneously into the scanning fiber, and focused to the same point on the illumination plane using a custom lens assembly, as shown in the schematic in Fig. 2A. The laser power coming out of the distal tip of the endoscope is <2 mW for each channel, a level consistent with a non- significant risk (NSR) determination by the U.S. Food and Drug Administration (FDA, 21 CFR 812) for future human clinical studies. The amplitude of the spiral scanner was reduced to achieve a divergence angle of 70 deg (max 100 deg) to minimize noise in the periphery of the image. Fluorescence is collected by a ring of 12 step-index plastic optical fibers (POF) with numerical aperture (N.A.) of 0.63 and outer diameter of 250 μιη (Toray Industries Inc, Tokyo, Japan).
[00152] The detection system, shown in Fig. 2B, uses longpass (XLP = 450 nm) and notch ( I = 532 nm and X 2 = 632.8 nm) filters (Edmund Optics Inc, Barrington, NJ) to reject the reflectance component (RGB laser excitation) of the light emerging from the collection fibers. The fluorescence component is deflected into three individual channels using dichroic beamsplitters DM1 (Xc = 460 nm) and DM2 (Xc = 550 nm) (Chroma Technology Corp, Bellows Falls, VT). An additive RGB set of dichroics (XR,G,B, part# 52-546, Edmund Optics Inc) is used to filter the individual fluorescence beams, which are focused onto separate PMT (H7826-01, Hamamatsu Corp, Hamamatsu City, Japan) detectors using an objective lens
25 mm, N.A. = 0.46). The PMT signals are sampled at 25 MHz to generate video rate (30 Hz) images.
[00153] The distal tip of the flexible multi- spectral endoscope had a 1.6 mm outer diameter). The distal end of the single illumination optical fiber was scanned in 250 circles in a growing spiral pattern at approximately 11.5 kHz. Real-time zooming to the diffraction limit of the optics can be performed by reducing the scan angle while capturing the same number of pixels over the FOV. The sub-millimeter lens assembly seals the distal tip of the instrument and extends the waist of the laser beam to define a depth of focus that ranges between 2 to 50 mm. A spatial resolution of <15 μιη was achieved at a distance of 3 mm from the distal tip to the illumination plane and <1 mm at the maximum depth of focus. This unique combination of scanning mechanism and optics allows for a flexible instrument to be realized in a much smaller package yet match the high-quality images from standard medical endoscopes.
Peptide Selection and Validation
[00154] Cell culture reagents were purchased from Invitrogen (Carlsbad, CA). Chemical reagents were purchased from Sigma- Aldrich (St. Louis, MO) unless otherwise noted. Mice were cared for under the approval of the University Committee on the Use and Care of Animals (UCUCA) at the University of Michigan. Five- to seven-month old CPC;Apc mice that have a Cre-regulated somatic mutation in one Ape allele, causing adenomas to develop spontaneously in the distal colon at approximately 3 months of age, were used. This mutation is commonly found in sporadic human colorectal cancer. All mice were housed in specific pathogen-free conditions and supplied water ad libitum throughout the study.
Peptide selection was performed with in vivo phage display technology using this mouse as the biopanning substrate.
[00155] A 7-month old CPC;Apc mouse was injected via tail vein with 2xl0u pfu of the parent M13-7mer Ph.D.7™ Phage Display Library (New England Biolabs, Beverly, MA). The library was allowed to circulate for 10 min, after which the mouse was euthanized by carbon dioxide asphyxiation and immediately heart-perfused with phosphate buffer solution with protease inhibitors (PBS-PI): 1 mM phenylmethanesulfonylfluoride (PMSF), 20 μg/mL aprotinin, and 1 μg/mL leupeptin). Organs were extracted after perfusion and kept on ice. The bound phages were recovered by homogenizing each tissue or organ (Bio-gen Pro 200) in DMEM-PI (Dulbecco's Modified Eagle Medium plus protease inhibitors: 1 mM
phenylmethanesulfonylfluoride (PMSF), 20 μg/mL aprotinin, and 1 μg/mL leupeptin). The tissue samples were washed 3x with ice-cold washing medium (DMEM-PI containing 1% bovine serum albumin (BSA)), centrifuging for 5 min at 3000 rpm between each wash. After the last wash, freshly starved Escherichia coli (ER2738) were added to each tissue homogenate and incubated for 30 min at room temperature (RT). Pre-warmed Luria-Bertani (LB) medium was then added to the bacteria-homogenate solution and incubated for an additional 30 min at RT. The supernatant was recovered after centrifugation and tittered to determine the number of bound phage within each tissue tested. This procedure constituted one round of biopanning. A total of 3 rounds of phage biopanning were performed, with amplification of the recovered eluate after each biopanning round. The input phage number (2xl0n pfu) was kept constant for each round of biopanning. Tittering was performed with appropriate serial dilutions for both eluted phage and amplified phage after each round of biopanning. Agar plates treated with IPTG (isopropyl-b-D-thiogalactosidase) and Xgal (5- bromo-4-chloro-3-indoyl-b-D-thiogalactosidase) were able to visually identify plaques using blue/white screening. Amplified phages from selected phage plaques were purified by
PEG/NaCl (polyethylene glycol/sodium chloride) precipitation. All Ml 3 DNA were sequenced after isolating single stranded DNA using an iodide buffer extraction via dideoxy chain termination using a DNA sequencer (Applied Biosystems, 3730XL DNA Analyzer, UM DNA Core) with the NEB-96 gill sequencing primer provided by New England Biolabs (# S1259S). The number of phages bound to each organ or tissue was calculated as the output pfu/(input pfu x tissue mass).
[00156] Specific binding of the candidate peptides to primary dysplastic colonic epithelial cells were validated on flow cytometry ex vivo and with small animal endoscopy in vivo using FITC-labeled peptides using a non-scanning white light endoscope.
[00157] After three rounds of in vivo phage biopanning that included heart perfusion as a method for clearing non-specific vascular binders, the preference of the phage pools collected during all rounds of biopanning indicated that the phages were binding more specifically to colonic adenomas in comparison to normal appearing adjacent colonic mucosa, kidney and liver. Phages that bound to colonic adenomas approximately 10 times greater in number than to normal appearing colonic mucosa were chosen. As a result, 42 individual phage clones were sequenced from the third round of biopanning, and were individually amplified and conjugated to 5'-FITC. Binding to isolated colonic epithelial cells from adenomas for each phage clone was analyzed using flow cytometry. A common 7-mer phage that expresses the sequence HAIYPRH (SEQ ID NO: 29) is a known contaminant, and was run (labeled # in Supplementary Fig. IB) to ensure the validity of the assay. The T/B ratio for clone
HAIYPRH was found to be 1.10+0.08, indicating minimal binding from a non-specific clone, as expected. Six phage clones with a T/B ratio (target to wild-type phage) >1.9 were identified as ALTPTPP (SEQ ID NO: 30), NLVNLLP (SEQ ID NO: 31), ANYPREP (SEQ ID NO: 32), ATTVPAS (SEQ ID NO: 33), LTTHYKL (SEQ ID NO: 26), and AKPGYLS (SEQ ID NO: 25). The KCCFPAQ (SEQ ID NO: 2) peptide had been previously found to bind to human HT29 cells.
[00158] The 7 peptides were synthesized and conjugated to 5'-FITC for evaluation of in vivo binding. The GGGAGGG (SEQ ID NO: 34) peptide used as a control. The target and control peptides were prepared using solid phase synthesis with standard Fmoc chemistry. Fmoc protected L-amino acids were used, and synthesis was assembled on rink amide MBHA resin using a PS3 (Protein Technologies, Inc. AZ) automatic peptide synthesizer. The candidate peptides for the validation study were labeled with 5'-FITC (Anaspec, Fremont, CA) at the C-terminus on the side chain of a lysine residue via a GGGSK linker (SEQ ID NO: 14). The candidate peptides for the multi- spectral study were labeled with three
different organic fhiorophores. 7-Diethylaminocoumarin-3-carboxylic acid (DEAC, Sigma- Aldrich, St. Louis, MO) has a peak absorption and emission at 432 and 472 nm, respectively. 5-Carboxytetramethylrhodamine (TAMRA, Chempep, Wellington, FL) has a peak absorption and emission at 541 and 568 nm, respectively. CF633 (Biotium Inc., Hay ward, CA) has a peak absorption and emission at 630 and 650 nm, respectively. These dyes have peak absorption that approximately match the laser sources. In addition, the peptide
GGGAGGGAGGGK (SEQ ID NO: 21) was used as a control.
[00159] In vivo imaging of the 8 FITC-labeled peptides with the non-scanning endoscope demonstrated that KCCFPAQ (SEQ ID NO: 2), AKPGYLS (SEQ ID NO: 25), and
LTTHYKL (SEQ ID NO: 26) exhibited the highest T/B ratio for binding to colonic adenomas in vivo, shown in Table 1.
[00160] Table 1 - Summary of imaging results. The average T/B ratios for in vivo imaging of colonic adenomas in CPC;Apc mice are shown for candidate peptides labeled with FITC for validation of specific binding using a non-scanning endoscope and for target peptides labeled with DEAC and TAMRA using the multi- spectral scanning fiber endoscope.
Non-scanning Endoscopy Results
Peptide n (Mice) n (Adenomas) Average T/B
KCCFPAQ-FITC 3 9 1.69 ± 0.70
AKPGYLS -FITC 4 7 1.53 ± 0.48
LTTHYKL-FITC 5 13 1.50 ± 0.73
ALTPTPP-FITC 3 10 1.19 ± 0.18
ATTVPAS-FITC 2 3 1.06 ± 0.33
NLVNLLP-FITC 1 2 0.99 ± 0.06
ANYPREP-FITC 1 2 0.94 ± 0.11
GGGAGGG-FITC 3 13 1.05 ± 0.05
Multi-Spectral Scanning Fiber Endoscopy Results
Peptide n (Mice) n (Adenomas) Average T/B
KCCFPAQ-DEAC 3 7 1.71 ± 0.19
AKPGYLS -TAMRA 3 6 1.67 ± 0.12
GGGAGGG-DEAC 2 4 1.19 ± 0.09
GGGAGGG-TAMRA 2 4 1.32 ± 0.10
[00161] The three peptides were subsequently conjugated to 7-Diethylaminocoumarin-3- carboxylic acid (DEAC), 5-Carboxytetramethylrhodamine (TAMRA), and CF633, respectively, for in vivo imaging with the multi- spectral scanning fiber endoscope. The control peptides GGGAGGGAGGGK (DEAC)-NH2 and GGGAGGGAGGGK (5-TAMRA)- NH2 were also synthesized.
Fluorescence Spectra from Multiple Peptides
[00162] A fiber-coupled spectrophotometer (Ocean Optics, Dundin, FL) was used to validate the excitation and emission spectra of the fluorescent-labeled peptides. Droplets of each fluorescent-labeled peptide at 1 μΜ concentration were analyzed individually. The optical collection fibers of the multi- spectral scanning fiber endoscope were disconnected from the base station and connected to the spectrophotometer. Directed data collection was performed by stopping the motion of the scanning fiber and aiming the illumination spot at the droplet. Readings were then acquired using a 3 ms integration time with Ocean Optics Spectra Suite software.
[00163] The excitation and emission spectra of the 3 RGB laser sources and fluorescent- labeled peptides over the visible spectrum were measured with the fiber coupled
spectrophotometer. The spectra were collected from the labeled peptides both with and without use of the respective dichroic (bandpass) filters
Excitation at 440 nm and peak emission at 486 nm were observed for the KCCFPAQ-DEAC peptide. Excitation at 532 nm and peak emission at 577 nm were observed for the AKPGYLS -TAMRA peptide.
Excitation at 635 nm and peak emission at 659 nm were observed for the LTTHYKL-CF633 peptide. These spectra showed minimal overlap (crosstalk) among the fluorescence emission bands for the 3 peptides. Moreover, these results showed that labeling the peptide with an organic dye causes only a small shift (9 to 14 nm) in the peak emission wavelength.
Individually and Combined Targeted In Vivo Images
[00164] The CP C; Ape mice were first imaged with white light using a non- scanning endoscope (Karl Storz Veterinary Endoscopy, Goleta, CA) to assess for the presence of colonic adenomas that have a size between -0.5 to 4 mm in diameter. Any adenomas were rinsed of debris including stool and mucous, by delivering tap water through a 3 Fr instrument channel. Then, the fluorescent-labeled peptides were delivered topically at a concentration of 100 μΜ in lx PBS in a volume of 1 mL to the distal 4 cm of the colon and rectum. The peptides were incubated for 5 minutes and then the unbound peptides were rinsed away with tap water 3 times. The colon was inspected for any residual peptide, and
when clean, the colon was insufflated with air and imaged with the multi- spectral scanning fiber endoscope. Cre-recombinase negative littermates that do not express colonic adenomas were used as controls.
[00165] Videos collected during endoscopy were exported as avi video files and converted into sequential png images using Apple QuickTime. White light and fluorescence images for each adenoma were analyzed in NIH Image J. The white light image was utilized to draw a region of interest (ROI) around the adenoma or adjacent normal appearing colonic mucosa which was then superimposed onto the fluorescence image The mean fluorescence intensities were calculated for each ROI, and a target/background (T/B) ratio was calculated for each colonic adenoma and compared to the surrounding normal appearing mucosa.
[00166] Images were collected with the fluorescent-labeled peptides A) KCCFPAQ- DEAC, B) AKPGYLS -TAMRA, and C) LTTHYKL-CF633 administrated. Specific binding of each peptide to colonic dysplasia is demonstrated by comparing the fluorescence images with the corresponding white light images collected with the non-scanning. The lesion margins on fluorescence appeared to be sharp in comparison to that on the white light images. The fluorescent-labeled peptides KCCFPAQ-DEAC and AKPGYLS -TAMRA clearly displayed specific binding to colonic dysplasia while that for the LTTHYKL-CF633 peptide appears to be more subtle. The average T/B ratios of peptide binding to dysplasia versus normal appearing adjacent colonic mucosa were 1.71 ± 0.19 (range 1.50 - 2.06) and 1.67 ± 0.12 (1.50 - 1.78) for KCCFPAQ-DEAC and AKPGYLS-TAMRA, respectively (Table 1), while that for LTTHYKL-CF633 was not measured because of low signal level.
Representative histology (H&E) of the adenoma and adjacent normal appearing mucosa showed dysplastic crypts with features, such as enlarged nuclei, disorganization,
hyperchromaticity, crowded lamina propria, and distorted architecture, similar to that seen in human sporadic adenomas.
[00167] Administration of KCCFPAQ-DEAC and AKPGYLS-TAMRA to normal colonic mucosa resulted in minimal signal, a result comparable to that found with no administration of peptide (autofluorescence). Also, minimal signal is seen for binding of the control peptides GGGAGGG-DEAC and GGGAGGG-TAMRA to the adenomas (arrows), resulting in T/B ratios of 1.19±0.09 and 1.32±0.10 (Table 1), respectively. Statistical differences between the target and control peptides for KCCFPAQ and AKPGYLS were p = 0.009 and p = 0.001, respectively. A quantitative comparison of fluorescence intensities for binding of the control peptide to adenomas and autofluorescence (no peptide) could not be made because the effect on the low signal levels by the system autogain function.
[00168] White light images of colonic adenomas from 3 different mice were examined. Sequential administration of the KCCFPAQ-DEAC and AKPGYLS-TAMRA peptides resulted in separate spatial patterns of binding to colonic dysplasia in the blue and green channels. This result suggests that each peptide binds to a different cell surface target.
Combined delivery of the control peptides GGGAGGG-DEAC and GGGAGGG-TAMRA resulted in similar intensity to that found for autofluorescence where no peptide was administered.
Statistical Analysis
[00169] All results are shown as mean + one standard deviation. After data normality was established using the Shapiro-Wilk test, two-sided independent samples t-tests were performed to determine statistical significance (significance level defined as a = 0.05) between the target and control peptides for specific binding to colonic adenomas (PASW Statistics 18, Chicago, IL).
Summary of Results
[00170] The average target/background ratios were 1.71±0.19 and 1.67±0.12 for
KCCFPAQ-DEAC and AKPGYLS-TAMRA, respectively. Administration of these two peptides together resulted in distinct binding patterns in the blue and green channels.
Specific binding of two or more peptides can be distinguished in vivo using the multi- spectral endoscope described herein to localize colonic dysplasia on real-time wide-field imaging. The ultrathin dimensions and flexibility of this multi- spectral endoscope allow for seamless integration with standard instrument channels of conventional medical endoscopes.
Moreover, the lasers, detectors and data acquisition system are conveniently contained within a portable cart that can be easily transported around a procedure room.
Example 13
[00171] A near-infrared (NIR) labeled multimer peptide was generated using trilysine as a dendritic wedge and peptide AKPGYLS (SEQ ID NO: 25). The multimer peptide was labeled with either Cy5.5 or FITC using solid phase synthesis and a real-time near-infrared endoscope was used to visualize the dysplastic lesions in vivo in CPC;Apc mice as follows.
Chemicals and Materials
[00172] Human colorectal adenocarcinoma (HT29, SW480) and non-malignant intestinal (CCD841Con) cells were obtained from the American Type Culture Collection (ATCC,
Manassas, VA). The HT29, SW480, and CCD841Con cells were cultured in McCoy's Medium, Dulbecco's Modified Eagle Medium, Eagle's Minimal Essential Medium, and Roswell Park Memorial Institute medium, respectively. All cells were cultured at 37°C in 5% C02, and supplemented with 10% fetal bovine serum (FBS), 1% penicillin/streptomycin, and 1% glutamax. The cells were passaged using 0.25% EDTA containing trypsin (Mediatech Inc, Mansas, VA). The cell number was determined using a hemocytometer. Peptide synthesis reagents were obtained from Anaspec (Anaspec, Fremont, CA) or AAPPTEC (AAPPTEC, Louisville, KY) and were of the highest grade available (>99 % purity) and used without further purification. Solvents and other chemical reagents were purchased from Sigma Aldrich (St. Louis, MO) unless otherwise mentioned.
Animals
[00173] Mice were cared for under the approval of the University Committee on the Use and Care of Animals, University of Michigan (UCUCA). All mice were housed in specific pathogen-free conditions and supplied water ad libitum under controlled conditions of humidity (50+10%), light (12/12 hr light/dark cycle) and temperature (25°C) throughout the study.
Peptide Synthesis
[00174] The peptides used in this study were prepared using standard Fmoc-mediated solid-phase peptide synthesis on Rink amide MBHA resin. Fmoc and Boc protected L-amino acids were used and synthesis was assembled on rink amide MBHA resin. The peptides synthesized were: 1) AKPGYLSGGGSK-CONH2 (AKP-monomer), 2) tetrameric version of AKPGYLS anchored on a trilysine core (AKP-multimer), and 3) trilysine core alone
(control). See, Fig. 3. Peptides were conjugated with either FITC or Cy5.5 for use on flow cytometry or NIR imaging, respectively. For the in vitro studies, FITC was selected because of ease for chemical incorporation and high quantum yield for quantitative assays. For in vivo imaging, Cy5.5 was selected because of lower autofluorescence background, reduced tissue scattering, and resistance to photobleaching.
[00175] The monomer peptide was synthesized on a PS3 automatic synthesizer (Protein Technologies Inc., Tucson, AZ). The C-terminal lysine was incorporated as Fmoc-Lys (ivDde)-OH and the N-terminal Ala was incorporated as Boc-Ala-OH to avoid unwanted Fmoc removal during deprotection of the ivDde moiety prior to dye labeling. Upon complete assembly of the peptide, the resin was transferred to a reaction vessel for manual labeling with dye. The ivDde side chain protecting group was removed with 5% hydrazine in DMF
(3x10 min) with continuous shaking at room temperature (RT). The resin was washed with Dimethylformamide (DMF) and dichloromethane (DCM) 3 times each for 1 min. The protected resin-bound peptide was incubated overnight either with 5-FITC (Anaspec, Fremont, CA) or Cy5.5-NHS ester (Lumiprobe LLC, Hallandale Beach, FL) with DIEA and the completion of the reaction was monitored by a qualitative Ninhydrin test. Upon completion of labeling, the peptide was cleaved from the resin using TFA: TIS: H20
(95:2.5:2.5 v/v/v; Sigma Aldrich, St. Louis, MO) for 4 hours with shaking in the dark at RT. After separation of the peptide from the resin, the filtrate was removed with N2 gas followed by precipitation with diethyl ether and stored overnight at -20°C. The precipitate was centrifuged at 3000 rpm for 5 min and washed with diethyl ether 3 times and centrifuged in between each washing step.
[00176] Similarly, the AKP-multimer was synthesized manually on a trilysine-core which has 4-reactive sites for peptide coupling. First, the C-terminus Fmoc-Lys-(ivDde)-OH was conjugated on the resin for specific labeling of the dye followed by deprotection of Fmoc group with 20% piperidine. Next, two consecutive coupling steps were performed with Fmoc-Lys (Fmoc)-OH. After the coupling of second Fmoc-Lys (Fmoc)-OH, the deprotection of Fmoc-group provided the 4-arms for assembling the peptide sequences in a tetrameric form. Then, stepwise solid phase synthesis was performed. As mentioned earlier in monomer synthesis, the Boc-Ala-OH was used at the N-terminus. All other steps after complete assembly were repeated similarly as for monomer peptide synthesis.
[00177] The crude peptides were dissolved in 1: 1 Acetonitrile/H20 (v/v) and purified by prep-HPLC with a C18 column (Waters Inc, Milford, MA) using a water (0.1% TFA)- acetonitrile (0.1% TFA) gradient. The final purity of the peptides was confirmed by analytical C18-column. Further characterization was performed with either ESI (Waters Inc, Milford, MA) or Q-TOF (Agilent Technologies, Santa Clara, CA) mass spectrometry. The chromatogram obtained from analytical RP-HPLC indicated a purity >95% for all peptides. On mass spectra, the experimental m/z (mass units) measured for the AKP-monomer-FITC, AKP-multimer-FITC, trilysine-FITC, AKP-monomer-Cy5.5, AKP-multimer-Cy5.5, and trilysine-Cy5.5 was 1510.0, 3786.0, 919.5, 1727.97, 4003.3, and 1136.7, respectively. These values agree with the expected molecular mass of 1509.8, 3785.9, 919.8, 1726.97, 4002.3, and 1136.7, respectively.
In Vivo Imaging
[00178] The binding activity of the synthetic peptides to colonic dysplasia was assessed in vivo in 3 cohorts of CPC;Apc mice: 1) AKP-multimer, n = 14 mice with n = 33 adenomas, 2) AKP-monomer, n =14 mice with n = 27 adenomas, and 3) trilysine core, n = 8 mice with n = 17 adenomas as a control. For the imaging studies, anesthesia was induced and maintained in the animals with inhaled isoflurane mixed with oxygen via a nose cone at a dose of 4% and 2% at a flow rate of 0.5 liter/min, respectively. Prior to applying the peptides, the colon was prepped using a tap water lavage. The adenomas were viewed endoscopically, and videos were recorded using white light with a small animal endoscope (Karl Storz Veterinary Endoscopy, Goleta, CA). The colon was rinsed with water until all mucous and other debris was removed. Adenomas from approximately 0.5-4 mm in diameter that were not covered in debris, including stool and mucous, were included in the study.
[00179] The Cy5.5-labeled peptides were delivered at a concentration of 100 μΜ in PBS containing 2.5% DMSO (dimethyl sulfoxide) through the instrument channel of the endoscope. During peptide administration, 1.5 mL of peptide was delivered to the distal colon in each mouse. The peptide was allowed to incubate for 5 min after which the colon was cleansed 3X with a tap water to remove the unbound peptide. Prior to imaging, the colon was inspected for residual peptide solution, and when clean, the colon was insufflated with air and imaged with the wide field endoscope which provides excitation at 671 nm. Fluorescence and reflectance videos were collected using Axiovision 4.8.1 software. Fluorescence videos were collected at 100 ms/frame (10 Hz), and transferred to the computer for storage by a firewire connection. A filter wheel was incorporated into the handle of the housing to quickly switch between collection of reflectance and fluorescence images. White light, fluorescence and reflectance images were collected from 1) n = 14 mice having n = 33 adenomas with AKP- multimer, 2) n =14 mice having n = 27 adenomas with AKP-monomer, and 3) n = 8 mice having n = 17 adenomas with the trilysine (control). The CPC;Apc mice imaged ranged in age from 3 to 6 months. Fluorescence images were exported as videos in zvi format (16 bit digital resolution) using Lab View software. Sequentially-collected white light and fluorescence images for each adenoma were analyzed. Separate regions of interest (ROI) were defined around the adenoma and adjacent normal- appearing mucosa on the white light image, and the ROI's were overlayed onto the fluorescence images. The target to-background (T/B) ratio was determined by ratioing the mean intensities from these 2 ROI's.
[00180] White light endoscopy was performed in to identify adenomas that range in diameter from -0.5 to 4 mm. No background (autofluorescence) was noticeable using NIR
excitation at λεχ = 671 nm from colonic mucosa prior to peptide administration. The reflectance image showed amorphous surface texture from dysplasia with little difference in intensity between normal colonic mucosa and adenoma. Several bright regions of specular reflection were appreciated. The AKP-monomer provideed a faint fluorescence intensity that was significantly amplified by the AKP-multimer. The trilysine core (control) showed negligible signal. The use of the AKP-multimer detected all lesions regardless of size whereas AKP-monomer did not visualize lesions smaller than ~1 mm.
[00181] A quantitative analysis of image intensities using neighboring regions-of-interest (ROI) revealed that the AKP-multimer produces ~ 1.8-fold greater average fluorescence intensity from colonic adenomas in comparison to that from the AKP-monomer and the trilysine control with T/B ratios of 3.84+0.26, 2.21+0.13, and 1.56+0.12, respectively, p<0.001. A non-parametric Mann- Whitney analysis showed that AKP-multimer peptide binds in significantly greater amounts to the adenomas than AKP-monomer.
Flow Cytometry
[00182] Peptides labeled with 5-FITC were used for the validation assays of cell binding. Preferential binding of the multimer peptide, monomer peptide, and trilysine to different human colorectal cancer (SW480, and HT29) and control cells (CCD841-Con) was validated on flow cytometry. A total of 5xl05 cells were used with each probe. The confluent cells were detached using enzyme free cell dissociation buffer (Invitrogen, Carlsbad, CA) or trypsin with 0.25% EDTA (Mediatech Inc, Manassa, VA) and immersed in blocking buffer, PBS with 1% bovine serum albumin (BSA), for 30 min at 4°C with continuous agitation. After blocking, cells were washed with IX PBS and spun down for 5 min at 1000 rpm. Then cells were incubated with the 5-FITC labeled peptides and trilysine (10 μΜ) for 60 min at 4°C with continuous agitation. The cells were then washed 3X with cold PBST followed by immediate fixation for 10 min with 4% paraformaldehyde. The cells were washed again (IX) with PBS and resuspended in 1 mL of PBS. Flow cytometry was performed using
FACSDiVa (BD® LSRII, BD Biosciences, San Jose, CA) and analyzed using Flowjo analysis program (Tree Star Inc, Ashland, OR). The gain was kept constant for all experiments.
[00183] The AKP-multimer peptide bound specifically to the plasma membrane of the SW480 and HT29 cells but not to CCD-841Con cells, as shown by an overlay of the FITC and DAPI images. The same concentration of AKP-monomer peptide revealed a lower fluorescence intensity at the cell surface. The trilysine core (control) did not stain any of the cells.
Fluorescence Microscopy
[00184] Preferential binding of the FITC-labeled peptides to the target and non-target cells as mentioned above was further validated via fluorescence microscopy. Cells (-7.5X10 ) were seeded on cover slips to -80% confluence. The cells were then incubated with 10 μΜ of 5-FITC-labeled peptides and trilysine at 4°C for 1 hr followed by staining with 1 μg/mL Hoechst dye (Sigma Aldrich, St. Louis, MO). The cells were washed 3X with PBS and fixed with 4% paraformaldehyde at RT for 10 min. After fixation, the cells were washed again with PBS (IX) and mounted with Pro Long Gold reagent (Invitrogen, Carlsbad, CA) and fluorescence images were collected with confocal microscopy (Leica TCS SP5
Microsystems, Bannockburn, IL). The specific peptide binding activity of the FITC-labeled AKP-multimer and AKP-monomer peptides was compared.
[00185] The counts reflecting the AKP-multimer binding to SW480, HT29, and CCD- 841Con cells were significantly higher by a factor of 20.2, 26.1, and 2.2 times, respectively, than that for unstained cells. As expected, AKP-monomer bound to a lower extent than the AKP-multimer, whereas trilysine (control) bound minimally as compared to cells unstained with peptide. In both experiments, the AKP-multimer peptide bound consistently with the primary human colon adenocarcinoma cell lines. Both cell-binding assays demonstrated that AKP-multimer had higher binding avidity than monomer, which can be attributed to the multivalency effect.
Measurement of Binding Affinity
[00186] The binding affinity of multimer and monomer peptide was measured by varying the concentration of the 5 -FITC-labeled peptides and trilysine incubated with the target cells (lxlO5) until saturation of fluorscence intensity was achieved [16]. The FITC-labeled peptide was serially diluted in PBS at concentrations that varied from 0 to 10 μΜ and incubated with the target cells at 4°C for 1 hr. The unbound peptide was rinsed off the cells by washing 3X with cold PBS/0.2% Tween-20 solution. The cells were fixed with 4% PFA, as mentioned above, washed IX with PBS, and resuspended in lmL of PBS. Cells were transferred to a 5 mL tube and subjected to flow-cytometric analysis. The median fluorescence intensity from each concentration of peptides was used to calculate the affinity constant. The equilibrium dissociation constants
of the peptide-cell interaction were obtained by fitting the data to the non-linear equation I[X] = (Io+ImaxKa[X])/ (Io+ Ka[X]). Io and Imax are the initial and maximum fluorescence intensities, corresponding to no peptide and at saturation, respectively, and [X] represents the concentration of the bound peptide. Origin 6.1 data
analysis software (Origin Lab Corp, Northampton, MA) was used to perform a non-linear least square fit of the data.
[00187] The relative fluorescence intensity as a function of the concentration of the fluorescent-labeled AKP-monomer and AKP-multimer peptides that bound to the HT29 cells was determined. A non-linear increase in fluorescence intensity with peptide concentration was observed until saturation was reached. A fit of the data with the model yields a iQ = 6.4 nM/L, R2 = 0.973 for the AKP-multimer and Kd = 310 nM/L, R2 = 0.876 for the AKP- monomer. Similar experiments performed with SW480 cell line also exhibited an improved binding affinity for the AKP-multimer, Kd = 101 nM/L, R = 0.953, in comparison to the AKP-monomer Kd = 1210 nM/L, R = 0.933. These results further support a multivalent approach to enhance the binding affinity of phage derived peptides through reconstruction of the phage architecture using trilysine core as a synthetic scaffold.
Kinetic Measurements
[00188] The binding kinetics for AKP-monomer and AKP-multimer peptide was further evaluated on the target cells in the presence of 10 μΜ peptide concentration. The target cells (5 X105) were detached and blocked as mentioned earlier and incubated with both monomer and multimer peptides at 4°C over time from 0-60 min. After completing the incubation for each time course, the samples were prepared for flow cytometry, as mentioned above. The kinetics of peptide binding with the cell surface was determined by measuring the shift in the intensity of FITC-channel as a function of time. The resulting data were converted to median values as a function of time, and the rate constant was calculated using first order rate kinetics Y = a-b*exp( kx); where a = maximum value, b = difference in intensity (I-I0), and K = rate constant. Curve fits were performed using Origin 6.1 data analysis software.
[00189] The binding kinetics of AKP-multimer and AKP-monomer with HT29 cells on flow cytometry were measured. Binding of AKP-multimer with HT29 cells was ~2 fold faster (K = 0.11364 min"1; R2 = 0.972), with kinetics comparable to that of the AKP-monomer (K =
0.0663 min - _11; R2 = 0.984). About 50% binding was observed at 5 min that seemed to become constant around 30 min and not changed even after incubating until 60 min. Even though the molecular weight of the AKP-multimer is about 2.3 fold greater than AKP-monomer, there was no slow down in reaction kinetics.
Statistical Analysis
[00190] Statistical analyses were calculated using Minitab software (Minitab Inc. State College, PA). First, the nonparametric Kruskal-Wallis test was used for each peptide to
determine if observed differences were statistically significant among all peptides. The non- parametric Mann- Whitney test was used for comparisons between two independent samples. p<0.05 was considered to indicate a statistically significant difference.
Summary of Results
[00191] The multimer demonstrated increased fluorescence intensity from binding to colonic adenomas in vivo with a target/background ratio (TBR) of 3.84+0.26 compared to 2.21+0.13 for the monomer and 1.56+0.12 for the trilysine core, p<0.001. The FITC-labeled multimer showed greater fluorescence intensity on the surface of HT29 and SW480 cells on microscopy and higher counts on flow cytometry. Binding affinity to HT29 cells yielded a K<j = 6.4 nM/L for multimer compared to K<j = 310 nM/L for monomer. Measurements of binding kinetics with HT29 cells revealed K = 0.1136 min 1 to multimer compared to K = 0.0663 min"1 for monomer. Thus the use of multimer peptides can significantly improve binding affinity and kinetics for targeted detection of dysplastic colonic mucosa on fluorescence endoscopy.
[00192] The near-infrared (NIR) labeled multimer peptide can be used longitudinally to evaluate molecular expression in small animal models, and can also be directly translated into the clinic for early cancer detection.
[00193] While the present invention has been described in terms of specific embodiments, it is understood that variations and modifications will occur to those skilled in the art.
Accordingly, only such limitations as appear in the claims should be placed on the invention.
[00194] All documents cited in this application are hereby incorporated by reference in their entirety.
Claims
1. A reagent comprising a peptide consisting of the amino acid sequence
QPIHPNNM set out in SEQ ID NO: 1, KCCFPAQ set out in SEQ ID NO: 2, VRPTLPM set out in SEQ ID NO: 22, NFMESLPRLGMH set out in SEQ ID NO: 23, AKPGYLS set out in SEQ ID NO: 25, LTTHKYL set out in SEQ ID NO: 26, or a multimer form thereof.
2. The reagent of claim 1 further comprising a detectable label attached to the peptide.
3. The reagent of claim 2 wherein the detectable label is detectable by microscopy, ultrasound or magnetic resonance imaging.
4. The reagent of claim 3 wherein the label detectable by microscopy is fluorescein isothiocyanate (FITC).
5. The reagent of claim 3 wherein the label detectable by microscopy is Cy5.5.
6. The reagent of claim 3 wherein the label detectable by microscopy is 7- Diethylaminocourmarin-3-carboxylic acid (DEAC).
7. The reagent of claim 3 wherein the label detectable by microscopy is 5- Carboxytetramethylrhodamine (TAMRA) .
8. The reagent of claim 3 wherein the label detectable by microscopy is CF633.
9. The reagent of claim 2 wherein the detectable label is attached to the peptide by a peptide linker.
10. The reagent of claim 9 wherein a terminal amino acid of the linker is lysine.
11. The reagent of claim 10 wherein the linker comprises the sequence GGGSK set out in SEQ ID NO: 14.
12. The reagent of any one of claims 1 through 11 further comprising a therapeutic moiety attached to the peptide.
13. The reagent of claim 12 wherein the therapeutic moiety is a therapeutic agent.
14. The reagent of claim 12 wherein the therapeutic agent is chemotherapeutic agent.
15. A composition comprising the reagent of any of the preceding claims and a pharmaceutically acceptable excipient.
16. A method for detecting colon dysplasia in a patient comprising the steps of administering the reagent of any of claims 2 through 14 to the colon of the patient and detecting binding of the reagent to dysplastic cells.
17. The method of claim 16 wherein the colon dysplasia is detected by a reagent comprising the peptide consisting of the amino acid sequence QPIHPNNM set out in SEQ NO: 1.
18. The method of claim 16 wherein the colon dysplasia is detected by a reagent comprising the peptide consisting of the amino acid sequence KCCFPAQ set out in SEQ ID NO: 2.
19. The method of claim 16 wherein the colon dysplasia is detected by the reagents comprising the peptides consisting of the amino acid sequence KCCFPAQ set out in SEQ ID NO: 2, AKPGYLS set out in SEQ ID NO: 25 and LTTHKYL set out in SEQ ID NO: 26.
20. The method of claim 16 wherein cells of flat and depressed lesions are detected by a reagent comprising the peptide KCCFPAQ set out in SEQ ID NO: 2.
21. A method of determining the effectiveness of a treatment for colon cancer and/or cancer metastasis, or recurrence of cancer in a patient comprising the step of administering the reagent of any of claims 2 through 14 to the colon of the patient, visualizing a first amount of cells labeled with the reagent, and comparing the first amount to a previously- visualized second amount of cells labeled with the reagent,
wherein a decrease in the first amount cells labeled relative to the previously- visualized second amount of cells labeled is indicative of effective treatment.
22. The method of claim 14 further comprising obtaining a biopsy of the cells labeled by the reagent.
23. A method for delivering a therapeutic agent to dysplastic colon cells of a patient comprising the step of administering the reagent of any one of claims 2 through 14 to the patient.
24. A method for delivering a therapeutic agent to colon cancer cells of a patient comprising the step of administering the reagent of any one of claims 2 through 14 to the patient.
25. A kit for administering the composition of claim 15 to a patient in need thereof, said kit comprising the composition of claim 15, instructions for use of the composition and a device for administering the composition to the patient.
26. A peptide consisting of the amino acid sequence QPIHPNNM set out in SEQ ID NO: 1, KCCFPAQ set out in SEQ ID NO: 2, VRPTLPM set out in SEQ ID NO: 22, NFMESLPRLGMH set out in SEQ ID NO: 23, AKPGYLS set out in SEQ ID NO: 25 or LTTHKYL set out in SEQ ID NO: 26.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201061425062P | 2010-12-20 | 2010-12-20 | |
US61/425,062 | 2010-12-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012087913A2 true WO2012087913A2 (en) | 2012-06-28 |
WO2012087913A3 WO2012087913A3 (en) | 2013-01-03 |
Family
ID=46314798
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/065804 WO2012087913A2 (en) | 2010-12-20 | 2011-12-19 | Peptide reagents and methods for detection of colon dysplasia |
Country Status (2)
Country | Link |
---|---|
US (1) | US8901276B2 (en) |
WO (1) | WO2012087913A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017096076A1 (en) * | 2015-12-02 | 2017-06-08 | The Regents Of The University Of Michigan | Micelles and methods |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201003939D0 (en) * | 2010-03-09 | 2010-04-21 | Isis Innovation | Multi-spectral scanning system |
DE102011122602A1 (en) * | 2011-12-30 | 2013-07-04 | Karl Storz Gmbh & Co. Kg | Apparatus and method for endoscopic fluorescence detection |
CN107073065B (en) * | 2014-08-22 | 2021-07-02 | 密歇根大学董事会 | Peptide reagents and methods for detection and targeting of dysplasia, early stage cancer, and cancer |
US10871490B2 (en) * | 2016-02-29 | 2020-12-22 | Multenyi Biotec, gmbH | Assay for detection of chimeric antigen receptor T cells |
KR102506219B1 (en) * | 2017-02-24 | 2023-03-07 | 리포트루, 엘스.엘. | Peptides and compositions for use in cosmetics |
US11406720B2 (en) * | 2017-06-22 | 2022-08-09 | The Regents Of The University Of Michigan | Fibroblast growth factor receptor 2-specific peptide reagents and methods |
WO2020172535A1 (en) * | 2019-02-21 | 2020-08-27 | The Regents Of The University Of Michigan | Detection of colonic neoplasia in vivo using near-infrared peptide targeted against overexpressed cmet |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060058228A1 (en) * | 2002-04-05 | 2006-03-16 | Kelly Kimberly A | Colon tumor specific binding peptides |
US20090136420A1 (en) * | 2001-07-24 | 2009-05-28 | Debiovision, Inc. | Neoplasm-specific polypeptides and their uses |
US20110125029A1 (en) * | 2009-10-30 | 2011-05-26 | The Regents Of The University Of Michigan | Targeted Dual-Axes Confocal Imaging Apparatus with Vertical Scanning Capabilities |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6551795B1 (en) * | 1998-02-18 | 2003-04-22 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics |
US6605709B1 (en) * | 1999-04-09 | 2003-08-12 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Proteus mirabilis for diagnostics and therapeutics |
US20040031072A1 (en) * | 1999-05-06 | 2004-02-12 | La Rosa Thomas J. | Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement |
US20090087878A9 (en) * | 1999-05-06 | 2009-04-02 | La Rosa Thomas J | Nucleic acid molecules associated with plants |
WO2002063280A1 (en) * | 2001-02-06 | 2002-08-15 | Auburn University | Ligand sensor devices and uses thereof |
GB0103508D0 (en) * | 2001-02-13 | 2001-03-28 | Univ Dundee | Screening method and agents |
US7629444B1 (en) * | 2004-06-15 | 2009-12-08 | Monsanto Technology Llc | Nucleotide and amino acid sequences from Xenorhabdus bovienii strain Xs85831 and uses thereof |
-
2011
- 2011-12-19 WO PCT/US2011/065804 patent/WO2012087913A2/en active Application Filing
- 2011-12-19 US US13/329,741 patent/US8901276B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090136420A1 (en) * | 2001-07-24 | 2009-05-28 | Debiovision, Inc. | Neoplasm-specific polypeptides and their uses |
US20060058228A1 (en) * | 2002-04-05 | 2006-03-16 | Kelly Kimberly A | Colon tumor specific binding peptides |
US20110125029A1 (en) * | 2009-10-30 | 2011-05-26 | The Regents Of The University Of Michigan | Targeted Dual-Axes Confocal Imaging Apparatus with Vertical Scanning Capabilities |
Non-Patent Citations (2)
Title |
---|
ELAHI, S. F. ET AL.: 'Targeted imaging of colorectal dysplasia in living mice with fluorescence microendoscopy' BIOMEDICAL OPTICS EXPRESS vol. 2, no. 4, 28 March 2011, pages 981 - 986 * |
MILLER, S. J. ET AL.: 'In Vivo Fluorescence-Based Endoscopic Detection of Colon Dysplasia in the Mouse Using a Novel Peptide Probe' PLOS ONE vol. 6, no. ISS. 3, 08 March 2011, page E17384 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017096076A1 (en) * | 2015-12-02 | 2017-06-08 | The Regents Of The University Of Michigan | Micelles and methods |
US11235066B2 (en) * | 2015-12-02 | 2022-02-01 | The Regents Of The University Of Michigan | Micelles and methods |
Also Published As
Publication number | Publication date |
---|---|
WO2012087913A3 (en) | 2013-01-03 |
US20120219505A1 (en) | 2012-08-30 |
US8901276B2 (en) | 2014-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8901276B2 (en) | Peptide reagents and methods for detection of colon dysplasia | |
AU2017203340B2 (en) | Synthesis And Composition Of Amino Acid Linking Groups Conjugated To Compounds Used For The Targeted Imaging Of Tumors | |
Miller et al. | In vivo fluorescence-based endoscopic detection of colon dysplasia in the mouse using a novel peptide probe | |
KR20170094268A (en) | Cyclic peptides with enhanced nerve-binding selectivity, nanoparticles bound with said cyclic peptides, and use of same for real-time in vivo nerve tissue imaging | |
Joshi et al. | Near-infrared-labeled peptide multimer functions as phage mimic for high affinity, specific targeting of colonic adenomas in vivo (with videos) | |
CN107073065B (en) | Peptide reagents and methods for detection and targeting of dysplasia, early stage cancer, and cancer | |
CN112546244B (en) | Fibroblast growth factor receptor 2 specific peptide reagents and methods | |
US20100310459A1 (en) | Targeted Detection of Dysplasia In Barrett's Esophagus With A Novel Fluorescence-Labeled Polypeptide | |
US11248022B2 (en) | Glypican-3 peptide reagents and methods | |
US10858396B2 (en) | HER2 peptide regents and methods | |
US20200102349A1 (en) | Peptide reagents and methods for detection and targeting of dysplasia, early cancer and cancer | |
US10746738B2 (en) | Claudin-1 peptide reagents and methods | |
CN114555623A (en) | Urokinase plasminogen activator receptor targeting peptides | |
US20220193271A1 (en) | Detection of colonic neoplasia in vivo using near-infrared peptide targeted against overexpressed cmet | |
CN110831634B (en) | Glypican-3 peptide reagents and methods | |
US20210253639A1 (en) | Heterodimeric peptide reagents and methods | |
US20160051704A1 (en) | Molecular imaging probes for lung cancer intraoperative guidance | |
WO2023086964A1 (en) | Cd44-binding peptide reagents and methods | |
Joshi et al. | Targeted detection of murine colonic dysplasia in vivo with flexible multispectral scanning fiber endoscopy | |
WO2024129711A2 (en) | Epithelial cell adhesion molecule-specific peptide conjugates and methods | |
Kwak et al. | Gastric cancer specific drug delivery with hydrophilic peptide probe conjugation | |
Miller et al. | Endoscopic detection of murine colonic dysplasia using a novel fluorescence-labeled peptide | |
WO2024031003A2 (en) | Grail-1 peptide products and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11852148 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11852148 Country of ref document: EP Kind code of ref document: A2 |